US20240034738A1 - Solid state forms of substituted pyrazolopyrimidines and uses thereof - Google Patents
Solid state forms of substituted pyrazolopyrimidines and uses thereof Download PDFInfo
- Publication number
- US20240034738A1 US20240034738A1 US18/334,976 US202318334976A US2024034738A1 US 20240034738 A1 US20240034738 A1 US 20240034738A1 US 202318334976 A US202318334976 A US 202318334976A US 2024034738 A1 US2024034738 A1 US 2024034738A1
- Authority
- US
- United States
- Prior art keywords
- acid
- crystalline form
- cancer
- formula
- solid state
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 223
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 198
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 197
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 63
- 239000003937 drug carrier Substances 0.000 claims abstract description 18
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 308
- 201000011510 cancer Diseases 0.000 claims description 187
- 239000013078 crystal Substances 0.000 claims description 171
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 152
- 239000002253 acid Substances 0.000 claims description 112
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 110
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 105
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 94
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 claims description 76
- 229960005219 gentisic acid Drugs 0.000 claims description 76
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 74
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 73
- 229960004889 salicylic acid Drugs 0.000 claims description 55
- 239000005711 Benzoic acid Substances 0.000 claims description 51
- 235000010233 benzoic acid Nutrition 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 50
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 49
- 238000001757 thermogravimetry curve Methods 0.000 claims description 48
- 206010006187 Breast cancer Diseases 0.000 claims description 40
- 208000026310 Breast neoplasm Diseases 0.000 claims description 40
- 206010033128 Ovarian cancer Diseases 0.000 claims description 40
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 40
- 229940074391 gallic acid Drugs 0.000 claims description 38
- 235000004515 gallic acid Nutrition 0.000 claims description 38
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 27
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 24
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 23
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 22
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 22
- 102000036365 BRCA1 Human genes 0.000 claims description 21
- 108700020463 BRCA1 Proteins 0.000 claims description 21
- 101150072950 BRCA1 gene Proteins 0.000 claims description 21
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 20
- 102000052609 BRCA2 Human genes 0.000 claims description 18
- 108700020462 BRCA2 Proteins 0.000 claims description 18
- 101150008921 Brca2 gene Proteins 0.000 claims description 18
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 claims description 18
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 18
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 16
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 16
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 claims description 16
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 16
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 16
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims description 16
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 16
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 16
- 239000012661 PARP inhibitor Substances 0.000 claims description 15
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 15
- 229960004365 benzoic acid Drugs 0.000 claims description 15
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 15
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 229960002920 sorbitol Drugs 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 12
- 230000002950 deficient Effects 0.000 claims description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 11
- 229940093503 ethyl maltol Drugs 0.000 claims description 11
- 229960003512 nicotinic acid Drugs 0.000 claims description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims description 11
- 239000011664 nicotinic acid Substances 0.000 claims description 11
- 229960002429 proline Drugs 0.000 claims description 11
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 11
- 239000001361 adipic acid Substances 0.000 claims description 10
- 235000011037 adipic acid Nutrition 0.000 claims description 10
- 229960000250 adipic acid Drugs 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 9
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 9
- 229930182821 L-proline Natural products 0.000 claims description 9
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 9
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 9
- 235000019277 ethyl gallate Nutrition 0.000 claims description 9
- 229940081974 saccharin Drugs 0.000 claims description 9
- 235000019204 saccharin Nutrition 0.000 claims description 9
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 9
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 claims description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 8
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims description 8
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 8
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 229960005261 aspartic acid Drugs 0.000 claims description 8
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 8
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 8
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 8
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 8
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims description 8
- 239000001530 fumaric acid Substances 0.000 claims description 8
- 239000000174 gluconic acid Substances 0.000 claims description 8
- 235000012208 gluconic acid Nutrition 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- 229940116298 l- malic acid Drugs 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 8
- 239000011976 maleic acid Substances 0.000 claims description 8
- 235000011090 malic acid Nutrition 0.000 claims description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 8
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 8
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- 235000006408 oxalic acid Nutrition 0.000 claims description 8
- 235000011007 phosphoric acid Nutrition 0.000 claims description 8
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims description 8
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 8
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 8
- 206010070308 Refractory cancer Diseases 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 201000008968 osteosarcoma Diseases 0.000 claims description 7
- 230000037361 pathway Effects 0.000 claims description 7
- 230000033616 DNA repair Effects 0.000 claims description 6
- 230000002489 hematologic effect Effects 0.000 claims description 6
- 230000001926 lymphatic effect Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 239000008184 oral solid dosage form Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 abstract description 336
- 238000002360 preparation method Methods 0.000 abstract description 37
- 239000000203 mixture Substances 0.000 description 110
- 238000000113 differential scanning calorimetry Methods 0.000 description 99
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 95
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 54
- 230000005855 radiation Effects 0.000 description 54
- 239000010949 copper Substances 0.000 description 51
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 42
- 239000003814 drug Substances 0.000 description 40
- 239000000725 suspension Substances 0.000 description 40
- 239000002904 solvent Substances 0.000 description 37
- 238000012512 characterization method Methods 0.000 description 36
- 239000012453 solvate Substances 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 239000011343 solid material Substances 0.000 description 29
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 238000002411 thermogravimetry Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- 230000000699 topical effect Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- QQYMBAZNFRBHMA-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)N1N=C(C=C1C)C(F)(F)F)OC QQYMBAZNFRBHMA-UHFFFAOYSA-N 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 239000012458 free base Substances 0.000 description 17
- 238000001802 infusion Methods 0.000 description 17
- 238000007918 intramuscular administration Methods 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 description 15
- 101710167636 Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 15
- 101001130401 Homo sapiens E3 ubiquitin-protein ligase RAD18 Proteins 0.000 description 14
- 102000001170 RAD18 Human genes 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 12
- 239000012296 anti-solvent Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000013480 data collection Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000007909 solid dosage form Substances 0.000 description 11
- 239000012265 solid product Substances 0.000 description 11
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 238000012937 correction Methods 0.000 description 10
- 238000002447 crystallographic data Methods 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000000003 thermogravimetry coupled to Fourier transform infrared spectroscopy Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000011179 visual inspection Methods 0.000 description 6
- -1 3rd Edition Substances 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 5
- 229920002799 BoPET Polymers 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
- 239000005041 Mylar™ Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000002577 cryoprotective agent Substances 0.000 description 5
- 238000005564 crystal structure determination Methods 0.000 description 5
- 229910003460 diamond Inorganic materials 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003517 fume Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 230000010287 polarization Effects 0.000 description 5
- 238000000373 single-crystal X-ray diffraction data Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- PIVQQUNOTICCSA-UHFFFAOYSA-N ANTU Chemical compound C1=CC=C2C(NC(=S)N)=CC=CC2=C1 PIVQQUNOTICCSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 238000001907 polarising light microscopy Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 230000004777 loss-of-function mutation Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 231100000822 oral exposure Toxicity 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZKKCSLDOCXQBJB-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[5-(trifluoromethyl)-1H-imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1NC=C(N=1)C(F)(F)F)OC ZKKCSLDOCXQBJB-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000001872 metatarsal bone Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- OXCYXNLVSUILPV-UHFFFAOYSA-N 2-hydroxybenzoic acid;propan-2-ol Chemical compound CC(C)O.OC(=O)C1=CC=CC=C1O OXCYXNLVSUILPV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 1
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical class C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present disclosure relates to solid state forms of substituted pyrazolopyrimidines, pharmaceutical compositions thereof, methods of treating cancer by administering one or more solid state forms of substituted pyrazolopyrimidines, and methods for preparing solid state forms of substituted pyrazolopyrimidines.
- Substituted pyrazolopyrirmidines such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) are inhibitors of ubiquitin-specific-processing protease 1 (USP1).
- USP1 ubiquitin-specific-processing protease 1
- USP1 inhibitors have characteristics affording the best potential to become useful therapeutics. Some of these characteristics include high affinity at the USP1, duration of USP1 deactivation, oral bioavailability, solubility, and stability (e.g., ability to formulate, ability to crystallize, or shelf life). Favorable characteristics can lead to improved safety, tolerability, efficacy, therapeutic index, patient compliance, cost efficiency, manufacturing ease, etc.
- substituted pyrazolopyrimidines such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) and corresponding pharmaceutical formulations having acceptable solid state properties (including chemical stability, thermal stability, solubility, hygroscopicity, and/or particle size), compound manufacturability (including yield, impurity rejection during crystallization, filtration properties, drying properties, and milling properties),
- acceptable solid state properties including chemical stability, thermal stability, solub
- substituted pyrazolopyrimidines such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) that have an acceptable balance of these properties and can be used in the preparation of pharmaceutically acceptable solid dosage forms.
- substituted pyrazolopyrimidines such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H
- the present disclosure relates to a solid state form of a compound of Formula (T):
- the solid state form is a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- the solid state form is a crystalline form of a compound of Formula (II).
- the crystalline form is a hydrate, anhydrate, or solvate thereof.
- the solvate is a dichloromethane solvate.
- the solid state form is an amorphous form of a compound of Formula (II).
- the amorphous form is a hydrate, anhydrate, or solvate thereof.
- the solid state form of a compound of Formula (II) is selected from the group consisting of:
- the solid state form of a compound of Formula (II) is selected from the group consisting of:
- the solid state form of a compound of Formula (II) is crystalline Form A.
- crystalline Form A is characterized by an XRPD pattern as shown in FIG. 1 .
- crystalline Form A is characterized by an endothermic peak at about 165° C., as determined by DSC.
- crystalline Form A is characterized by a DSC profile as shown in FIG. 2 .
- crystalline Form A is characterized by an about 0.93 wt % loss between room temperature and about 150° C., as determined by TGA.
- crystalline Form A is characterized by a TGA profile as shown in FIG. 2 .
- crystalline Form A is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 1 ; b) a DSC profile as shown in FIG. 2 ; or c) a TGA profile as shown in FIG. 2 .
- crystalline Form A is substantially free of other polymorphic forms. In some embodiments, crystalline Form A has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- crystalline Form A has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form A has a unit cell with an a value of about 12.054 ⁇ , a b value of about 8.775 ⁇ , and a c value of about 24.837 ⁇ . In some embodiments, crystalline Form A has a unit cell with a volume of about 2603.68 ⁇ 3 .
- the present disclosure relates to a mixture comprising crystalline Form A and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form A as compared to other solid state forms of a compound of Formula (II).
- the compositions of mixtures of solid state forms disclosed herein can be determined using methods known in the art (see, for example, Varasteh, M., et al., Int. J. Pharm. 366(1-2): 74-81 (2009)).
- the solid state form of a compound of Formula (II) is crystalline Form C.
- crystalline Form C is characterized by an XRPD pattern as shown in FIG. 3 .
- crystalline Form C is substantially free of other polymorphic forms. In some embodiments, crystalline Form C has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form C and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form C as compared to other solid state forms of a compound of Formula (II).
- the solid state form of a compound of Formula (II) is crystalline Form D.
- crystalline Form D is characterized by an XRPD pattern as shown in FIG. 4 .
- crystalline Form D is substantially free of other polymorphic forms. In some embodiments, crystalline Form D has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form D and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form D as compared to other solid state forms of a compound of Formula (II).
- the solid state form of a compound of Formula (II) is crystalline Form E.
- crystalline Form E is characterized by an XRPD pattern as shown in FIG. 5 .
- crystalline Form E is characterized by an endothermic peak at about 107° C., as determined by DSC.
- crystalline Form E is characterized by a DSC profile as shown in FIG. 6 .
- crystalline Form E is characterized by an about 13.5 wt % loss between room temperature and about 200° C., as determined by TGA.
- crystalline Form E is characterized by a TGA profile as shown in FIG. 6 .
- crystalline Form E is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 5 ; b) a DSC profile as shown in FIG. 6 ; or c) a TGA profile as shown in FIG. 6 .
- crystalline Form E is substantially free of other polymorphic forms. In some embodiments, crystalline Form E has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form E and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form E as compared to other solid state forms of a compound of Formula (II).
- the solid state form of a compound of Formula II is crystalline Form F.
- crystalline Form F is characterized by an XRPD pattern as shown in FIG. 25 .
- crystalline Form F is characterized by an endothermic peak at about 157° C., as determined by DSC.
- crystalline Form F is characterized by a DSC profile as shown in FIG. 26 .
- crystalline Form F is characterized by at least one of the following: a) an XRPD pattern as shown in FIG. 25 ; or b) a DSC profile as shown in FIG. 26 .
- crystalline Form F is substantially free of other polymorphic forms. In some embodiments, crystalline Form F has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or least 95%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form F and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form F as compared to other solid state forms of a compound of Formula (II).
- the solid state form of a compound of Formula (II) is a pharmaceutically acceptable salt of a compound of Formula (II).
- a pharmaceutically acceptable salt is formed between a compound of Formula (II) and a pharmaceutically acceptable acid.
- the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group.
- the benzoic acid derivative substituted with one hydroxy group is salicylic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments the pharmaceutically acceptable acid is benzoic acid. In some embodiments the pharmaceutically acceptable acid is salicylic acid. In some embodiments the pharmaceutically acceptable acid is gallic acid.
- the solid state form of a compound of Formula (II) is a crystalline form of a pharmaceutically acceptable salt of a compound of Formula (II).
- the crystalline form of the pharmaceutically acceptable salt is a hydrate, anhydrate, or solvate thereof.
- the solid state form of a compound of Formula (II) is an amorphous form of a pharmaceutically acceptable salt of a compound of Formula (II).
- the amorphous form of the pharmaceutically acceptable salt is a hydrate, anhydrate, or solvate thereof.
- the pharmaceutically acceptable salt of a compound of Formula (II) is a hydrochloric acid salt.
- the hydrochloric acid salt is crystalline Form 1 characterized by an XRPD pattern having peaks at 12.5 ⁇ 0.2, 22.4 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta.
- the hydrochloric acid salt is characterized by an XRPD pattern as shown in FIG. 7 .
- the hydrochloric acid salt is characterized by an endothermic peak at about 142.1° C., as determined by DSC.
- the hydrochloric acid salt is characterized by a DSC profile as shown in FIG. 8 .
- the hydrochloric acid salt is characterized by an about 4.04 wt % loss between about 30° C. and about 100° C., as determined by TGA. In some embodiments, the hydrochloric acid salt is characterized by a TGA profile as shown in FIG. 8 .
- crystalline Form 1 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 7 ; b) a DSC profile as shown in FIG. 8 ; or c) a TGA profile as shown in FIG. 8 .
- crystalline Form 1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form 1 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form 1 as compared to other solid state forms of a compound of Formula (II).
- the solid state form of a compound of Formula (II) is a pharmaceutically acceptable co-crystal of a compound of Formula (II) and a second pharmaceutically acceptable compound.
- a pharmaceutically acceptable co-crystal is formed between a compound of Formula (II) and a pharmaceutically acceptable acid.
- the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nico
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid.
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid.
- the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments the pharmaceutically acceptable acid is gallic acid.
- the pharmaceutically acceptable co-crystal of a compound of Formula (II) is a gentisic acid co-crystal.
- the gentisic acid co-crystal is crystalline Form 2 characterized by an XRPD pattern having peaks at 16.6 ⁇ 0.2, 18.7:0.2, and 22.5:0.2 degrees two theta.
- the gentisic acid co-crystal is characterized by an XRPD pattern as shown in FIG. 9 .
- the gentisic acid co-crystal is characterized by an endothermic peak at about 186.0° C., as determined by DSC.
- the gentisic acid co-crystal is characterized by a DSC profile as shown in FIG. 10 . In some embodiments, the gentisic acid co-crystal is characterized by an about 3.17 wt % loss between room temperature and about 170° C., as determined by TGA. In some embodiments, the gentisic acid co-crystal is characterized by a TGA profile as shown in FIG. 10 .
- crystalline Form 2 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 9 ; b) a DSC profile as shown in FIG. 10 ; or c) a TGA profile as shown in FIG. 10 .
- crystalline Form 2 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 2 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- crystalline Form 2 has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form 2 has a unit cell with an a value of about 11.113 ⁇ , a b value of about 12.356 ⁇ , and a c value of about 24.048 ⁇ . In some embodiments, crystalline Form 2 has a unit cell with a volume of about 3223.93 ⁇ 3 .
- the present disclosure relates to a mixture comprising crystalline Form 2 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form 2 as compared to other solid state forms of a compound of Formula (II).
- the pharmaceutically acceptable co-crystal of a compound of Formula (II) is a benzoic acid co-crystal.
- the benzoic acid co-crystal is crystalline Form 8 characterized by an XRPD pattern having peaks at 12.1 ⁇ 0.2, 14.2 ⁇ 0.2, and 16.5 ⁇ 0.2 degrees two theta.
- the benzoic acid co-crystal is characterized by an XRPD pattern as shown in FIG. 29 .
- the benzoic acid co-crystal is characterized by an endothermic peak at about 105° C., as determined by DSC.
- the benzoic acid co-crystal is characterized by a DSC profile as shown in FIG. 30 .
- the benzoic acid cocrystal is characterized by an about 18.8% wt loss between about 120° C. and 300° C. In some embodiments, the benzoic acid co-crystal is characterized by a TG-FTIR profile as shown in FIG. 31 .
- crystalline Form 8 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 29 ; b) a DSC profile as shown in FIG. 30 ; or c) a TG-FTIR profile as shown in FIG. 31 .
- crystalline Form 8 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 8 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- crystalline Form 8 has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form 8 has a unit cell with an a value of about 10.61070(10) ⁇ , a b value of about 12.39940(10) ⁇ , and a c value of about 24.15170(10) ⁇ . In some embodiments, crystalline Form 8 has a unit cell with a volume of about 3114.74(4) ⁇ 3 .
- the present disclosure relates to a mixture comprising crystalline Form 8 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form 8 as compared to other solid state forms of a compound of Formula (II).
- the pharmaceutically acceptable co-crystal of a compound of Formula (II) is a salicylic acid co-crystal.
- the salicylic acid co-crystal is crystalline Form 9 characterized by an XRPD pattern having peaks at 11.0 ⁇ 0.2, 16.5 ⁇ 0.2, 17.3 ⁇ 0.2 and 25.3 ⁇ 0.2 degrees two theta.
- the salicylic acid co-crystal is characterized by an XRPD pattern as shown in FIG. 33 .
- the salicylic acid co-crystal is characterized by an 1 H NMR spectrum as shown in FIG. 34 .
- crystalline Form 9 is characterized by at least one of the following: a) an XRPD pattern as shown in FIG. 33 ; or b) an 1 H NMR profile as shown in FIG. 34 .
- crystalline Form 9 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 9 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- crystalline Form 9 has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form 9 has a unit cell with an a value of about 10.8387(11) ⁇ , a b value of about 12.3761(12) ⁇ , and a c value of about 24.242(2) ⁇ . In some embodiments, crystalline Form 9 has a unit cell with a volume of about 3173.1(5) 3.
- the present disclosure relates to a mixture comprising crystalline Form 9 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form 9 as compared to other solid state forms of a compound of Formula (II).
- the solid state form is a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- the solid state form is a crystalline form of a compound of Formula (III).
- the crystalline form is a hydrate, anhydrate, or solvate thereof.
- the solid state form is an amorphous form of a compound of Formula (III).
- the amorphous form is a hydrate, anhydrate, or solvate thereof.
- the solid state form of a compound of Formula (III) is selected from the group consisting of:
- the solid state form of a compound of Formula (III) is crystalline Form A1.
- crystalline Form A1 is characterized by an XRPD pattern as shown in FIG. 11 .
- crystalline Form A1 is characterized by an endothermic peak at about 150.5° C., as determined by DSC.
- crystalline Form A1 is characterized by a DSC profile as shown in FIG. 12
- crystalline Form A1 is characterized by an about 0.95 wt % loss between room temperature and about 120° C., as determined by TGA.
- crystalline Form A1 is characterized by a TGA profile as shown in FIG. 12 .
- crystalline Form A1 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 11 ; b) a DSC profile as shown in FIG. 12 ; or c) a TGA profile as shown in FIG. 12 .
- crystalline Form A1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form A1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- crystalline Form A1 has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form A1 has a unit cell with an a value of about 12.545 ⁇ , a b value of about 8.640 ⁇ , and a c value of about 21.660 ⁇ . In some embodiments, crystalline Form A1 has a unit cell with a volume of about 2336.13 ⁇ 3 .
- the present disclosure relates to a mixture comprising crystalline Form A1 and a second solid state form of a compound of Formula (III). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form A1 as compared to other solid state forms of a compound of Formula (III).
- the solid state form of a compound of Formula (III) is crystalline Form B1.
- crystalline Form B1 is characterized by an XRPD pattern as shown in FIG. 13 .
- crystalline Form B1 is characterized by an endothermic peak at about 161.2° C., as determined by DSC.
- crystalline Form B1 is characterized by a DSC profile as shown in FIG. 14 .
- crystalline Form B1 is characterized by an about 1.58 wt % loss between room temperature and about 120° C., as determined by TGA.
- crystalline Form B1 is characterized by a TGA profile as shown in FIG. 14 .
- crystalline Form B1 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 13 ; b) a DSC profile as shown in FIG. 14 ; or c) a TGA profile as shown in FIG. 14 .
- crystalline Form B1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form B1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form B1 and a second solid state form of a compound of Formula (III). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form B1 as compared to other solid state forms of a compound of Formula (III).
- the solid state form of a compound of Formula (III) is a pharmaceutically acceptable salt or co-crystal of a compound of Formula (III).
- a pharmaceutically acceptable salt or co-crystal is formed between a compound of Formula (III) and a pharmaceutically acceptable acid.
- the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nic
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid.
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid.
- the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising one or more of the solid state forms or mixtures discussed above and one or more pharmaceutically acceptable carriers or diluents.
- the present disclosure relates to a solid dosage form comprising one or more of the solid state forms or mixtures discussed above.
- the present disclosure relates to a method for treating cancer comprising administering one or more of the solid state forms, mixtures, pharmaceutical compositions, or solid dosage forms discussed above to a patient in need thereof.
- the present disclosure relates to a use of one or more of the solid state forms, mixtures, pharmaceutical compositions, or solid dosage forms discussed above for the manufacture of a medicament for treating cancer.
- the present disclosure relates to one or more of the solid state forms, mixtures, pharmaceutical compositions, or solid dosage forms discussed above for use in a method for treating cancer.
- the present disclosure relates to a method for preparing crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- the method for preparing crystalline Form 2 of a gentisic acid co-crystal of a compound of Formula (II) further comprises adding a suitable anti-solvent after step c) and before step d).
- the suitable solvent is ethyl acetate.
- the suitable anti-solvent is n-heptane.
- the present disclosure relates to a method for preparing crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II), the method comprising:
- the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
- the present disclosure relates to Crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods discussed above.
- FIG. 1 is a powder X-ray diffraction pattern (“XRPD”) corresponding to crystalline Form A.
- FIG. 2 is a differential scanning calorimetry thermogram (“DSC”) and a thermogravimetric analysis thermogram (“TGA”) corresponding to crystalline Form A.
- DSC differential scanning calorimetry thermogram
- TGA thermogravimetric analysis thermogram
- FIG. 3 is an XRPD pattern corresponding to crystalline Form C.
- FIG. 4 is an XRPD pattern corresponding to crystalline Form D.
- FIG. 5 is an XRPD pattern corresponding to crystalline Form E.
- FIG. 6 is a DSC and TGA thermogram corresponding to crystalline Form E.
- FIG. 7 is an XRPD pattern corresponding to crystalline Form 1.
- FIG. 8 is a DSC and TGA thermogram corresponding to crystalline Form 1.
- FIG. 9 is an XRPD pattern corresponding to crystalline Form 2.
- FIG. 10 is a DSC and TGA thermogram corresponding to crystalline Form 2.
- FIG. 11 is an XRPD pattern corresponding to crystalline Form A1.
- FIG. 12 is a DSC and TGA thermogram corresponding to crystalline Form A11.
- FIG. 13 is an XRPD pattern corresponding to crystalline Form B1.
- FIG. 14 is a DSC and TGA thermogram corresponding to crystalline Form B1.
- FIG. 15 is an XRPD pattern corresponding to crystalline Form 3.
- FIG. 16 is an XRPD pattern corresponding to crystalline Form 4.
- FIG. 17 is an XRPD pattern corresponding to crystalline Form 5.
- FIG. 18 is an XRPD pattern corresponding to crystalline Form 6.
- FIG. 19 is an XRPD pattern corresponding to crystalline Form 7.
- FIG. 20 is an asymmetric unit of crystalline Form A from a single crystal structure.
- FIG. 21 is an asymmetric unit of crystalline Form 2 from a single crystal structure.
- FIG. 22 is an asymmetric unit of crystalline Form A1 from a single crystal structure.
- FIG. 23 is a plasma concentration vs. time profile for crystalline Form A after a 300 mg/kg dose in NOD/SCID mice.
- FIG. 24 is a plasma concentration vs. time profile for crystalline Form 2 after a 300 mg/kg dose in NOD/SCID mice.
- FIG. 25 is an XRPD pattern corresponding to crystalline Form F.
- FIG. 26 is a DSC thermogram corresponding to crystalline Form F.
- FIG. 27 is an XRPD pattern corresponding to crystalline Form C.
- FIG. 28 is a Raman spectrum corresponding to crystalline Form C.
- FIG. 29 is an XRPD pattern corresponding to crystalline Form 8.
- FIG. 30 is a DSC thermogram corresponding to crystalline Form 8.
- FIG. 31 is a TG-FTIR thermogram corresponding to crystalline Form 8.
- FIG. 32 is an asymmetric unit of crystalline Form 8 from a single crystal structure.
- FIG. 33 is an XRPD pattern corresponding to crystalline Form 9.
- FIG. 34 1 H NMR spectrum corresponding to crystalline Form 9.
- FIG. 35 is an asymmetric unit of crystalline Form 9 from a single crystal structure.
- FIG. 36 is a plasma concentration vs. time profile for crystalline Form 8 after 300 mg/kg dose in NOD/SCID mice.
- FIG. 37 is a brain and plasma concentration vs. time profile for crystalline Form 2 after 100 and 300 mg/kg QD repeated oral dose in NOD/SCID female mice.
- FIG. 38 is a brain and plasma concentration vs. time profile for crystalline Form 2 after 100 mg/kg oral dose in SD male and female rats.
- R can be selected from methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.
- Compound of Formula (II) refers to 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine having the structure below:
- Compound of Formula (III) refers to 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine having the structure below:
- subject refers to an animal, including, but not limited to, a primate (e.g., human), cow, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
- primate e.g., human
- cow, sheep, goat horse
- dog cat
- rabbit rat
- patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject.
- beneficial or desired clinical results covers any administration or application of a therapeutic for disease in a mammal, including a human.
- beneficial or desired clinical results include, but are not limited to, any one or more of alleviation of one or more symptoms, diminishment of extent of disease, preventing or delaying spread (for example, metastasis) of disease, preventing or delaying recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, and remission (whether partial or total).
- treatment is a reduction of pathological consequence of a proliferative disease.
- the methods provided herein contemplate any one or more of these aspects of treatment. In-line with the above, the term treatment does not require one-hundred percent removal of all aspects of the disorder.
- the terms “treat,” “treating,” and “treatment” include, but are not limited to, inhibiting growth of cancer cells, inhibiting replication of cancer cells, lessening of overall tumor burden, and delaying, halting, or slowing tumor growth, progression, or metastasis.
- cancer refers to or describe the physiological condition in mammals in which a population of cells are characterized by unregulated cell growth.
- the terms encompass solid and hematological/lymphatic cancers.
- cancer include but are not limited to, DNA repair pathway deficient cancers and homologous recombination deficiency (HRD) cancers.
- HRD homologous recombination deficiency
- Additional examples of cancer include, but are not limited to, ovarian cancer, breast cancer (including triple negative breast cancer), non-small cell lung cancer (NSCLC), and osteosarcoma.
- the cancer can be BRCA1 and/or BRCA2 wildtype.
- the cancer can also be BRCA1 and/or BRCA2 mutant.
- the cancer can further be a PARP inhibitor refractory or resistant cancer, or a PARP inhibitor refractory or resistant BRCA1 or BRCA2-mutant cancer.
- disease or “condition” or “disorder” as used herein refers to a condition where treatment is needed and/or desired and denotes disturbances and/or anomalies that as a rule are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and/or malfunctions.
- Compounds of the Disclosure can be used in treating diseases and conditions such as proliferative diseases like cancer.
- a “therapeutically effective amount” of a substance can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the substance are outweighed by the therapeutically beneficial effects.
- a therapeutically effective amount can be delivered in one or more administrations.
- a therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic effect.
- administer refers to methods that can be used to enable delivery of the therapeutic agent to the desired site of biological action.
- Administration techniques that can be employed with the agents and methods described herein are found in e.g., Goodman and Gilman, The Pharmacological Basis of Therapeutics , current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.
- composition refers to a preparation which is in such form as to permit the biological activity of the active ingredient(s) to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- Such formulations may be sterile.
- pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
- a pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the pharmaceutically acceptable carrier is appropriate for the formulation employed.
- each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- active ingredient and “active substance” refer to a compound, which is administered, alone or in combination with one or more pharmaceutically acceptable excipients, to a subject for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease.
- active ingredient and active substance may be an optically active isomer of a compound described herein.
- drug refers to a compound, or a pharmaceutical composition thereof, which is administered to a subject for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease.
- solvate refers to a compound provided herein or a salt thereof, which further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces.
- the solvent is water
- the solvate is a hydrate.
- the solvent includes ethanol
- the compound can be an ethanol solvate.
- polymorph refers to a crystalline form of a compound or a salt, hydrate, or solvate thereof, in a particular crystal packing arrangement. All polymorphs have the same elemental composition.
- crystalline refers to a solid state form which consists of orderly arrangement of structural units. Different crystalline forms of the same compound, or a salt, co-crystal, hydrate, or solvate thereof, arise from different packing of the molecules in the solid state, which results in different crystal symmetries and/or unit cell parameter. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility.
- Crystalline forms are most commonly characterized by X-ray powder diffraction (XRPD).
- XRPD pattern of reflections (peaks, typically expressed in degrees 2-theta) is commonly considered a fingerprint of a particular crystalline form.
- the relative intensities of the XRPD peaks can widely vary depending on, inter alia, the sample preparation technique, crystal size distribution, filters, the sample mounting procedure, and the particular instrument employed. In some instances, new peaks may be observed or existing peaks may disappear, depending on the type of instrument or the settings.
- any particular peak in an XRPD pattern may appear as a singlet, doublet, triplet, quartet, or multiplet, depending on the type of instrument or the settings, the sensitivity of the instrument, measuring conditions, and/or purity of the crystalline form.
- any particular peak in an XRPD may appear in a symmetric shape or in an asymmetric shape, e.g., having a shoulder. A skilled artisan understanding these variations is capable of discriminating or ascertaining the defining features or characteristics of a particular crystal form using XRPD, as well as using other known physicochemical techniques.
- amorphous refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterized by a change of state, typically second order (“glass transition”).
- anhydrate as applied to a compound refers to a solid state wherein the compound contains no structural water within the crystal lattice.
- the present disclosure relates to solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III).
- a compound of Formula (II) As with all pharmaceutical compounds and compositions, the chemical and physical properties of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III) are important in their commercial development.
- These properties include, but are not limited to: (1) packing properties such as molar volume, bulk density and hygroscopicity, (2) thermodynamic properties such as melting temperature, vapor pressure and solubility, (3) kinetic properties such as dissolution rate and stability (including stability at ambient conditions, especially to moisture and under storage conditions), (4) surface properties such as surface area, wettability, interfacial tension and shape, (5) mechanical properties such as hardness, tensile strength, compactibility, handling, flow and blend; and (6) filtration properties. These properties can affect, for example, the processing and storage of the compounds and pharmaceutical compositions comprising the compounds.
- Solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III) that improve upon one or more of these properties relative to other solid state forms of the compounds are desirable. Isolating pharmaceutically acceptable solid state forms of the compounds that can be manufactured and formulated on a commercial-scale has been a challenge.
- the present disclosure relates to a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- the solid state form is an amorphous form of a compound of Formula (II).
- the amorphous form is a hydrate, anhydrate, or solvate thereof.
- the amorphous form is substantially free of other polymorphic forms.
- the present disclosure relates to a mixture comprising a majority of the amorphous form as compared to other solid state forms of a compound of Formula (II).
- the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the solid state form is a crystalline form of a compound of Formula (II).
- the crystalline form is a hydrate, anhydrate, or solvate thereof.
- the solvate is a dichloromethane solvate.
- the solid state form of a compound of Formula (II) is selected from the group consisting of:
- the solid state form of a compound of Formula (II) is selected from the group consisting of:
- the solid state form is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II).
- the pharmaceutically acceptable salt is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and a pharmaceutically acceptable acid.
- the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid.
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid.
- the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, the pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, the pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is an amorphous form. In some embodiments, the amorphous form is substantially free of other polymorphic forms.
- the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a crystalline form.
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrate, anhydrate, or solvate thereof.
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-m ethoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrochloric acid salt.
- the hydrochloric acid salt is crystalline Form 1 characterized by an XRPD pattern having peaks at 12.5 ⁇ 0.2, 22.4 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta.
- the hydrochloric acid salt is crystalline Form 1 characterized by an XRPD pattern as shown in FIG. 7 .
- the hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is crystalline Form 3 characterized by an XRPD pattern as shown in FIG. 15 .
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrobromic acid salt.
- the hydrobromic acid salt is crystalline Form 4 characterized by an XRPD pattern as shown in FIG. 16 .
- the hydrobromic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is crystalline Form 5 characterized by an XRPD pattern as shown in FIG. 17 .
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is an ethanedisulfonic acid salt.
- the ethanedisulfonic acid salt is crystalline Form 6 characterized by an XRPD pattern as shown in FIG. 18 .
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a methanesulfonic acid salt.
- the methanesulfonic acid salt is crystalline Form 7 characterized by an XRPD pattern as shown in FIG. 19 .
- the solid state form is a pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (H) and a second pharmaceutically acceptable compound.
- the second pharmaceutically acceptable compound is a pharmaceutically acceptable acid.
- the pharmaceutically acceptable co-crystal is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and a pharmaceutically acceptable acid.
- the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid.
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid.
- the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, the pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, the pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments the, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.
- the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrate, anhydrate, or solvate thereof.
- the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a gentisic acid co-crystal.
- the gentisic acid co-crystal is crystalline Form 2 characterized by an XRPD pattern having peaks at 16.6 ⁇ 0.2, 18.7 ⁇ 0.2, and 22.5 ⁇ 0.2 degrees two theta.
- the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a benzoic acid co-crystal.
- the benzoic acid co-crystal is crystalline Form 8 characterized by an XRPD pattern having peaks at 12.1 ⁇ 0.2, 14.2 ⁇ 0.2, and 16.5 ⁇ 0.2 degrees two theta.
- the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a salicylic acid co-crystal.
- the salicylic acid co-crystal is crystalline Form 9 characterized by an XRPD pattern substantially as shown in FIG. 33 .
- the present disclosure relates to crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form A is a 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrate.
- the melting point of crystalline Form A is about 165° C.
- crystalline Form A is characterized by an XRPD pattern having peaks at 14.3 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form A is characterized by an XRPD pattern having peaks at 7.1 ⁇ 0.2, 14.3 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form A is characterized by an XRPD pattern having peaks at 7.1 ⁇ 0.2, 14.3 ⁇ 0.2, 19.1 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form A is characterized by an XRPD pattern having peaks at 7.1 ⁇ 0.2, 14.3 ⁇ 0.2, 15.2 ⁇ 0.2, 19.1 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form A is characterized by an XRPD pattern substantially as shown in FIG. 1 .
- crystalline Form A is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 1 below.
- crystalline Form A is characterized by an endothermic peak at from about 162° C. to about 168° C., or from about 163° C. to about 167° C., or from about 164° C. to about 166° C., as determined by DSC. In some embodiments, crystalline Form A is characterized by an endothermic peak at about 165° C., as determined by DSC.
- crystalline Form A is characterized by a DSC profile substantially as shown in FIG. 2 .
- crystalline Form A is characterized by from an about 0.88 wt % to an about 0.98 wt % loss between room temperature and about 150° C. In some embodiments, crystalline Form A is characterized by from an about 0.90 wt % to an about 0.96 wt % loss between room temperature and about 150° C. In some embodiments, crystalline Form A is characterized by from an about 0.93 wt % loss between room temperature and about 150° C.
- crystalline Form A is characterized by a TGA profile substantially as shown in FIG. 2 .
- crystalline Form A is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 1 ; b) a DSC profile as shown in FIG. 2 ; or c) a TGA profile as shown in FIG. 2 .
- crystalline Form A has a unit cell that indexes as monoclinic.
- crystalline Form A has a unit cell with an a value of about 12.054 ⁇ , a b value of about 8.775 ⁇ , and a c value of about 24.837 ⁇ . In other embodiments, Form A has a unit cell with a volume of about 2603.68 ⁇ 3 .
- crystalline Form A is substantially free of other polymorphic forms.
- crystalline Form A has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- crystalline Form A has a polymorphic purity of at least 80%.
- the present disclosure relates to a mixture comprising crystalline Form A and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, or crystalline Form 1, or crystalline Form 2, or crystalline Form 8, or crystalline Form 9.
- the second solid state form of a compound of Formula (II) is crystalline Form C, or crystalline Form D, or crystalline Form F, or crystalline Form 1, or crystalline Form 2.
- the present disclosure relates to a mixture comprising a majority of crystalline Form A as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form C is an anhydrate.
- crystalline Form C is characterized by an XRPD pattern having peaks at 14.2 ⁇ 0.2, 17.0 ⁇ 0.2, and 19.1 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form C is characterized by an XRPD pattern having peaks at 14.2 ⁇ 0.2, 17.0 ⁇ 0.2, 19.1 ⁇ 0.2, and 21.5 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form C is characterized by an XRPD pattern having peaks at 14.2 ⁇ 0.2, 17.0 ⁇ 0.2, 19.1 ⁇ 0.2, 19.8 ⁇ 0.2, and 21.5 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form C is characterized by an XRPD pattern having peaks at 14.2 ⁇ 0.2, 17.0 ⁇ 0.2, 19.1 ⁇ 0.2, 19.8 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form C is characterized by an XRPD pattern substantially as shown in FIG. 3 .
- crystalline Form C is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 below.
- crystalline Form C is substantially free of other polymorphic forms.
- crystalline Form C has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89° %, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form C and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form D, or crystalline Form E, or crystalline Form F, or crystalline Form 1, or crystalline Form 2, or crystalline Form 8, or crystalline Form 9.
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form D, or crystalline Form E, or crystalline Form 1, or crystalline Form 2.
- the present disclosure relates to a mixture comprising a majority of crystalline Form C as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form D of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form D is an anhydrate.
- crystalline Form D is characterized by an XRPD pattern having peaks at 13.9 ⁇ 0.2, 15.2 ⁇ 0.2, and 19.3 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form D is characterized by an XRPD pattern having peaks at 13.9 ⁇ 0.2, 15.2 ⁇ 0.2, 16.4 ⁇ 0.2, and 19.3 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form D is characterized by an XRPD pattern having peaks at 13.9 ⁇ 0.2, 15.2 ⁇ 0.2, 16.4 ⁇ 0.2, 19.3 ⁇ 0.2, and 20.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form D is characterized by an XRPD pattern having peaks at 13.9 ⁇ 0.2, 15.2 ⁇ 0.2, 16.4 ⁇ 0.2, 19.3 ⁇ 0.2, 20.9 ⁇ 0.2, and 21.6 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form D is characterized by an XRPD pattern substantially as shown in FIG. 4 .
- crystalline Form D is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 below.
- crystalline Form D is substantially free of other polymorphic forms.
- crystalline Form D has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form D and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form E, or crystalline Form F, or crystalline Form 1, or crystalline Form 2, or crystalline Form 8, or crystalline Form 9.
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form E, or crystalline Form 1, or crystalline Form 2.
- the present disclosure relates to a mixture comprising a majority of crystalline Form D as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form E of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form E is a solvate. In some embodiments, crystalline Form E is a dichloromethane solvate.
- the melting point of crystalline Form E is about 107° C.
- crystalline Form E is characterized by an XRPD pattern having peaks at 10.6 0.2, 18.7 ⁇ 0.2, and 20.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form E is characterized by an XRPD pattern having peaks at 10.6 ⁇ 0.2, 18.7 ⁇ 0.2, 20.9 ⁇ 0.2, and 21.2 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form E is characterized by an XRPD pattern having peaks at 10.6 ⁇ 0.2, 16.4 ⁇ 0.2, 18.7 ⁇ 0.2, 20.9 ⁇ 0.2, and 21.2 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form E is characterized by an XRPD pattern having peaks at 10.6 ⁇ 0.2, 16.4 ⁇ 0.2, 18.7 ⁇ 0.2, 20.9 ⁇ 0.2, 21.2 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form E is characterized by an XRPD pattern substantially as shown in FIG. 5 .
- crystalline Form E is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 4 below.
- crystalline Form E is characterized by an endothermic peak at from about 102° C. to about 112° C., or from about 104° C. to about 110° C., or from about 106° C. to about 108° C., as determined by DSC. In some embodiments, crystalline Form E is characterized by an endothermic peak at about 107° C., as determined by DSC.
- crystalline Form E is characterized by a DSC profile substantially as shown in FIG. 6 .
- crystalline Form E is characterized by from an about 13.0 wt % to an about 14.0 wt % loss between room temperature and about 200° C. In some embodiments, crystalline Form E is characterized by from an about 13.2 wt % to an about 13.8 wt % loss between room temperature and about 200° C. In some embodiments, crystalline Form E is characterized by from an about 13.5 wt % loss between room temperature and about 200° C.
- crystalline Form E is characterized by a TGA profile substantially as shown in FIG. 6 .
- crystalline Form E is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 5 ; b) a DSC profile as shown in FIG. 6 ; or c) a TGA profile as shown in FIG. 6 .
- crystalline Form E is substantially free of other polymorphic forms.
- crystalline Form E has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form E and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form F, or crystalline Form 1, or crystalline Form 2, or crystalline Form 8, or crystalline Form 9.
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form 1, or crystalline Form 2.
- the present disclosure relates to a mixture comprising a majority of crystalline Form E as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form F of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form F is an anhydrate.
- crystalline Form F is characterized by an XRPD pattern having peaks at 10.7 ⁇ 0.2, 14.3 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form F is characterized by an XRPD pattern having peaks at 10.7 ⁇ 0.2, 14.3 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form F is characterized by an XRPD pattern having peaks at 10.7 ⁇ 0.2, 14.3 ⁇ 0.2, 15.8 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form F is characterized by an XRPD pattern having peaks at 10.7 ⁇ 0.2, 14.3 0.2, 15.8 0.2, 21.5 ⁇ 0.2, 21.8 ⁇ 0.2, and 25.0 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form F is characterized by an XRPD pattern substantially as shown in FIG. 25 .
- crystalline Form F is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 5 below.
- crystalline Form F is characterized by an endothermic peak at from about 153° C. to about 160° C., or from about 154° C. to about 159° C., or from about 155° C. to about 158° C., as determined by DSC. In some embodiments, crystalline Form F is characterized by an endothermic peak at about 157° C., as determined by DSC.
- crystalline Form F is characterized by a DSC profile substantially as shown in FIG. 26 .
- crystalline Form F is characterized by at least one of the following: a) an XRPD pattern as shown in FIG. 25 ; or b) a DSC profile as shown in FIG. 26 .
- crystalline Form F is substantially free of other polymorphic forms.
- crystalline Form F has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form F and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form 1, or crystalline Form 2, or crystalline Form 8, or crystalline Form 9.
- the present disclosure relates to a mixture comprising a majority of crystalline Form F as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form 1 of a hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 1 is a 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride hydrate.
- the melting point of crystalline Form 1 is from about 140° C. to about 145° C. In some embodiments, the melting point of crystalline Form 1 is from about 140° C. to about 143° C. In some embodiments, the melting point of crystalline Form 1 is about 140.8° C.
- crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5 ⁇ 0.2, 22.4 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5 ⁇ 0.2, 17.2 ⁇ 0.2, 22.4 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5 ⁇ 0.2, 17.2 ⁇ 0.2, 19.7 ⁇ 0.2, 22.4 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5 ⁇ 0.2, 17.2 ⁇ 0.2, 19.7 ⁇ 0.2, 22.4 ⁇ 0.2, 23.1 ⁇ 0.2, and 23.9 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form 1 is characterized by an XRPD pattern substantially as shown in FIG. 7 .
- crystalline Form 1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 6 below.
- crystalline Form 1 is characterized by an endothermic peak at from about 136° C. to about 146° C., or from about 138° C. to about 144° C., or from about 140° C. to about 143° C., as determined by DSC. In some embodiments, crystalline Form 1 is characterized by an endothermic peak at about 142.1° C., as determined by DSC.
- crystalline Form 1 is characterized by a DSC profile substantially as shown in FIG. 8 .
- crystalline Form 1 is characterized by from an about 3.0 wt % to an about 5.0 wt % loss between about 30° C. and about 100° C. In some embodiments, crystalline Form 1 is characterized by from an about 3.5 wt % to an about 4.5 wt % loss between about 30° C. and about 100° C. In some embodiments, crystalline Form 1 is characterized by an about 4.04 wt % loss between about 30° C. and about 100° C.
- crystalline Form 1 is characterized by a TGA profile substantially as shown in FIG. 8 .
- crystalline Form 1 is characterized by from an about 12.0 wt % to an about 14.0 wt % loss between room temperature and about 180° C. In some embodiments, crystalline Form 1 is characterized by from an about 12.8 wt % to an about 13.4 wt % loss between room temperature and about 180° C. In some embodiments, crystalline Form 1 is characterized by an about 13.13 wt % loss between room temperature and about 180° C.
- crystalline Form 1 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 7 ; b) a DSC profile as shown in FIG. 8 ; or c) a TGA profile as shown in FIG. 8 .
- crystalline Form 1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form 1 and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, or crystalline Form 2, or crystalline Form 8, or crystalline Form 9.
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form 2.
- the present disclosure relates to a mixture comprising a majority of crystalline Form 1 as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 2 is an anhydrate.
- the melting point of crystalline Form 2 is from about 184° C. to about 190° C. In some embodiments, the melting point of crystalline Form 2 is from about 186° C. to about 188° C. In some embodiments, the melting point of crystalline Form 2 is about 187° C.
- crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6 ⁇ 0.2, 18.7:0.2, and 22.5 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6 ⁇ 0.2, 18.7 ⁇ 0.2, 22.3 ⁇ 0.2, and 22.5 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6 ⁇ 0.2, 18.7 ⁇ 0.2, 22.3 ⁇ 0.2, 22.5 ⁇ 0.2, and 26.0 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6 ⁇ 0.2, 18.7 ⁇ 0.2, 20.8 ⁇ 0.2, 22.3 ⁇ 0.2, 22.5 ⁇ 0.2, and 26.0 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form 2 is characterized by an XRPD pattern substantially as shown in FIG. 9 .
- crystalline Form 2 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 7 below.
- crystalline Form 2 is characterized by an endothermic peak at from about 181° C. to about 191° C., or from about 183° C. to about 189° C., or from about 185° C. to about 187° C., as determined by DSC. In some embodiments, crystalline Form 2 is characterized by an endothermic peak at about 186.0° C., as determined by DSC.
- crystalline Form 2 is characterized by a DSC profile substantially as shown in FIG. 10 .
- crystalline Form 2 is characterized by from an about 2.5 wt % to an about 3.5 wt % loss between room temperature and about 170° C. In some embodiments, crystalline Form 2 is characterized by from an about 3.0 wt % to an about 3.4 wt % loss between room temperature and about 170° C. In some embodiments, crystalline Form 2 is characterized by an about 3.17 wt % loss between room temperature and about 170° C.
- crystalline Form 2 is characterized by a TGA profile substantially as shown in FIG. 10 .
- crystalline Form 2 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 9 ; b) a DSC profile as shown in FIG. 10 ; or c) a TGA profile as shown in FIG. 10 .
- crystalline Form 2 has a unit cell that indexes as monoclinic.
- crystalline Form 2 has a unit cell with an a value of about 11.113 ⁇ , a b value of about 12.356 ⁇ , and a c value of about 24.048 ⁇ . In other embodiments, Form 2 has a unit cell with a volume of about 3223.93 ⁇ 3 .
- crystalline Form 2 is substantially free of other polymorphic forms.
- crystalline Form 2 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89° %, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form 2 and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, or crystalline Form 1, or crystalline Form 8, or crystalline Form 9.
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form 1.
- the present disclosure relates to a mixture comprising a majority of crystalline Form 2 as compared to other solid state forms of a compound of Formula (II).
- Crystalline Form 2 exhibits chemical and physical properties that are unexpected and bioavailablity properties that are advantageous compared to the free base forms.
- 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and gentisic acid exhibit significant hydrogen bonding interactions despite being an interaction between a weak base and a weak acid, respectively.
- crystalline Form 2 surprisingly exhibits increased mouse oral exposure levels as compared to other solid state forms of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II).
- crystalline Form 2 (gentisic acid co-crystal) exhibits higher exposure levels at about 300 mg/kg than crystalline Form A (freebase).
- the present disclosure relates to crystalline Form 3 of a hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula
- crystalline Form 3 is characterized by an XRPD pattern substantially as shown in FIG. 15 .
- the present disclosure relates to crystalline Form 4 of a hydrobromic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 4 is characterized by an XRPD pattern substantially as shown in FIG. 16 .
- the present disclosure relates to crystalline Form 5 of a hydrobromic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 5 is characterized by an XRPD pattern substantially as shown in FIG. 17 .
- the present disclosure relates to crystalline Form 6 of an ethanedisulfonic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 6 is characterized by an XRPD pattern substantially as shown in FIG. 18 .
- the present disclosure relates to crystalline Form 7 of a methanesulfonic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 7 is characterized by an XRPD pattern substantially as shown in FIG. 19 .
- the present disclosure relates to crystalline Form 8 of a benzoic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- crystalline Form 8 is an anhydrate.
- the melting point of crystalline Form 8 is from about 100° C. to about 110° C. In some embodiments, the melting point of crystalline Form 8 is from about 102° C. to about 108° C. In some embodiments, the melting point of crystalline Form 8 is about 105° C.
- crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1 ⁇ 0.2, 14.2 ⁇ 0.2, and 16.5 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1 ⁇ 0.2, 16.5 ⁇ 0.2, 19.0 ⁇ 0.2, and 21.0 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1 ⁇ 0.2, 14.2 ⁇ 0.2, 16.5 ⁇ 0.2, and 21.0 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1 ⁇ 0.2, 16.5 ⁇ 0.2, 21.0 ⁇ 0.2, 23.0 ⁇ 0.2, and 25.7 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form 8 is characterized by an XRPD pattern substantially as shown in FIG. 29 .
- crystalline Form 8 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 8 below.
- crystalline Form 8 is characterized by an endothermic peak at from about 100° C. to about 110° C., or from about 102° C. to about 108° C., or from about 104° C. to about 106° C., as determined by DSC. In some embodiments, crystalline Form 8 is characterized by an endothermic peak at about 105.3° C., as determined by DSC.
- crystalline Form 8 is characterized by a DSC profile substantially as shown in FIG. 30 .
- crystalline Form 8 is characterized by from an about 14 wt % to an about 24 wt % loss between about 120° C. and about 300° C. In some embodiments, crystalline Form 8 is characterized by from an about 16 wt % to an about 20 wt % loss between about 120° C. and about 300° C. In some embodiments, crystalline Form 8 is characterized by from an about 18 wt % to an about 19 wt % loss between about 120° C. and about 300° C. In some embodiments, crystalline Form 8 is characterized by an about 18.8 wt % loss between about 120° C. and about 300° C.
- crystalline Form 8 is characterized by a TG-FTIR profile substantially as shown in FIG. 31 .
- crystalline Form 8 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 29 ; b) a DSC profile as shown in FIG. 30 ; or c) a TG-FTIR profile as shown in FIG. 31 .
- crystalline Form 8 has a unit cell that indexes as monoclinic.
- crystalline Form 8 has a unit cell with an a value of about 10.61070(10) ⁇ , a b value of about 12.39940(10) ⁇ , and a c value of about 24.15170(10) A. In other embodiments, Form 8 has a unit cell with a volume of about 3114.74(4) ⁇ 3 .
- the unit cell parameters for crystalline Form 8 are as follows:
- crystalline Form 8 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 8 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form 8 and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, or crystalline Form 1, or crystalline Form 2, or crystalline Form 9.
- the present disclosure relates to a mixture comprising a majority of crystalline Form 8 as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to crystalline Form 9 of a salicylic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II).
- crystalline Form 9 is an anhydrate.
- crystalline Form 9 is characterized by an XRPD pattern having peaks at 11.0 ⁇ 0.2, 16.5 ⁇ 0.2, and 25.3 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form 9 is characterized by an XRPD pattern having peaks at 11.0 ⁇ 0.2, 16.5 ⁇ 0.2, 17.3 ⁇ 0.2, and 25.3 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form 9 is characterized by an XRPD pattern substantially as shown in FIG. 33 .
- crystalline Form 9 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 9 below.
- crystalline Form 9 is characterized by a 1 H NMR profile substantially as shown in FIG. 34 .
- crystalline Form 9 is characterized by at least one of the following: a) an XRPD pattern as shown in FIG. 33 ; or b) F H NMR profile as shown in FIG. 34 .
- crystalline Form 9 has a unit cell that indexes as monoclinic.
- crystalline Form 9 has a unit cell with an a value of about 10.8387(11) ⁇ , a b value of about 12.3761(12) ⁇ , and a c value of about 24.242(2) ⁇ . In other embodiments, Form 9 has a unit cell with a volume of about 3173.1(5) ⁇ 3 .
- crystalline Form 9 is substantially free of other polymorphic forms. In some embodiments, crystalline Form 9 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form 9 and a second solid state form of a compound of Formula (II).
- the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, or crystalline Form 1, or crystalline Form 2, or crystalline Form 8.
- the present disclosure relates to a mixture comprising a majority of crystalline Form 9 as compared to other solid state forms of a compound of Formula (II).
- the present disclosure relates to a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-11H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- the solid state form is an amorphous form of a compound of Formula (III).
- the amorphous form is a hydrate, anhydrate, or solvate thereof.
- the amorphous form is substantially free of other polymorphic forms.
- the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising a majority of the amorphous form as compared to other solid state forms of a compound of Formula (III).
- the solid state form is a crystalline form of a compound of Formula (III).
- the crystalline form is a hydrate, anhydrate, or solvate thereof.
- the solid state form of a compound of Formula (III) is selected from the group consisting of:
- the solid state form is a pharmaceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III).
- the pharmaceutically acceptable salt or co-crystal is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) and a pharmaceutically acceptable acid.
- the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid.
- the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid.
- the pharmaceutically acceptable acid is a benzoic acid derivative.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups.
- the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid.
- the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments the, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments the pharmaceutically acceptable acid is gallic acid.
- the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) is an amorphous form. In some embodiments, the amorphous form is substantially free of other polymorphic forms.
- the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the pharmaceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) is a crystalline form.
- the pharmaceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) is a hydrate, anhydrate, or solvate thereof.
- the present disclosure relates to crystalline Form A1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- crystalline Form A1 is an anhydrate.
- the melting point of crystalline Form A1 is from about 148° C. to about 152° C. In some embodiments, the melting point of crystalline Form A1 is from about 150° C. to about 152° C. In some embodiments, the melting point of crystalline Form A1 is about 150.5° C.
- crystalline Form A1 is characterized by an XRPD pattern having peaks at 16.1 ⁇ 0.2, 16.7 ⁇ 0.2, and 24.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form A1 is characterized by an XRPD pattern having peaks at 16.1 ⁇ 0.2, 16.7 ⁇ 0.2, 22.2 ⁇ 0.2, and 24.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form A1 is characterized by an XRPD pattern having peaks at 16.1 ⁇ 0.2, 16.7 ⁇ 0.2, 20.6+0.2, 22.2 ⁇ 0.2, and 24.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form A1 is characterized by an XRPD pattern having peaks at 8.1 ⁇ 0.2, 16.1 ⁇ 0.2, 16.7 ⁇ 0.2, 20.6 ⁇ 0.2, 22.2 ⁇ 0.2, and 24.8 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form A1 is characterized by an XRPD pattern substantially as shown in FIG. 11 .
- crystalline Form A1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 10 below.
- crystalline Form A1 is characterized by an endothermic peak at from about 146° C. to about 154° C., or from about 148° C. to about 152° C., or from about 150° C. to about 152° C., as determined by DSC. In some embodiments, crystalline Form A1 is characterized by an endothermic peak at about 150.5° C., as determined by DSC.
- crystalline Form A1 is characterized by a DSC profile substantially as shown in FIG. 12 .
- crystalline Form A1 is characterized by from an about 0.90 wt % to an about 1.0 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form A1 is characterized by from an about 0.92 wt % to an about 0.98 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form A1 is characterized by from an about 0.95 wt % loss between room temperature and about 120° C.
- crystalline Form A1 is characterized by a TGA profile substantially as shown in FIG. 12 .
- crystalline Form A1 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 11 ; b) a DSC profile as shown in FIG. 12 ; or c) a TGA profile as shown in FIG. 12 .
- crystalline Form A1 has a unit cell that indexes as monoclinic.
- crystalline Form A1 has a unit cell with an a value of about 12.545 ⁇ , a b value of about 8.640 ⁇ , and a c value of about 21.660 ⁇ . In other embodiments, Form A has a unit cell with a volume of about 2336.13 ⁇ 3 .
- crystalline Form A1 is substantially free of other polymorphic forms.
- crystalline Form A1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- crystalline Form A1 has a polymorphic purity of at least 80%.
- the present disclosure relates to a mixture comprising crystalline Form A1 and a second solid state form of a compound of Formula (III).
- the second solid state form of a compound of Formula (III) is crystalline Form B1.
- the present disclosure relates to a mixture comprising a majority of crystalline Form A1 as compared to other solid state forms of a compound of Formula (III).
- the present disclosure relates to crystalline Form B1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- crystalline Form B1 is an anhydrate.
- the melting point of crystalline Form B1 is from about 160° C. to about 164° C. In some embodiments, the melting point of crystalline Form B1 is from about 161° C. to about 163° C. In some embodiments, the melting point of crystalline Form B1 is about 162.1° C.
- crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9 ⁇ 0.2, 14.5 ⁇ 0.2, and 22.6 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9 ⁇ 0.2, 14.5 ⁇ 0.2, 16.7 ⁇ 0.2, and 22.6 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation. In another embodiment, crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9 ⁇ 0.2, 14.5 ⁇ 0.2, 16.7 ⁇ 0.2, 22.6 ⁇ 0.2, 24.2 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9 ⁇ 0.2, 14.5 ⁇ 0.2, 16.7 ⁇ 0.2, 20.7 ⁇ 0.2, 22.6 ⁇ 0.2, 24.2 ⁇ 0.2 degrees two theta when measured by Cu K ⁇ radiation.
- crystalline Form B1 is characterized by an XRPD pattern substantially as shown in FIG. 13 .
- crystalline Form B1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 11 below.
- crystalline Form B1 is characterized by an endothermic peak at from about 156° C. to about 166° C., or from about 159° C. to about 163° C., or from about 160° C. to about 162° C., as determined by DSC. In some embodiments, crystalline Form B1 is characterized by an endothermic peak at about 161.2° C., as determined by DSC.
- crystalline Form B1 is characterized by a DSC profile substantially as shown in FIG. 14 .
- crystalline Form B1 is characterized by from an about 1.0 wt % to an about 2.0 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form B1 is characterized by from an about 1.2 wt % to an about 1.8 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form B1 is characterized by an about 1.58 wt % loss between room temperature and about 120° C.
- crystalline Form B1 is characterized by a TGA profile substantially as shown in FIG. 14 .
- crystalline Form B1 is characterized by at least two of the following: a) an XRPD pattern as shown in FIG. 13 ; b) a DSC profile as shown in FIG. 14 ; or c) a TGA profile as shown in FIG. 14 .
- crystalline Form B1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form B1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- the present disclosure relates to a mixture comprising crystalline Form B1 and a second solid state form of a compound of Formula (III).
- the second solid state form of a compound of Formula (III) is crystalline Form A1.
- the present disclosure relates to a mixture comprising a majority of crystalline Form B1 as compared to other solid state forms of a compound of Formula (III).
- Such a carrier can be selected from pharmaceutically acceptable excipients and auxiliaries.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995.
- Solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III), as disclosed herein, and mixtures thereof, may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form A of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form C of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form D of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form E of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form F of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 1 of the hydrochloric acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 2 of the gentisic acid co-crystal of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 3 of the hydrochloric acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 4 of the hydrobromic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 5 of the hydrobromic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 6 of the ethanedisulfonic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 7 of the methanesulfonic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 8 of the benzoic acid cocrystal of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form 9 of the salicylic acid cocrystal of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form A1 of the compound of Formula (III) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- crystalline Form B1 of the compound of Formula (III) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
- rectal intranasal
- topical or transdermal e.g., through the use of a patch
- the present disclosure relates to a solid dosage form comprising one or more of the solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III), as disclosed herein, and one or more pharmaceutically acceptable carriers or diluents.
- Solid dosage forms can include, but are not limited to, tablets, capsules, pills, granules, powders, sachets, chewables, and films.
- the present disclosure provides a solid dosage form comprising a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein the solid dosage form is for use in a method for treating cancer.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising one or more of the solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III), as disclosed herein, and one or more pharmaceutically acceptable carriers or diluents.
- the pharmaceutical composition comprises crystalline Form A of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form C of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form D of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form E of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form F of the compound of Formula (II).
- the pharmaceutical composition comprises crystalline Form 1 of the hydrochloric acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 2 of the gentisic acid co-crystal of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 3 of the hydrochloric acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 4 of the hydrobromic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 5 of the hydrobromic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 6 of the ethanedisulfonic acid salt of the compound of Formula (II).
- the pharmaceutical composition comprises crystalline Form 7 of the methanesulfonic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 8 of the benzoic acid cocrystal of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 9 of the salicylic acid cocrystal of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises an amorphous form of the compound of Formula (II).
- the pharmaceutical composition comprises a mixture of two or more solid state forms of the compound of Formula (II).
- the pharmaceutical composition comprises crystalline Form A1 of the compound of Formula (III). In some embodiments, the pharmaceutical composition comprises crystalline Form B1 of the compound of Formula (III). In some embodiments, the pharmaceutical composition comprises an amorphous form of the compound of Formula (III).
- the pharmaceutical composition comprises a mixture of two or more solid state forms of the compound of Formula (III).
- the pharmaceutical composition is an orally acceptable dosage form comprising one or more of crystalline Forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, and 9 and amorphous form of a compound of Formula (II).
- the pharmaceutical composition is an orally acceptable dosage form comprising one or more of crystalline Forms A1 and B1, and amorphous form of a compound of Formula (III).
- the orally acceptable dosage form can include, but is not limited to, capsules, tablets, aqueous suspensions, and solutions.
- microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (preferably corn, potato or tapioca starch), methylcellulose, alginic acid and certain complex silicates, together with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and acacia, can be included in a tablet.
- disintegrants such as starch (preferably corn, potato or tapioca starch), methylcellulose, alginic acid and certain complex silicates, together with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and acacia
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes.
- Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
- Preferred materials in this connection include lactose or milk sugar as well as high molecular weight polyethylene glycols.
- the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
- the pharmaceutical composition is a parenteral formulation comprising one or more of crystalline Forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, and 9 and amorphous form of a compound of Formula (II).
- the pharmaceutical composition is a parenteral formulation comprising one or more of crystalline Forms A1 and B1, and amorphous form of a compound of Formula (III).
- solutions containing a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) can be prepared in either sesame or peanut oil, in aqueous propylene glycol, or in sterile water or saline.
- the aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- These aqueous solutions are suitable for intravenous injection purposes.
- the oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
- the pharmaceutical composition may be prepared as liquid suspension or solution using a liquid, such as an oil, water, an alcohol, and combinations of these.
- the pharmaceutical composition may be prepared as a sterile injectable, which may be aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art.
- the pharmaceutical composition may be administered in the form of suppositories for rectal administration.
- the pharmaceutical composition may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract.
- Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.
- Topically-transdermal patches may also be used.
- the pharmaceutical compositions may be formulated in a suitable ointment, lotion, or cream containing the active component suspended or dissolved in one or more carriers.
- the pharmaceutical composition may also be administered ophthalmically and formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
- the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
- the pharmaceutical composition may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- the pharmaceutical compositions to be used for in vivo administration can be sterile. This is readily accomplished by filtration through, e.g., sterile filtration membranes.
- compositions within the scope of the present disclosure include all compositions where a solid state form of a compound of Formula (I), a compound of Formula (11), or a compound for Formula (III) is combined with one or more pharmaceutically acceptable carriers or diluents.
- a solid state form of the compound of Formula (I), the compound of Formula (II), or the compound for Formula (III) is present in the composition in an amount that is effective to achieve its intended therapeutic purpose.
- compositions of the present disclosure can be administered to any patient that may experience the beneficial effects of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III).
- a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III) are administered to any patient that may experience the beneficial effects of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III).
- mammals e.g., humans and companion animals, although the disclosure is not intended to be so limited.
- the patient is a human.
- kits which comprise a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III) packaged in a manner that facilitates their use to practice methods of the present disclosure.
- the kit includes a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III) (or a composition thereof) packaged in a container, such as a sealed bottle or vessel, with a label affixed to the container or included in the kit that describes use of the compound or composition to practice the method of the disclosure.
- the compound or composition is packaged in a unit dosage form.
- the kit further can include a device suitable for administering the composition according to the intended route of administration.
- the present disclosure provides a kit which comprises a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a patient having cancer.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or diluent, wherein the pharmaceutical composition is for use in a method for treating cancer.
- a method of inhibiting a USP1 protein comprises contacting the USP1 protein with a solid state form of a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), or combinations thereof.
- the contacting can occur in vitro or in vivo.
- a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) can be used to treat a “USP1 protein mediated disorder.”
- a USP1 protein mediated disorder is any pathological condition in which a USP1 protein is known to play a role.
- a USP1 protein mediated disorder is a proliferative disease such as cancer.
- methods of treating cancer with the solid state forms of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) comprise administering to a subject with cancer a therapeutically effective amount of a Compound of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III).
- the cancer to be treated with a solid state form disclosed herein is selected from a hematological cancer, a lymphatic cancer, and a DNA repair pathway deficient cancer.
- the cancer to be treated is a cancer that comprises cancer cells with a mutation in a gene encoding p53.
- the cancer to be treated is a cancer that comprises cancer cells with a loss of function mutation in a gene encoding p53.
- the cancer to be treated with a solid state form disclosed herein is selected from non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer.
- NSCLC non-small cell lung cancer
- the cancer is ovarian cancer or breast cancer.
- the cancer is ovarian cancer.
- the cancer is breast cancer.
- the cancer is a triple negative breast cancer.
- the cancer to be treated with a solid state form disclosed herein is selected from the group consisting of bone cancer, including osteosarcoma and chondrosarcoma; brain cancer, including glioma, glioblastoma, astrocytoma, medulloblastoma, and meningioma; soft tissue cancer, including rhabdoid and sarcoma; kidney cancer; bladder cancer; skin cancer, including melanoma; and lung cancer, including non-small cell lung cancer.
- bone cancer including osteosarcoma and chondrosarcoma
- brain cancer including glioma, glioblastoma, astrocytoma, medulloblastoma, and meningioma
- soft tissue cancer including rhabdoid and sarcoma
- kidney cancer including melanoma
- lung cancer including non-small cell lung cancer.
- the present disclosure provides a method for treating cancer comprising administering one or more of the solid state forms disclosed herein to a patient in need thereof. In some embodiments, the present disclosure provides a method for treating cancer comprising administering one or more of the pharmaceutical compositions disclosed herein to a patient in need thereof. In some embodiments, the present disclosure provides a method for treating cancer comprising administering one or more of the solid dosage forms disclosed herein to a patient in need thereof.
- the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof a solid state form as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof.
- the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form A.
- the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form F.
- the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form 1. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form 2. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form 8. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form 9. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form A1. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form B1.
- the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof a solid state form as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof.
- the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form A.
- the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form F. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form 1. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form 2. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form 8. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form 9. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form A1. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form B1.
- the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof a solid state form as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof.
- the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form A.
- the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form F. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form 1. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form 2. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form 8. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form 9.
- the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form A1. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form B1.
- a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is administered to a subject with cancer, wherein the cancer comprises cancer cells with elevated levels of RAD18.
- the elevated levels of RAD18 are elevated RAD18 protein levels.
- the elevated levels of RAD18 are elevated RAD18 mRNA levels.
- elevated levels ofRAD18 e.g., RAD18 protein and/or RAD18 mRNA
- RAD18 protein and/or RAD18 mRNA have been detected (e.g., in a cancer sample obtained from the subject) prior to the administration. That is, in some embodiments, a subject's cancer has been tested for RAD 18 protein or mRNA prior to beginning treatment with a USP1 inhibitor.
- such methods for treating cancer comprise (a) identifying a cancer in a subject as a USP1 inhibitor-sensitive cancer and then (b) administering a therapeutically effective amount of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) to the subject.
- such methods comprise (a) detecting levels ofRAD18 (e.g., RAD18 protein and/or RAD18 mRNA) in cancer cells (e.g., in a cancer sample obtained from the subject) and then (b) administering a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) to a subject having a cancer comprising cells with elevated levels of RAD18.
- RAD18 e.g., RAD18 protein and/or RAD18 mRNA
- cancer cells e.g., in a cancer sample obtained from the subject
- administering a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) to a subject having a cancer comprising cells with elevated levels of RAD18.
- such methods comprise administering to a subject with triple negative breast cancer a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III).
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a homologous-recombination deficient cancer.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer comprises cancer cells with a mutation in a gene encoding p53.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer comprises cancer cells with a loss of function mutation in a gene encoding p53.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer that does not have a defect in the homologous recombination pathway.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a BRCA1 mutant cancer.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a BRCA2 mutant cancer.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a BRCA1 mutant cancer and a BRCA2 mutant cancer.
- the cancer is not a BRCA1 mutant cancer or a BRCA2 mutant cancer.
- the cancer is a BRCA1 deficient cancer.
- the cancer is a BRCA2 deficient cancer.
- the cancer is a BRCA1 deficient cancer and a BRCA2 mutant cancer.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a PARP inhibitor resistant cancer.
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a PARP inhibitor resistant BRCA1-deficient cancer.
- the cancer is a BRCA1 and/or BRCA2 mutant cancer, wherein the cancer comprises cells with elevated levels of RAD18, e.g., wherein the elevated levels of RAD18 are at least as high as the RAD18 protein and/or mRNA levels in ES2 cells or wherein the elevated levels ofRAD18 are higher than the RAD18 protein and/or mRNA levels in HEP3B217 cells.
- a triple negative breast cancer is a BRCA1 and/or BRCA2 mutant cancer.
- the cancer is a solid cancer. In some instances, the cancer is a hematological/lymphatic cancer. In some instances, the cancer is a DNA repair pathway deficient cancer. In some instances, the cancer is a homologous-recombination deficient cancer. In some instances, the cancer comprises cancer cells with a mutation in a gene encoding p53. In some instances, the cancer comprises cancer cells with a loss of function mutation in a gene encoding p53. In some instances, the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer (including triple negative breast cancer). In some instances, the cancer is ovarian cancer or breast cancer (including triple negative breast cancer). In some instances, the cancer is ovarian cancer. In some instances, the cancer is breast cancer (including triple negative breast cancer).
- NSCLC non-small cell lung cancer
- osteosarcoma osteosarcoma
- ovarian cancer and breast cancer (including triple negative breast cancer).
- the cancer is
- a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used in combination with one or more additional therapeutic agents to treat cancer. It has been reported that p53 status determines PARP inhibitor sensitization by ionizing radiation in multiple BRCA1 and HR-proficient tumor types (Sizemore et al., Mol. Cancer Res. 16: 1092-1102 (2018)). As shown below, p53 mutant cancers and BRCA mutant cancers have increased sensitivity to USP1 inhibitors. Accordingly, in some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used in combination with a PARP inhibitor to treat cancer.
- the present disclosure provides a use of one or more of the solid state forms disclosed herein for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of one or more of the pharmaceutical compositions disclosed herein for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of one or more of the solid dosage forms disclosed herein for the manufacture of a medicament for treating cancer.
- the present disclosure provides a use of one or more solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for the manufacture of a medicament for treating cancer.
- the present disclosure provides a use of crystalline Form A for the manufacture of a medicament for treating cancer.
- the present disclosure provides a use of crystalline Form F for the manufacture of a medicament for treating cancer.
- the present disclosure provides a use of crystalline Form 1 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form 2 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form 8 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form 9 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form A1 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form B1 for the manufacture of a medicament for treating cancer.
- the present disclosure provides a use of one or more solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for the manufacture of a medicament for treating breast cancer.
- the present disclosure provides a use of crystalline Form A for the manufacture of a medicament for treating breast cancer.
- the present disclosure provides a use of crystalline Form F for the manufacture of a medicament for treating breast cancer.
- the present disclosure provides a use of crystalline Form 1 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form 2 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form 8 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form 9 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form A1 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form B1 for the manufacture of a medicament for treating breast cancer.
- the present disclosure provides a use of one or more solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for the manufacture of a medicament for treating ovarian cancer.
- the present disclosure provides a use of crystalline Form A for the manufacture of a medicament for treating ovarian cancer.
- the present disclosure provides a use of crystalline Form F for the manufacture of a medicament for treating ovarian cancer.
- the present disclosure provides a use of crystalline Form 1 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form 2 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form 8 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form 9 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form A1 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form B1 for the manufacture of a medicament for treating ovarian cancer.
- the present disclosure provides a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein the solid state form is for use in a method for treating cancer.
- the present disclosure provides a solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for use in a method for treating cancer.
- the present disclosure provides crystalline Form A for use in a method for treating cancer.
- the present disclosure provides crystalline Form F for use in a method for treating cancer.
- the present disclosure provides crystalline Form 1 for use in a method for treating cancer.
- the present disclosure provides crystalline Form 2 for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form 8 for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form 9 for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form A1 for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form B1 for use in a method for treating cancer.
- the present disclosure provides a solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9 crystalline Form A1, crystalline Form B1, and mixtures thereof, for use in a method for treating breast cancer.
- the present disclosure provides crystalline Form A for use in a method for treating breast cancer.
- the present disclosure provides crystalline Form F for use in a method for treating breast cancer.
- the present disclosure provides crystalline Form 1 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form 2 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form 8 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form 9 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form A1 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form B1 for use in a method for treating breast cancer.
- the present disclosure provides a solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F, crystalline Form 1, crystalline Form 2, crystalline Form 3, crystalline Form 4, crystalline Form 5, crystalline Form 6, crystalline Form 7, crystalline Form 8, crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for use in a method for treating ovarian cancer.
- the present disclosure provides crystalline Form A for use in a method for treating ovarian cancer.
- the present disclosure provides crystalline Form F for use in a method for treating ovarian cancer.
- the present disclosure provides crystalline Form 1 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form 2 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form 8 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form 9 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form A1 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form B1 for use in a method for treating ovarian cancer.
- the present disclosure relates to methods for preparing a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III).
- the method comprises:
- a suitable pharmaceutically acceptable acid is added during step a).
- the suitable solvent system is selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropyl alcohol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyl tetrahydrofuran, n-heptane, n-methyl pyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof.
- the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
- the method comprises:
- the method further comprises adding a suitable pharmaceutically acceptable acid during step a).
- the method further comprises adding a suitable anti-solvent after step c) and before step d).
- the suitable solvent and anti-solvent are selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropyl alcohol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyl tetrahydrofuran, n-heptane, n-methyl pyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof.
- the suitable solvent and anti-solvent are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof. In some embodiments, the suitable solvent is ethyl acetate. In some embodiments, the suitable anti-solvent is n-heptane.
- the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is added to the suitable solvent system at a temperature of from about room temperature to about 100° C., or from about room temperature to about 75° C., or from about room temperature to about 50° C., or from about room temperature to about 40° C. In some embodiments, the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is added to the suitable solvent system at about room temperature.
- the present disclosure relates to a method for preparing crystalline Form 2 of a gentisic acid co-crystal of a compound of Formula (II), the method comprising:
- the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
- the present disclosure relates to a method for preparing crystalline Form 2 of a gentisic acid co-crystal of a compound of Formula (II), the method comprising:
- the method further comprises adding a suitable anti-solvent after step c) and before step d).
- the suitable solvent is ethyl acetate. In some embodiments, the suitable anti-solvent is n-heptane.
- the present disclosure relates to Crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form D of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form E of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form 1 of a hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form 8 of a benzoic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form 9 of a salicylic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form A1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) prepared by any of the methods disclosed herein.
- the present disclosure relates to Crystalline Form B1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) prepared by any of the methods disclosed herein.
- X-ray powder diffraction (XRPD) patterns were measured on an X'pert 3 X-ray powder diffractomneter using Cu-k ⁇ radiation. Each sample was spread on the middle of a zero-background silicon holder. The tube voltage and amperage were set to 45 kV and 40 mA, respectively. A two-theta (2 ⁇ °) continuous scan at 46.7 seconds/step from 3° to 40° 2 ⁇ was used. XRPD analysis conditions are shown in the table below.
- XRPD patterns were measured on an PANanlytical & Xpert 3 X-ray powder diffractometer using Cu-k ⁇ radiation. Each sample was spread on the middle of a zero-background silicon holder. The tube voltage and amperage were set to 45 kV and 40 mA, respectively. A two-theta (2 ⁇ °) continuous scan at 20.96 seconds/step from 2° to 50 ⁇ 2 ⁇ was used. XRPD analysis conditions are shown in the table below.
- TGA Thermogravimetric analysis
- DSC Differential scanning calorimetry
- DSC data was collected using a Perkin Elmer DSC 4000. DSC analysis conditions are shown in the table below.
- Polarized light microscopy (PLM) images were captured with a ZEISS Scope A1 microscope.
- 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine was prepared according to the procedures disclosed in U.S. Provisional Patent Application Nos. 62/783,014; 62/799,423; and 62/868,616.
- reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 ⁇ 200 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- TLC thin layer chromatography
- LCMS liquid chromatography-mass spectrometry
- a suitable single crystal with good diffraction quality was selected from the block-like crystal samples and was wrapped with Paratone-N (an oil based cryoprotectant).
- the crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K.
- Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software using the setting angles of 49260 reflections in the range 3.563° ⁇ 75.668°.
- the data were collected to a minimum diffraction angle ( ⁇ ) of 3.591° and a maximum diffraction angle ( ⁇ ) of 76.0110 at 120 K.
- the final point group completeness is 100%.
- the mean I/ ⁇ of the data is 69.7 and the highest resolution is truncated at 0.79 ⁇ .
- the structure was solved in the space group P2 1 /c with the ShelXT structure solution program using Intrinsic Phasing and refined with ShelL (Version 2018′3) refinement package using full-matrix least-squares on F 2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were calculated geometrically and refined using the riding model.
- a calculated XRPD pattern was generated for copper (“Cu”) radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure. Crystal structure representations were generated by Olex2 and Diamond. The atomic thermal displacement ellipsoids drawing was generated by ORTEP-III.
- a suitable single crystal was separated from the block-like crystals and selected for single-crystal X-ray diffraction data collection.
- the crystal system of the single crystal was monoclinic and the space group is P2 1 /c. Crystallographic data and the refinement parameters are shown in Table 12.
- the asymmetric unit of the single crystal structure is comprised of one freebase compound of Formula (II) molecule and a non-integer number of water molecules, which suggested that crystalline Form A is hydrate.
- the number of water molecule in the asymmetric unit was freely refined to be 0.42, according to the thermal parameters.
- a suitable amount of crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) was purged with nitrogen gas (N 2 ) for 20 minutes at 30° C. to form a new crystalline form.
- the new crystalline Form was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 3 , and the XRPD peaks are shown in Table 2, above.
- the new crystalline form was determined to be an anhydrate and was named crystalline Form C.
- a suitable amount of crystalline Form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) was heated to 150° C. under nitrogen gas to form a new crystalline form.
- the new crystalline Form was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 4 , and the XRPD peaks are shown in Table 3, above.
- the new crystalline form was determined to be an anhydrate and was named crystalline Form D.
- the resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above.
- the resulting XRPD pattern, DSC profile, and TGA profile are shown in FIGS. 5 - 6 , respectively, and the XRPD peaks are shown in Table 4, above.
- the obtained solid material was determined to be a crystalline DCM solvate and was named crystalline Form E.
- crystalline Form A Approximately 20 mg of crystalline Form A was mixed in a 1:1 ratio with hydrochloric acid in an HPLC vial. 0.5 mL of EtOAc/n-heptane (1:1, v/v) was then added to form a suspension, which was stirred at about 1000 rpm at room temperature for about 3 days. The resulting solid material was isolated by centrifugation and dried under vacuum at room temperature.
- the resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above.
- the resulting XRPD pattern, DSC profile, and TGA profile are shown in FIGS. 7 - 8 , respectively, and the XRPD peaks are shown in Table 6, above.
- the obtained solid material was determined to be a crystalline hydrate of an HCl salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and was named crystalline Form 1.
- Method A Approximately 40 mg of crystalline Form A and 11.6 mg of gentisic acid were combined with 0.5 mL EtOAc/n-Heptane to obtain a suspension. The suspension was stirred at room temperature for 2 days, and the solid material was isolated by vacuum filtration and dried under vacuum at room temperature. The resulting solid material can be used as “seeds” to prepare crystalline Form 1 at larger scales.
- Method B Approximately 500 mg of crystalline Form A and 11.6 mg of gentisic acid were combined with 7 mL EtOAc to obtain a solution. 5.0 mL n-heptane was then added dropwise, along with 10.2 mg of gentisic acid co-crystal “seeds” prepared according to method A, and finally 8.0 mL n-heptane to obtain a suspension. The suspension was stirred at room temperature for two days. The resulting solid material was isolated by vacuum filtration and dried under vacuum at room temperature.
- the resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above.
- the resulting XRPD pattern, DSC profile, and TGA profile are shown in FIGS. 9 - 10 , respectively, and the XRPD peaks are shown in Table 7, above.
- the obtained solid material was determined to be a crystalline anhydrate of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and was named crystalline Form 2.
- a suitable single crystal with good diffraction quality was selected out from the block-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant).
- the crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K.
- Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software using the setting angles of 50053 reflections in the range 3.5390 ⁇ 75.936°.
- the data were collected to a minimum diffraction angle ( ⁇ ) of 3.765° and a maximum diffraction angle ( ⁇ ) of 76.018° at 120 K.
- the final point group completeness is 100%.
- the mean I/ ⁇ of the data is 75.8 and the highest resolution is truncated at 0.79 ⁇ .
- the structure was solved in the space group P2 1 /c with the ShelXT structure solution program using Intrinsic Phasing and refined with ShelXL (Version 2018.3) refinement package using full-matrix least-squares on F 2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically.
- the hydrogen atoms (H2) connected with the oxygen atoms (O2) was determined and refine freely based on the Fourier Map. Other hydrogen atoms were calculated geometrically and refined using the riding model.
- a calculated XRPD pattern was generated for copper (“Cu”) radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure. Crystal structure representations were generated by Olex2 and Diamond. The thermal ellipsoids drawing was generated by ORTEP-III.
- a suitable single crystal was separated and selected out from the block-like crystals and selected for single-crystal x-ray diffraction data collection.
- the crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P2 1 /c. Crystallographic data and the refinement parameters are listed in Table 13.
- the asymmetric unit of the single crystal structure is comprised of one neutral compound of Formula (II) molecule and one gentisic acid neutral molecule, which indicated that crystalline Form 2 was actually a co-crystal of the starting compound with gentisic acid.
- Form A crystalline Form A was mixed with hydrochloric acid in a 1:2 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of MTBE was then added to form a suspension, which was magnetically stirred ( ⁇ 1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- the resulting solid material was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 15 .
- the new crystalline form was named crystalline Form 3.
- Form A crystalline Form A was mixed with hydrobromic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of MTBE was then added to form a suspension, which was magnetically stirred ( ⁇ 1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- the resulting solid material was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 16 .
- the new crystalline form was named crystalline Form 4.
- Form A crystalline Form A was mixed with hydrobromic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial.
- the resulting solid material was dried at room temperature under vacuum.
- the resulting solid material was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 17 .
- the new crystalline form was named crystalline Form 5.
- Form A crystalline Form A was mixed with ethanedisulfonic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of Acetone/n-Heptane (1:4, v/v) was then added to form a suspension, which was magnetically stirred ( ⁇ 1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- the resulting solid material was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 18 .
- the new crystalline form was named crystalline Form 6.
- Form A crystalline Form A was mixed with methanesulfonic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of Acetone/n-Heptane (1:4, v/v) was then added to form a suspension, which was magnetically stirred ( ⁇ 1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- the resulting solid material was subjected to XRPD analysis using the conditions discussed above.
- the resulting XRPD pattern is shown in FIG. 19 .
- the new crystalline form was named crystalline Form 7.
- crystalline Form A1 was added into a 3 mL glass vial with 0.5 mL EtOH/n-heptane (1:3, v/v) solvent mixture. After being shaken by an ultrasonic cleaner to accelerate dissolution, the suspension was filtered and the obtained clear solution was transferred to a clean 4 mL shell vial (44.6 mm ⁇ 14.65 mm). The shell vial was sealed by PE-Plug with one pinhole. The shell vial was then placed in a fume hood at room temperature for slow evaporation. After 5 days of slow evaporation, thin rod-like crystals were observed.
- a suitable single crystal with good diffraction quality was selected from the thin rod-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant).
- the crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K.
- Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software using the setting angles of 24455 reflections in the range 3.516° ⁇ 75.351°.
- the data were collected to a minimum diffraction angle ( ⁇ ) of 3.541° and a maximum diffraction angle ( ⁇ ) of 75.982° at 120 K.
- the final point group completeness is 100%.
- the mean I/ ⁇ of the data is 71.4 and the highest resolution is truncated at 0.79 ⁇ .
- the structure was solved in the space group P2 1 /c with the ShelXT structure solution program using Intrinsic Phasing and refined with ShelXL (Version 2018/3) refinement package using full-matrix least-squares on F 2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were calculated geometrically and refined using the riding model.
- the calculated XRPD pattern was generated for Cu radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure.
- the crystal structure representations were generated by Olex2 and Diamond.
- the atomic thermal displacement ellipsoids drawing was generated by ORTEP-III.
- a suitable single crystal was separated out from the thin rod-like crystals and selected for single-crystal X-ray diffraction data collection.
- the crystal system of the single crystal was determined to be monoclinic and the space group was P2 1 /c. Crystallographic data and the refinement parameters are listed in Table 14.
- the asymmetric unit of the single crystal structure was comprised of only one compound of Formula (III) molecule, which suggested that crystalline Form A1 is an anhydrate.
- the resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above.
- the resulting XRPD pattern, DSC profile, and TGA profile are shown in FIGS. 13 - 14 , respectively, and the XRPD peaks are shown in Table 11, above.
- the obtained solid material was determined to be a crystalline anhydrate and was named crystalline Form B1.
- the PK studies consisted of single dose oral exposure studies, which were conducted in female NOD/SCID mice (approximately 6 to 8 weeks, and 20-30 g at the time of study) using a compound dose of 300 mg/kg and a dosing volume of 10 mL/kg. The mice were fasted overnight prior to dosing. Animals had free access to food and water post-dosing.
- Blood was sampled serially from the dorsal metatarsal vein at pre-dose, 0.25, 0.5, 1, 2, 4, 8, 24, 48 (crystalline Form 2 only), and 72 hours (crystalline Form 2 only) post PO dosing. Approximately 0.03 mL blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4° C. to provide plasma. The plasma samples were then stored in a freezer at ⁇ 75 ⁇ 15° C. prior to LC-MS/MS analysis.
- the resulting white solid material was subjected to XRPD and DSC analysis using the conditions discussed above.
- the resulting XRPD pattern and DSC profile are shown in FIGS. 25 and 26 , respectively, and the XRPD peaks are shown in Table 5.
- the obtained solid material was determined to be a crystalline anhydrate and was named crystalline Form F.
- DSC Differential scanning calorimetry
- X-ray powder diffraction was carried out with a Stoe Stadi P diffractometer equipped with a Mythen1K detector operating with Cu-Kcal radiation. The measurements with this instrument were performed in transmission at a tube voltage of 40 kV and 40 mA tube power. A curved Ge monochromator allows testing with Cu-K ⁇ 1 radiation. The following parameters were set: 0.020 2 ⁇ step size, 12 s step time, 1.5-50.5° 2 ⁇ scanning range, and 1° 2 ⁇ detector step (detector mode in step scan). For a typical sample preparation about 10 mg of sample was placed between two acetate foils and mounted into a Stoe transmission sample holder. The sample was rotated during the measurement. All sample preparation and measurement was done in an ambient air atmosphere.
- TG-FTIR measurements were carried out with a Netzsch Thermo-Microblanace TG209 coupled to a Bruker FTIR Spectrometer Vector 22 (sample pans with a pinhole, N 2 atmosphere, heating rate 10° C./min to 300 or 350° C.).
- the starting material was a freebase form of Formula (II).
- Cocrystal screening experiments with Formula II were carried out with adipic acid, benzoic acid, ethyl maltol, gallic acid (3,4,5-trihydroxybenzoic acid), gallic acid ethyl ester, 4-hydroxy benzoic acid, 4-hydroxy benzoic acid methyl ester, nicotinic acid, nicotinamide, L-proline, saccharin, salicylic acid, D-sorbitol, and succinic acid.
- the experimental parameters and results for the cocrystal screening experiments are listed in Table 17.
- the resulting white solid was submitted to XRPD. 4 80 mg of Formula (II) and 20 mg of benzoic acid XRPD Free base + (1:1.1 eq) were ground together in a ball mill for 10 free benzoic min with 50 ⁇ L of ethyl acetate as solvent. The acid resulting white solid was submitted to XRPD. 5 80 mg of Formula (II) and 80 mg of benzoic acid XRPD Crystalline, (1:4.4 eq) were dissolved together in EtOAc (1 mL), benzoic acid then 4 mL of heptane were added. A light turbidity cocrystal. formed, and the suspension was agitated for 3 days.
- the benzoic acid cocrystal from experiment 5 in Table 17 was analyzed via XRPD. DSC, and TG-FTIR analysis using the aforementioned conditions.
- the resulting XRPD pattern, DSC profile, and TG-FTIR profile are shown in FIGS. 29 - 31 , respectively, and the XRPD peaks are shown in Table 8.
- the obtained solid material was determined to be a benzoic acid cocrystal and was named crystalline Form 8.
- a suitable single crystal with good diffraction quality was selected out from the block-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant).
- the crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K.
- Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.67a, Rigaku, 2019) software using the setting angles of 37110 reflections in the range 3.716° ⁇ 75.227°.
- the data were collected to a minimum diffraction angle ( ⁇ ) of 3.734° and a maximum diffraction angle ( ⁇ ) of 76.055° at 120 K. The completeness is 100%.
- the mean 1/ ⁇ of the data is 64.1 and the highest resolution is truncated at 0.79 ⁇ .
- the structure was solved in the space group P2 1 /n with the ShelXT(Sheldrick, G. M. Acta Cryst. 2015, A71, 3-8) structure solution program using Intrinsic Phasing and refined with ShelXL (Version 2018:3) refinement package (Sheldrick, G. M. Acta Cryst. 2015, C71, 3-8) using full-matrix least-squares on F 2 contained in OLEX2 (Dolomanov, O. V., Bourhis, L. J., Gildea, R. J, Howard, J. A. K. & Puschmann, H. J. Appl. Cryst. 2009, 42, 339-341). All non-hydrogen atoms were refined anisotropically. The hydrogen atoms (H2) connected with the oxygen atoms (O2) was determined and refined freely based on the Fourier Map. Other hydrogen atoms were calculated geometrically and refined using the riding model.
- the calculated XRPD pattern was generated for Cu radiation using Mercwy program (Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., Taylor, R., Towler, M. & van de Streek, J. J. Appl. Cryst. 2006, 39, 453-457) and the atomic coordinates, space group, and unit cell parameters from the single crystal structure.
- the crystal structure representations were generated by Olex2 and Diamond (Brandenburg, K. DIAMOND, 1999, Crystal Impact GbR, Bonn, Germany).
- the thermal ellipsoids drawing was generated by ORTEP-III (L. J. Farrugia. J. Appl. Cryst. 2012, 45, 849-854).
- a suitable single crystal was separated and selected out from the block-like crystals and selected for single-crystal x-ray diffraction data collection.
- the crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P21/n. Crystallographic data and refinement parameters are shown in Table 18.
- the asymmetric unit of the single crystal structure was comprised of one neutral Formula (II) molecule and one neutral benzoic acid molecule, which indicated that the crystal is a benzoic acid cocrystal of Formula (II).
- the salicylic acid cocrystal from experiment 29 in Table 17 was analyzed via XRPD and 1 H NMR analysis using the aforementioned conditions.
- the resulting XRPD and 1 H NMR patterns are shown in FIGS. 33 - 34 , respectively.
- the obtained solid material was determined to be a salicylic acid cocrystal and was named crystalline Form 9.
- a suitable single crystal with good diffraction quality was selected out from the rod-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant).
- the crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 184 K.
- Preliminary examination and data collection were performed on a Bruker D8 Venture (METALJET Ga X-ray source, PHOTON II) diffractometer and analyzed with the APEX3 software package.
- Cell parameters and an orientation matrix for data collection were retrieved and refined by SAINT (Version: 8.37A) software using the setting angles of 9918 reflections in the range 3.2520 ⁇ 54.786°.
- the data were collected to a minimum diffraction angle ( ⁇ ) of 3.506° and a maximum diffraction angle ( ⁇ ) of 55.323° at 184 K.
- the completeness is 99.84%.
- the mean 1/ ⁇ of the data is 13.0 and the highest resolution is truncated at 0.82 ⁇ .
- the structure was solved in the space group P2 1 /c with the ShelXT 1 structure solution program using Intrinsic Phasing and refined with ShelXL 2 (Version 2018/3) refinement package using full-matrix least-squares on F 2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically.
- the hydrogen atoms (H2) connected with the oxygen atoms (O2) was determined and refined freely based on the Fourier Map. Other hydrogen atoms were calculated geometrically and refined using the riding model.
- the calculated XRPD pattern was generated for Cu radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure.
- the crystal structure representations were generated by Olex2 and Diamond.
- a suitable single crystal was separated and selected out from the block-like crystals and selected for single-crystal x-ray diffraction data collection.
- the crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P2 1 /c. Crystallographic data and the refinement parameters are listed in Table 19.
- the asymmetric unit of the single crystal structure was comprised of one neutral Formula (II) molecule and a neutral salicylic acid molecule, which indicated that the crystal is a salicylic acid cocrystal of Formula (II).
- the PK studies consisted of single dose oral exposure studies, which were conducted in female NOD/SCID mice (approximately 6 to 8 weeks, and 20-30 g at the time of study) using a compound dose of 300 mg/kg and a dosing volume of 10 mL/kg. The mice were fasted overnight prior to dosing. Animals had free access to food and water post-dosing.
- Blood was sampled serially from the dorsal metatarsal vein at pre-dose, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post PO dosing. Approximately 0.03 mL blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4° C. to provide plasma. The plasma samples were then stored in a freezer at ⁇ 75 ⁇ 15° C. prior to LC-MS/MS analysis.
- PK Concentrations of compound in the plasma samples were then analyzed using an LC-MS/MS method. WinNonlin (PhoenixTM, version 6.1) or other similar software was used for PK calculations. The following PK parameters were calculated, whenever possible from the plasma concentration versus time data: C max , T max , T 1/2 , AUC inf , and AUC last . The PK data were described using descriptive statistics such as mean with standard deviation.
- mice of an age between 6-8 weeks and a body weight range of 18-22 g were purchased from Beijing Anikeeper Biotech Co, Ltd. Animals were habituated to the environment for at least 7 days prior to study initiation. Mice were dosed with Crystalline Form 2 at either 100 mg/kg or 300 mg/kg dose levels via oral gavage for 28 days. After 24 hours following 27 doses of compound, three mice were euthanized via CO 2 . After four hours following 28 doses of compound, three mice were euthanized via CO 2 . At each time point the whole brain was collected. In addition, approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000G for 5 minutes at 4° C. to provide plasma.
- Rats Male and female Sprague Dawley rats were purchased from Beijing Anikeeper Biotech Co, Ltd. Animals were habituated to the environment prior to study initiation. Rats were dosed with single dose of 100 mg/kg crystalline Form 2 via oral gavage. The rats were fasted overnight prior to dosing. Animals had access to food from 2 hours post dose and free access to water throughout the study. Approximately 0.2 mL of blood was sampled via jugular vein at each time point and centrifuged at 4000G for 5 minutes at 4° C. to provide plasma. Samples were then stored in a freezer at ⁇ 75 ⁇ 15° C. prior to LC-MS/MS analysis. Whole brain was collected after hemoperfusion and snap frozen on dry ice prior to storage at ⁇ 75 ⁇ 15° C.
Abstract
Description
- This application claims the priority benefit of U.S. Provisional Application No. 63/107,765, filed Oct. 30, 2020, which is hereby incorporated by reference herein in its entirety.
- The present disclosure relates to solid state forms of substituted pyrazolopyrimidines, pharmaceutical compositions thereof, methods of treating cancer by administering one or more solid state forms of substituted pyrazolopyrimidines, and methods for preparing solid state forms of substituted pyrazolopyrimidines.
- Substituted pyrazolopyrirmidines, such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) are inhibitors of ubiquitin-specific-processing protease 1 (USP1).
- Not all compounds that are USP1 inhibitors have characteristics affording the best potential to become useful therapeutics. Some of these characteristics include high affinity at the USP1, duration of USP1 deactivation, oral bioavailability, solubility, and stability (e.g., ability to formulate, ability to crystallize, or shelf life). Favorable characteristics can lead to improved safety, tolerability, efficacy, therapeutic index, patient compliance, cost efficiency, manufacturing ease, etc.
- In addition, the isolation and commercial-scale preparation of solid state forms of substituted pyrazolopyrimidines, such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) and corresponding pharmaceutical formulations having acceptable solid state properties (including chemical stability, thermal stability, solubility, hygroscopicity, and/or particle size), compound manufacturability (including yield, impurity rejection during crystallization, filtration properties, drying properties, and milling properties), and formulation feasibility (including stability with respect to pressure or compression forces during tableting) present a number of challenges.
- Accordingly, there is a current need for one or more solid state forms of substituted pyrazolopyrimidines, such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) that have an acceptable balance of these properties and can be used in the preparation of pharmaceutically acceptable solid dosage forms.
- In one aspect, the present disclosure relates to a solid state form of a compound of Formula (T):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R is C1-3 alkyl; and
- X1 and X2 are independently selected from the group consisting of N and C.
- In some embodiments, the solid state form is a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the solid state form is a crystalline form of a compound of Formula (II). In some embodiments, the crystalline form is a hydrate, anhydrate, or solvate thereof. In some embodiments, the solvate is a dichloromethane solvate.
- In some embodiments, the solid state form is an amorphous form of a compound of Formula (II). In some embodiments, the amorphous form is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the solid state form of a compound of Formula (II) is selected from the group consisting of:
-
- a) crystalline Form A, wherein Form A is characterized by an XRPD pattern having peaks at 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta;
- b) crystalline Form C, wherein Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, and 19.1±0.2 degrees two theta;
- c) crystalline Form D, wherein Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, and 19.3±0.2 degrees two theta;
- d) crystalline Form E, wherein Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 18.7±0.2, and 20.9±0.2 degrees two theta; and
- e) crystalline Form F, wherein Form F is characterized by an XRPD pattern having peaks at 10.7±0.2, 14.3±0.2, and 21.8±0.2 degrees two theta.
- In some embodiments, the solid state form of a compound of Formula (II) is selected from the group consisting of:
-
- a) crystalline Form A, wherein Form A is characterized by an XRPD pattern having peaks at 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta;
- b) crystalline Form C, wherein Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, and 19.1±0.2 degrees two theta;
- c) crystalline Form D, wherein Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, and 19.3±0.2 degrees two theta; and
- d) crystalline Form E, wherein Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 18.7±0.2, and 20.9±0.2 degrees two theta.
- In some embodiments, the solid state form of a compound of Formula (II) is crystalline Form A. In some embodiments, crystalline Form A is characterized by an XRPD pattern as shown in
FIG. 1 . In some embodiments, crystalline Form A is characterized by an endothermic peak at about 165° C., as determined by DSC. In some embodiments, crystalline Form A is characterized by a DSC profile as shown inFIG. 2 . In some embodiments, crystalline Form A is characterized by an about 0.93 wt % loss between room temperature and about 150° C., as determined by TGA. In some embodiments, crystalline Form A is characterized by a TGA profile as shown inFIG. 2 . - In some embodiments, crystalline Form A is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 1 ; b) a DSC profile as shown inFIG. 2 ; or c) a TGA profile as shown inFIG. 2 . - In some embodiments, crystalline Form A is substantially free of other polymorphic forms. In some embodiments, crystalline Form A has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- In some embodiments, crystalline Form A has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form A has a unit cell with an a value of about 12.054 Å, a b value of about 8.775 Å, and a c value of about 24.837 Å. In some embodiments, crystalline Form A has a unit cell with a volume of about 2603.68 Å3.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form A and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form A as compared to other solid state forms of a compound of Formula (II). The compositions of mixtures of solid state forms disclosed herein can be determined using methods known in the art (see, for example, Varasteh, M., et al., Int. J. Pharm. 366(1-2): 74-81 (2009)).
- In some embodiments, the solid state form of a compound of Formula (II) is crystalline Form C. In some embodiments, crystalline Form C is characterized by an XRPD pattern as shown in
FIG. 3 . - In some embodiments, crystalline Form C is substantially free of other polymorphic forms. In some embodiments, crystalline Form C has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form C and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form C as compared to other solid state forms of a compound of Formula (II).
- In some embodiments, the solid state form of a compound of Formula (II) is crystalline Form D. In some embodiments, crystalline Form D is characterized by an XRPD pattern as shown in
FIG. 4 . - In some embodiments, crystalline Form D is substantially free of other polymorphic forms. In some embodiments, crystalline Form D has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form D and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form D as compared to other solid state forms of a compound of Formula (II).
- In some embodiments, the solid state form of a compound of Formula (II) is crystalline Form E. In some embodiments, crystalline Form E is characterized by an XRPD pattern as shown in
FIG. 5 . In some embodiments, crystalline Form E is characterized by an endothermic peak at about 107° C., as determined by DSC. In some embodiments, crystalline Form E is characterized by a DSC profile as shown inFIG. 6 . In some embodiments, crystalline Form E is characterized by an about 13.5 wt % loss between room temperature and about 200° C., as determined by TGA. In some embodiments, crystalline Form E is characterized by a TGA profile as shown inFIG. 6 . - In some embodiments, crystalline Form E is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 5 ; b) a DSC profile as shown inFIG. 6 ; or c) a TGA profile as shown inFIG. 6 . - In some embodiments, crystalline Form E is substantially free of other polymorphic forms. In some embodiments, crystalline Form E has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form E and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form E as compared to other solid state forms of a compound of Formula (II).
- In some embodiments, the solid state form of a compound of Formula II is crystalline Form F. In some embodiments, crystalline Form F is characterized by an XRPD pattern as shown in
FIG. 25 . In some embodiments, crystalline Form F is characterized by an endothermic peak at about 157° C., as determined by DSC. In some embodiments, crystalline Form F is characterized by a DSC profile as shown inFIG. 26 . - In some embodiments, crystalline Form F is characterized by at least one of the following: a) an XRPD pattern as shown in
FIG. 25 ; or b) a DSC profile as shown inFIG. 26 . - In some embodiments, crystalline Form F is substantially free of other polymorphic forms. In some embodiments, crystalline Form F has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or least 95%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form F and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form F as compared to other solid state forms of a compound of Formula (II).
- In some embodiments, the solid state form of a compound of Formula (II) is a pharmaceutically acceptable salt of a compound of Formula (II).
- In some embodiments, a pharmaceutically acceptable salt is formed between a compound of Formula (II) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, gallic acid ethyl ester, 4-hydroxybenzoic acid, 4-hydroxybenzoic acid methyl ester, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments the pharmaceutically acceptable acid is benzoic acid. In some embodiments the pharmaceutically acceptable acid is salicylic acid. In some embodiments the pharmaceutically acceptable acid is gallic acid.
- In some embodiments, the solid state form of a compound of Formula (II) is a crystalline form of a pharmaceutically acceptable salt of a compound of Formula (II). In some embodiments, the crystalline form of the pharmaceutically acceptable salt is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the solid state form of a compound of Formula (II) is an amorphous form of a pharmaceutically acceptable salt of a compound of Formula (II). In some embodiments, the amorphous form of the pharmaceutically acceptable salt is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the pharmaceutically acceptable salt of a compound of Formula (II) is a hydrochloric acid salt. In some embodiments, the hydrochloric acid salt is
crystalline Form 1 characterized by an XRPD pattern having peaks at 12.5±0.2, 22.4±0.2, and 23.9±0.2 degrees two theta. In some embodiments, the hydrochloric acid salt is characterized by an XRPD pattern as shown inFIG. 7 . In some embodiments, the hydrochloric acid salt is characterized by an endothermic peak at about 142.1° C., as determined by DSC. In some embodiments, the hydrochloric acid salt is characterized by a DSC profile as shown inFIG. 8 . In some embodiments, the hydrochloric acid salt is characterized by an about 4.04 wt % loss between about 30° C. and about 100° C., as determined by TGA. In some embodiments, the hydrochloric acid salt is characterized by a TGA profile as shown inFIG. 8 . - In some embodiments,
crystalline Form 1 is characterized by at least two of the following: a) an XRPD pattern as shown inFIG. 7 ; b) a DSC profile as shown inFIG. 8 ; or c) a TGA profile as shown inFIG. 8 . - In some embodiments,
crystalline Form 1 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 1 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority ofcrystalline Form 1 as compared to other solid state forms of a compound of Formula (II). - In some embodiments, the solid state form of a compound of Formula (II) is a pharmaceutically acceptable co-crystal of a compound of Formula (II) and a second pharmaceutically acceptable compound.
- In some embodiments, a pharmaceutically acceptable co-crystal is formed between a compound of Formula (II) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, gallic acid ethyl ester, 4-hydroxybenzoic acid, 4-hydroxybenzoic acid methyl ester, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments the pharmaceutically acceptable acid is gallic acid.
- In some embodiments, the pharmaceutically acceptable co-crystal of a compound of Formula (II) is a gentisic acid co-crystal. In some embodiments, the gentisic acid co-crystal is
crystalline Form 2 characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7:0.2, and 22.5:0.2 degrees two theta. In some embodiments, the gentisic acid co-crystal is characterized by an XRPD pattern as shown inFIG. 9 . In some embodiments, the gentisic acid co-crystal is characterized by an endothermic peak at about 186.0° C., as determined by DSC. In some embodiments, the gentisic acid co-crystal is characterized by a DSC profile as shown inFIG. 10 . In some embodiments, the gentisic acid co-crystal is characterized by an about 3.17 wt % loss between room temperature and about 170° C., as determined by TGA. In some embodiments, the gentisic acid co-crystal is characterized by a TGA profile as shown inFIG. 10 . - In some embodiments,
crystalline Form 2 is characterized by at least two of the following: a) an XRPD pattern as shown inFIG. 9 ; b) a DSC profile as shown inFIG. 10 ; or c) a TGA profile as shown inFIG. 10 . - In some embodiments,
crystalline Form 2 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 2 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%. - In some embodiments,
crystalline Form 2 has a unit cell that indexes as monoclinic. In some embodiments,crystalline Form 2 has a unit cell with an a value of about 11.113 Å, a b value of about 12.356 Å, and a c value of about 24.048 Δ. In some embodiments,crystalline Form 2 has a unit cell with a volume of about 3223.93 Δ3. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 2 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority ofcrystalline Form 2 as compared to other solid state forms of a compound of Formula (II). - In some embodiments, the pharmaceutically acceptable co-crystal of a compound of Formula (II) is a benzoic acid co-crystal. In some embodiments, the benzoic acid co-crystal is
crystalline Form 8 characterized by an XRPD pattern having peaks at 12.1±0.2, 14.2±0.2, and 16.5±0.2 degrees two theta. In some embodiments, the benzoic acid co-crystal is characterized by an XRPD pattern as shown inFIG. 29 . In some embodiments, the benzoic acid co-crystal is characterized by an endothermic peak at about 105° C., as determined by DSC. In some embodiments, the benzoic acid co-crystal is characterized by a DSC profile as shown inFIG. 30 . - In some embodiments, the benzoic acid cocrystal is characterized by an about 18.8% wt loss between about 120° C. and 300° C. In some embodiments, the benzoic acid co-crystal is characterized by a TG-FTIR profile as shown in
FIG. 31 . - In some embodiments,
crystalline Form 8 is characterized by at least two of the following: a) an XRPD pattern as shown inFIG. 29 ; b) a DSC profile as shown inFIG. 30 ; or c) a TG-FTIR profile as shown inFIG. 31 . - In some embodiments,
crystalline Form 8 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 8 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%. - In some embodiments,
crystalline Form 8 has a unit cell that indexes as monoclinic. In some embodiments,crystalline Form 8 has a unit cell with an a value of about 10.61070(10) Å, a b value of about 12.39940(10) Å, and a c value of about 24.15170(10) Å. In some embodiments,crystalline Form 8 has a unit cell with a volume of about 3114.74(4) Å3. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 8 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority ofcrystalline Form 8 as compared to other solid state forms of a compound of Formula (II). - In some embodiments, the pharmaceutically acceptable co-crystal of a compound of Formula (II) is a salicylic acid co-crystal. In some embodiments, the salicylic acid co-crystal is
crystalline Form 9 characterized by an XRPD pattern having peaks at 11.0±0.2, 16.5±0.2, 17.3±0.2 and 25.3±0.2 degrees two theta. In some embodiments, the salicylic acid co-crystal is characterized by an XRPD pattern as shown inFIG. 33 . In some embodiments, the salicylic acid co-crystal is characterized by an 1H NMR spectrum as shown inFIG. 34 . - In some embodiments,
crystalline Form 9 is characterized by at least one of the following: a) an XRPD pattern as shown inFIG. 33 ; or b) an 1H NMR profile as shown inFIG. 34 . - In some embodiments,
crystalline Form 9 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 9 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%. - In some embodiments,
crystalline Form 9 has a unit cell that indexes as monoclinic. In some embodiments,crystalline Form 9 has a unit cell with an a value of about 10.8387(11) Å, a b value of about 12.3761(12) Å, and a c value of about 24.242(2) Å. In some embodiments,crystalline Form 9 has a unit cell with a volume of about 3173.1(5) 3. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 9 and a second solid state form of a compound of Formula (II). In some embodiments, the present disclosure relates to a mixture comprising a majority ofcrystalline Form 9 as compared to other solid state forms of a compound of Formula (II). - In some embodiments, the solid state form is a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the solid state form is a crystalline form of a compound of Formula (III). In some embodiments, the crystalline form is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the solid state form is an amorphous form of a compound of Formula (III). In some embodiments, the amorphous form is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the solid state form of a compound of Formula (III) is selected from the group consisting of:
-
- a) crystalline Form A1, wherein Form A1 is characterized by an XRPD pattern having peaks at 16.1±0.2, 16.7±0.2, and 24.8±0.2 degrees two theta; and
- b) crystalline Form B1, wherein Form B1 is characterized by an XRPD pattern having peaks at 12.9±0.2, 14.5±0.2, and 22.6±0.2 degrees two theta.
- In some embodiments, the solid state form of a compound of Formula (III) is crystalline Form A1. In some embodiments, crystalline Form A1 is characterized by an XRPD pattern as shown in
FIG. 11 . In some embodiments, crystalline Form A1 is characterized by an endothermic peak at about 150.5° C., as determined by DSC. In some embodiments, crystalline Form A1 is characterized by a DSC profile as shown inFIG. 12 In some embodiments, crystalline Form A1 is characterized by an about 0.95 wt % loss between room temperature and about 120° C., as determined by TGA. In some embodiments, crystalline Form A1 is characterized by a TGA profile as shown inFIG. 12 . - In some embodiments, crystalline Form A1 is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 11 ; b) a DSC profile as shown inFIG. 12 ; or c) a TGA profile as shown inFIG. 12 . - In some embodiments, crystalline Form A1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form A1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- In some embodiments, crystalline Form A1 has a unit cell that indexes as monoclinic. In some embodiments, crystalline Form A1 has a unit cell with an a value of about 12.545 Å, a b value of about 8.640 Å, and a c value of about 21.660 Å. In some embodiments, crystalline Form A1 has a unit cell with a volume of about 2336.13 Å3.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form A1 and a second solid state form of a compound of Formula (III). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form A1 as compared to other solid state forms of a compound of Formula (III).
- In some embodiments, the solid state form of a compound of Formula (III) is crystalline Form B1. In some embodiments, crystalline Form B1 is characterized by an XRPD pattern as shown in
FIG. 13 . In some embodiments, crystalline Form B1 is characterized by an endothermic peak at about 161.2° C., as determined by DSC. In some embodiments, crystalline Form B1 is characterized by a DSC profile as shown inFIG. 14 . In some embodiments, crystalline Form B1 is characterized by an about 1.58 wt % loss between room temperature and about 120° C., as determined by TGA. In some embodiments, crystalline Form B1 is characterized by a TGA profile as shown inFIG. 14 . - In some embodiments, crystalline Form B1 is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 13 ; b) a DSC profile as shown inFIG. 14 ; or c) a TGA profile as shown inFIG. 14 . - In some embodiments, crystalline Form B1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form B1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form B1 and a second solid state form of a compound of Formula (III). In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form B1 as compared to other solid state forms of a compound of Formula (III).
- In some embodiments, the solid state form of a compound of Formula (III) is a pharmaceutically acceptable salt or co-crystal of a compound of Formula (III).
- In some embodiments, a pharmaceutically acceptable salt or co-crystal is formed between a compound of Formula (III) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, gallic acid ethyl ester, 4-hydroxybenzoic acid, 4-hydroxybenzoic acid methyl ester, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.
- In one aspect, the present disclosure relates to a pharmaceutical composition comprising one or more of the solid state forms or mixtures discussed above and one or more pharmaceutically acceptable carriers or diluents.
- In another aspect, the present disclosure relates to a solid dosage form comprising one or more of the solid state forms or mixtures discussed above.
- In another aspect, the present disclosure relates to a method for treating cancer comprising administering one or more of the solid state forms, mixtures, pharmaceutical compositions, or solid dosage forms discussed above to a patient in need thereof.
- In another aspect, the present disclosure relates to a use of one or more of the solid state forms, mixtures, pharmaceutical compositions, or solid dosage forms discussed above for the manufacture of a medicament for treating cancer.
- In another aspect, the present disclosure relates to one or more of the solid state forms, mixtures, pharmaceutical compositions, or solid dosage forms discussed above for use in a method for treating cancer.
- In another aspect, the present disclosure relates to a method for preparing crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- the method comprising:
-
- a) dissolving a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid in a suitable amount of a suitable solvent at room temperature to make a solution;
- b) adding a suitable amount of a suitable anti-solvent;
- c) adding seed crystals of
crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II); - d) stirring the resulting suspension; and
- e) collecting the solid product produced from step d).
- In some embodiments, the method for preparing
crystalline Form 2 of a gentisic acid co-crystal of a compound of Formula (II) further comprises adding a suitable anti-solvent after step c) and before step d). - In some embodiments, the suitable solvent is ethyl acetate.
- In some embodiments, the suitable anti-solvent is n-heptane.
- In another aspect, the present disclosure relates to a method for preparing
crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II), the method comprising: -
- a) adding a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid to a suitable amount of a suitable solvent system at room temperature to obtain a suspension;
- b) stirring the suspension from step a);
- c) collecting the solid product produced from step b).
- In some embodiments, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
- In another aspect, the present disclosure relates to
Crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods discussed above. -
FIG. 1 is a powder X-ray diffraction pattern (“XRPD”) corresponding to crystalline Form A. -
FIG. 2 is a differential scanning calorimetry thermogram (“DSC”) and a thermogravimetric analysis thermogram (“TGA”) corresponding to crystalline Form A. -
FIG. 3 is an XRPD pattern corresponding to crystalline Form C. -
FIG. 4 is an XRPD pattern corresponding to crystalline Form D. -
FIG. 5 is an XRPD pattern corresponding to crystalline Form E. -
FIG. 6 is a DSC and TGA thermogram corresponding to crystalline Form E. -
FIG. 7 is an XRPD pattern corresponding tocrystalline Form 1. -
FIG. 8 is a DSC and TGA thermogram corresponding tocrystalline Form 1. -
FIG. 9 is an XRPD pattern corresponding tocrystalline Form 2. -
FIG. 10 is a DSC and TGA thermogram corresponding tocrystalline Form 2. -
FIG. 11 is an XRPD pattern corresponding to crystalline Form A1. -
FIG. 12 is a DSC and TGA thermogram corresponding to crystalline Form A11. -
FIG. 13 is an XRPD pattern corresponding to crystalline Form B1. -
FIG. 14 is a DSC and TGA thermogram corresponding to crystalline Form B1. -
FIG. 15 is an XRPD pattern corresponding to crystalline Form 3. -
FIG. 16 is an XRPD pattern corresponding tocrystalline Form 4. -
FIG. 17 is an XRPD pattern corresponding tocrystalline Form 5. -
FIG. 18 is an XRPD pattern corresponding tocrystalline Form 6. -
FIG. 19 is an XRPD pattern corresponding tocrystalline Form 7. -
FIG. 20 is an asymmetric unit of crystalline Form A from a single crystal structure. -
FIG. 21 is an asymmetric unit ofcrystalline Form 2 from a single crystal structure. -
FIG. 22 is an asymmetric unit of crystalline Form A1 from a single crystal structure. -
FIG. 23 is a plasma concentration vs. time profile for crystalline Form A after a 300 mg/kg dose in NOD/SCID mice. -
FIG. 24 is a plasma concentration vs. time profile forcrystalline Form 2 after a 300 mg/kg dose in NOD/SCID mice. -
FIG. 25 is an XRPD pattern corresponding to crystalline Form F. -
FIG. 26 is a DSC thermogram corresponding to crystalline Form F. -
FIG. 27 is an XRPD pattern corresponding to crystalline Form C. -
FIG. 28 is a Raman spectrum corresponding to crystalline Form C. -
FIG. 29 is an XRPD pattern corresponding tocrystalline Form 8. -
FIG. 30 is a DSC thermogram corresponding tocrystalline Form 8. -
FIG. 31 is a TG-FTIR thermogram corresponding tocrystalline Form 8. -
FIG. 32 is an asymmetric unit ofcrystalline Form 8 from a single crystal structure. -
FIG. 33 is an XRPD pattern corresponding tocrystalline Form 9. -
FIG. 34 1H NMR spectrum corresponding tocrystalline Form 9. -
FIG. 35 is an asymmetric unit ofcrystalline Form 9 from a single crystal structure. -
FIG. 36 is a plasma concentration vs. time profile forcrystalline Form 8 after 300 mg/kg dose in NOD/SCID mice. -
FIG. 37 is a brain and plasma concentration vs. time profile forcrystalline Form 2 after 100 and 300 mg/kg QD repeated oral dose in NOD/SCID female mice. -
FIG. 38 is a brain and plasma concentration vs. time profile forcrystalline Form 2 after 100 mg/kg oral dose in SD male and female rats. - To facilitate understanding of the disclosure set forth herein, a number of terms are defined below.
- Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
- The characterizing data for XRPD, DSC, and TGA that is referenced throughout the application and claims are determined using the instruments and conditions specified at the beginning of the Examples section under the subheading “Instrumental Conditions.”
- In this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. The terms “a” (or “an”), as well as the terms “one or more,” and “at least one” can be used interchangeably herein. In certain aspects, the term “a” or “an” means “single.” In other aspects, the term “a” or “an” includes “two or more” or “multiple.”
- Furthermore, “and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following aspects; A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
- The term “Compound of Formula (I)” refers to a compound encompassed within the structure below:
-
- or a pharmaceutically acceptable salt thereof,
- wherein R is CI-3 alkyl; and
- X1 and X2 are independently selected from the group consisting of N and C.
- In some embodiments, R can be selected from methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.
- The term “Compound of Formula (II)” refers to 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine having the structure below:
- The term “Compound of Formula (III)” refers to 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine having the structure below:
- The term “subject” refers to an animal, including, but not limited to, a primate (e.g., human), cow, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms “subject” and “patient” are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject.
- The terms “treat,” “treating,” and “treatment” are meant to include approaches for obtaining beneficial or desired clinical results. “Treatment” as used herein, covers any administration or application of a therapeutic for disease in a mammal, including a human. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, any one or more of alleviation of one or more symptoms, diminishment of extent of disease, preventing or delaying spread (for example, metastasis) of disease, preventing or delaying recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, and remission (whether partial or total). Also encompassed by “treatment” is a reduction of pathological consequence of a proliferative disease. The methods provided herein contemplate any one or more of these aspects of treatment. In-line with the above, the term treatment does not require one-hundred percent removal of all aspects of the disorder.
- In the context of cancer, the terms “treat,” “treating,” and “treatment” include, but are not limited to, inhibiting growth of cancer cells, inhibiting replication of cancer cells, lessening of overall tumor burden, and delaying, halting, or slowing tumor growth, progression, or metastasis.
- As used herein, the terms “cancer” and “tumor” refer to or describe the physiological condition in mammals in which a population of cells are characterized by unregulated cell growth. The terms encompass solid and hematological/lymphatic cancers. Examples of cancer include but are not limited to, DNA repair pathway deficient cancers and homologous recombination deficiency (HRD) cancers. Additional examples of cancer include, but are not limited to, ovarian cancer, breast cancer (including triple negative breast cancer), non-small cell lung cancer (NSCLC), and osteosarcoma. The cancer can be BRCA1 and/or BRCA2 wildtype. The cancer can also be BRCA1 and/or BRCA2 mutant. The cancer can further be a PARP inhibitor refractory or resistant cancer, or a PARP inhibitor refractory or resistant BRCA1 or BRCA2-mutant cancer.
- The term “disease” or “condition” or “disorder” as used herein refers to a condition where treatment is needed and/or desired and denotes disturbances and/or anomalies that as a rule are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and/or malfunctions. As demonstrated below, Compounds of the Disclosure can be used in treating diseases and conditions such as proliferative diseases like cancer.
- A “therapeutically effective amount” of a substance can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the substance are outweighed by the therapeutically beneficial effects. A therapeutically effective amount can be delivered in one or more administrations. A therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic effect.
- The terms “administer,” “administering,” “administration,” and the like refer to methods that can be used to enable delivery of the therapeutic agent to the desired site of biological action. Administration techniques that can be employed with the agents and methods described herein are found in e.g., Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.
- The terms “pharmaceutical formulation” and “pharmaceutical composition” refer to a preparation which is in such form as to permit the biological activity of the active ingredient(s) to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. Such formulations may be sterile.
- The terms “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” “physiologically acceptable carrier,” or “physiologically acceptable excipient” refer to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. The pharmaceutically acceptable carrier is appropriate for the formulation employed. In one embodiment, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio. See Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins: Philadelphia, P A, 2005; Handbook of Pharmaceutical Excipients, 5th Edition, Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Handbook of Pharmaceutical Additives, 3rd Edition, Ash and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca Raton, F L, 2004 (incorporated herein by reference).
- The term “about,” as used herein, includes the recited number ±10%. Thus, “about 10” means 9 to 11. As is understood by one skilled in the art, reference to “about” a value or parameter herein includes (and describes) instances that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.”
- The terms “active ingredient” and “active substance” refer to a compound, which is administered, alone or in combination with one or more pharmaceutically acceptable excipients, to a subject for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease. As used herein, “active ingredient” and “active substance” may be an optically active isomer of a compound described herein.
- The terms “drug,” “therapeutic agent,” and “chemotherapeutic agent” refer to a compound, or a pharmaceutical composition thereof, which is administered to a subject for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease.
- The term “solvate” refers to a compound provided herein or a salt thereof, which further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate. Where the solvent includes ethanol, the compound can be an ethanol solvate.
- The term “polymorph” as used herein refers to a crystalline form of a compound or a salt, hydrate, or solvate thereof, in a particular crystal packing arrangement. All polymorphs have the same elemental composition. The term “crystalline,” as used herein, refers to a solid state form which consists of orderly arrangement of structural units. Different crystalline forms of the same compound, or a salt, co-crystal, hydrate, or solvate thereof, arise from different packing of the molecules in the solid state, which results in different crystal symmetries and/or unit cell parameter. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA, 173 (1990); The United States Pharmacopeia, 23rd ed., 1843-1844 (1995) (incorporated herein by reference).
- Crystalline forms are most commonly characterized by X-ray powder diffraction (XRPD). An XRPD pattern of reflections (peaks, typically expressed in degrees 2-theta) is commonly considered a fingerprint of a particular crystalline form. The relative intensities of the XRPD peaks can widely vary depending on, inter alia, the sample preparation technique, crystal size distribution, filters, the sample mounting procedure, and the particular instrument employed. In some instances, new peaks may be observed or existing peaks may disappear, depending on the type of instrument or the settings. In some instances, any particular peak in an XRPD pattern may appear as a singlet, doublet, triplet, quartet, or multiplet, depending on the type of instrument or the settings, the sensitivity of the instrument, measuring conditions, and/or purity of the crystalline form. In some instances, any particular peak in an XRPD may appear in a symmetric shape or in an asymmetric shape, e.g., having a shoulder. A skilled artisan understanding these variations is capable of discriminating or ascertaining the defining features or characteristics of a particular crystal form using XRPD, as well as using other known physicochemical techniques.
- The term “amorphous” as applied to a compound refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterized by a change of state, typically second order (“glass transition”).
- The term “anhydrate” as applied to a compound refers to a solid state wherein the compound contains no structural water within the crystal lattice.
- Unless the context requires otherwise, the terms “comprise,” “comprises,” and “comprising” are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that Applicant intends each of those words to be so interpreted in construing this patent, including the claims below.
- The present disclosure relates to solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III). As with all pharmaceutical compounds and compositions, the chemical and physical properties of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III) are important in their commercial development. These properties include, but are not limited to: (1) packing properties such as molar volume, bulk density and hygroscopicity, (2) thermodynamic properties such as melting temperature, vapor pressure and solubility, (3) kinetic properties such as dissolution rate and stability (including stability at ambient conditions, especially to moisture and under storage conditions), (4) surface properties such as surface area, wettability, interfacial tension and shape, (5) mechanical properties such as hardness, tensile strength, compactibility, handling, flow and blend; and (6) filtration properties. These properties can affect, for example, the processing and storage of the compounds and pharmaceutical compositions comprising the compounds.
- Solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III) that improve upon one or more of these properties relative to other solid state forms of the compounds are desirable. Isolating pharmaceutically acceptable solid state forms of the compounds that can be manufactured and formulated on a commercial-scale has been a challenge.
- In one aspect, the present disclosure relates to a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the solid state form is an amorphous form of a compound of Formula (II). In some embodiments, the amorphous form is a hydrate, anhydrate, or solvate thereof. In some embodiments, the amorphous form is substantially free of other polymorphic forms.
- In some embodiments, the present disclosure relates to a mixture comprising a majority of the amorphous form as compared to other solid state forms of a compound of Formula (II). In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In some embodiments, the solid state form is a crystalline form of a compound of Formula (II). In some embodiments, the crystalline form is a hydrate, anhydrate, or solvate thereof. In some embodiments, the solvate is a dichloromethane solvate.
- In some embodiments, the solid state form of a compound of Formula (II) is selected from the group consisting of:
-
- a) crystalline Form A, wherein Form A is characterized by an XRPD pattern having peaks at 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta;
- b) crystalline Form C, wherein Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, and 19.1±0.2 degrees two theta;
- c) crystalline Form D, wherein Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, and 19.3±0.2 degrees two theta;
- d) crystalline Form E, wherein Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 18.7±0.2, and 20.9±0.2 degrees two theta; and
- (e) crystalline Form F, wherein Form F is characterized by an XRPD pattern having peaks at 10.7±0.2, 14.3±0.2, and 21.8±0.2 degrees two theta.
- In some embodiments, the solid state form of a compound of Formula (II) is selected from the group consisting of:
-
- a) crystalline Form A, wherein Form A is characterized by an XRPD pattern having peaks at 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta;
- b) crystalline Form C, wherein Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, and 19.1±0.2 degrees two theta;
- c) crystalline Form D, wherein Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, and 19.3±0.2 degrees two theta; and
- d) crystalline Form E, wherein Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 18.7±0.2, and 20.9±0.2 degrees two theta.
- In some embodiments, the solid state form is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II). In some embodiments, the pharmaceutically acceptable salt is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and a pharmaceutically acceptable acid.
- In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, gallic acid ethyl ester, 4-hydroxybenzoic acid, 4-hydroxybenzoic acid methyl ester, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, the pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, the pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.
- In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is an amorphous form. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a crystalline form.
- In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-m ethoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrochloric acid salt. In some embodiments, the hydrochloric acid salt is
crystalline Form 1 characterized by an XRPD pattern having peaks at 12.5±0.2, 22.4±0.2, and 23.9±0.2 degrees two theta. In some embodiments, the hydrochloric acid salt iscrystalline Form 1 characterized by an XRPD pattern as shown inFIG. 7 . - In some embodiments, the hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is crystalline Form 3 characterized by an XRPD pattern as shown in
FIG. 15 . - In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrobromic acid salt. In some embodiments, the hydrobromic acid salt is
crystalline Form 4 characterized by an XRPD pattern as shown inFIG. 16 . - In some embodiments, the hydrobromic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is
crystalline Form 5 characterized by an XRPD pattern as shown inFIG. 17 . - In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is an ethanedisulfonic acid salt. In some embodiments, the ethanedisulfonic acid salt is
crystalline Form 6 characterized by an XRPD pattern as shown inFIG. 18 . - In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a methanesulfonic acid salt. In some embodiments, the methanesulfonic acid salt is
crystalline Form 7 characterized by an XRPD pattern as shown inFIG. 19 . - In some embodiments, the solid state form is a pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (H) and a second pharmaceutically acceptable compound. In some embodiments, the second pharmaceutically acceptable compound is a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable co-crystal is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and a pharmaceutically acceptable acid.
- In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, gallic acid ethyl ester, 4-hydroxybenzoic acid, 4-hydroxybenzoic acid methyl ester, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, the pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, the pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments the, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.
- In some embodiments, the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a gentisic acid co-crystal. In some embodiments, the gentisic acid co-crystal is
crystalline Form 2 characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7±0.2, and 22.5±0.2 degrees two theta. - In some embodiments, the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a benzoic acid co-crystal. In some embodiments, the benzoic acid co-crystal is
crystalline Form 8 characterized by an XRPD pattern having peaks at 12.1±0.2, 14.2±0.2, and 16.5±0.2 degrees two theta. - In some embodiments, the pharmaceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) is a salicylic acid co-crystal. In some embodiments, the salicylic acid co-crystal is
crystalline Form 9 characterized by an XRPD pattern substantially as shown inFIG. 33 . - The sections below discuss solid state forms of a compound of Formula (II) that have been identified and selected properties of those solid state forms.
- In one aspect, the present disclosure relates to crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments, crystalline Form A is a 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrate.
- In some embodiments, the melting point of crystalline Form A is about 165° C.
- In some embodiments, crystalline Form A is characterized by an XRPD pattern having peaks at 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form A is characterized by an XRPD pattern having peaks at 7.1±0.2, 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form A is characterized by an XRPD pattern having peaks at 7.1±0.2, 14.3±0.2, 19.1±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form A is characterized by an XRPD pattern having peaks at 7.1±0.2, 14.3±0.2, 15.2±0.2, 19.1 0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form A is characterized by an XRPD pattern substantially as shown in
FIG. 1 . - In some embodiments, crystalline Form A is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 1 below.
-
TABLE 1a Selected XRPD Peaks for Crystalline Form A Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 7.14 12.39 4.09 14.29 6.20 100.00 15.20 5.83 5.85 17.08 5.19 5.08 19.13 4.64 7.52 21.49 4.13 26.71 21.80 4.08 20.57 -
TABLE 1b XRPD Peaks for Crystalline Form A Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 7.14 12.39 4.09 10.64 8.32 1.01 14.29 6.20 100.00 15.20 5.83 5.85 15.80 5.61 3.61 17.08 5.19 5.08 17.74 5.00 0.83 19.13 4.64 7.52 19.84 4.48 2.39 21.49 4.13 26.71 21.80 4.08 20.57 23.78 3.74 1.78 24.47 3.64 3.29 25.00 3.56 1.42 28.82 3.10 1.11 - In some embodiments, crystalline Form A is characterized by an endothermic peak at from about 162° C. to about 168° C., or from about 163° C. to about 167° C., or from about 164° C. to about 166° C., as determined by DSC. In some embodiments, crystalline Form A is characterized by an endothermic peak at about 165° C., as determined by DSC.
- In some embodiments, crystalline Form A is characterized by a DSC profile substantially as shown in
FIG. 2 . - In some embodiments, crystalline Form A is characterized by from an about 0.88 wt % to an about 0.98 wt % loss between room temperature and about 150° C. In some embodiments, crystalline Form A is characterized by from an about 0.90 wt % to an about 0.96 wt % loss between room temperature and about 150° C. In some embodiments, crystalline Form A is characterized by from an about 0.93 wt % loss between room temperature and about 150° C.
- In some embodiments, crystalline Form A is characterized by a TGA profile substantially as shown in
FIG. 2 . - In some embodiments, crystalline Form A is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 1 ; b) a DSC profile as shown inFIG. 2 ; or c) a TGA profile as shown inFIG. 2 . - In some embodiments, crystalline Form A has a unit cell that indexes as monoclinic.
- In some embodiments, crystalline Form A has a unit cell with an a value of about 12.054 Å, a b value of about 8.775 Å, and a c value of about 24.837 Å. In other embodiments, Form A has a unit cell with a volume of about 2603.68 Å3.
- In some embodiments, crystalline Form A is substantially free of other polymorphic forms. In some embodiments, crystalline Form A has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. In some embodiments, crystalline Form A has a polymorphic purity of at least 80%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form A and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, or
crystalline Form 1, orcrystalline Form 2, orcrystalline Form 8, orcrystalline Form 9. In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form C, or crystalline Form D, or crystalline Form F, orcrystalline Form 1, orcrystalline Form 2. - In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form A as compared to other solid state forms of a compound of Formula (II).
- In one aspect, the present disclosure relates to crystalline Form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments, crystalline Form C is an anhydrate.
- In some embodiments, crystalline Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, and 19.1±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, 19.1±0.2, and 21.5±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, 19.1±0.2, 19.8±0.2, and 21.5±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form C is characterized by an XRPD pattern having peaks at 14.2±0.2, 17.0±0.2, 19.1±0.2, 19.8±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form C is characterized by an XRPD pattern substantially as shown in
FIG. 3 . - In some embodiments, crystalline Form C is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 below.
-
TABLE 2a Select XRPD Peaks for Crystalline Form C Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 13.81 6.41 4.35 14.23 6.22 100.00 14.66 6.04 4.35 15.16 5.85 10.66 15.76 5.62 9.01 16.98 5.22 13.50 17.67 5.02 4.06 19.06 4.66 15.28 19.76 4.49 10.52 21.02 4.23 4.39 21.45 4.14 32.88 21.67 4.10 21.20 21.78 4.08 24.52 23.75 3.75 4.77 24.42 3.65 5.72 24.94 3.57 6.06 -
TABLE 2b XRPD Peaks for Crystalline Form C Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 7.08 12.49 2.69 10.62 8.33 3.56 12.37 7.16 1.58 13.12 6.75 2.06 13.81 6.41 4.35 14.23 6.22 100.00 14.66 6.04 4.35 15.16 5.85 10.66 15.34 5.78 2.88 15.76 5.62 9.01 16.70 5.22 13.50 17.67 5.02 4.06 18.21 4.87 3.14 19.06 4.66 15.28 19.76 4.49 10.52 20.53 4.33 2.48 21.02 4.23 4.39 21.45 4.14 32.88 21.67 4.10 21.20 21.78 4.08 24.52 22.89 3.89 1.96 23.75 3.75 4.77 24.42 3.65 5.72 24.62 3.62 3.59 24.94 3.57 6.06 25.40 3.51 1.50 25.97 3.43 2.00 26.45 3.37 4.00 27.54 3.24 1.77 28.80 3.10 2.79 29.31 3.05 1.84 29.84 2.99 1.17 30.66 2.92 1.57 32.39 2.77 1.12 34.00 2.64 0.94 35.63 2.52 0.60 38.52 2.34 0.42 - In some embodiments, crystalline Form C is substantially free of other polymorphic forms. In some embodiments, crystalline Form C has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89° %, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form C and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form D, or crystalline Form E, or crystalline Form F, or
crystalline Form 1, orcrystalline Form 2, orcrystalline Form 8, orcrystalline Form 9. In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form D, or crystalline Form E, orcrystalline Form 1, orcrystalline Form 2. - In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form C as compared to other solid state forms of a compound of Formula (II).
- In one aspect, the present disclosure relates to crystalline Form D of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments, crystalline Form D is an anhydrate.
- In some embodiments, crystalline Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, and 19.3±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, 16.4±0.2, and 19.3±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, 16.4±0.2, 19.3±0.2, and 20.9±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form D is characterized by an XRPD pattern having peaks at 13.9±0.2, 15.2±0.2, 16.4±0.2, 19.3±0.2, 20.9±0.2, and 21.6±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form D is characterized by an XRPD pattern substantially as shown in
FIG. 4 . - In some embodiments, crystalline Form D is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 below.
-
TABLE 3a Select XRPD Peaks for Crystalline Form D Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 6.91 12.80 6.57 12.20 7.25 4.64 13.88 6.38 100.00 14.38 6.16 4.57 15.19 5.83 22.20 15.84 5.59 7.07 16.07 5.52 5.88 16.38 5.41 17.20 18.25 4.86 8.93 19.32 4.60 23.69 20.71 4.29 15.59 20.90 4.25 19.49 21.35 4.16 4.03 21.64 4.11 27.64 22.59 3.94 5.07 23.24 3.83 10.00 24.95 3.57 4.33 -
TABLE 3b XRPD Peaks for Crystalline Form D Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 6.91 12.80 6.57 9.58 9.23 0.69 10.62 8.33 2.07 12.20 7.25 4.64 12.35 7.17 2.45 13.88 6.38 100.00 14.38 6.16 4.57 15.19 5.83 22.20 15.84 5.59 7.07 16.07 5.52 5.88 16.38 5.41 17.20 17.16 5.17 2.19 17.70 5.01 3.49 18.25 4.86 8.93 19.32 4.60 23.69 20.71 4.29 15.59 20.90 4.25 19.49 21.35 4.16 4.03 21.64 4.11 27.64 22.59 3.94 5.07 23.24 3.83 10.00 24.10 3.69 2.88 24.61 3.62 3.99 24.95 3.57 4.33 25.24 3.53 3.09 25.56 3.49 3.39 26.62 3.35 2.47 27.02 3.30 2.00 28.48 3.13 1.42 28.93 3.09 1.02 29.45 3.03 1.23 30.26 2.95 1.13 30.70 2.91 0.81 32.27 2.77 0.35 35.46 2.53 0.24 - In some embodiments, crystalline Form D is substantially free of other polymorphic forms. In some embodiments, crystalline Form D has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form D and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form E, or crystalline Form F, or
crystalline Form 1, orcrystalline Form 2, orcrystalline Form 8, orcrystalline Form 9. In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form E, orcrystalline Form 1, orcrystalline Form 2. - In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form D as compared to other solid state forms of a compound of Formula (II).
- In one aspect, the present disclosure relates to crystalline Form E of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments, crystalline Form E is a solvate. In some embodiments, crystalline Form E is a dichloromethane solvate.
- In some embodiments, the melting point of crystalline Form E is about 107° C.
- In some embodiments, crystalline Form E is characterized by an XRPD pattern having peaks at 10.6 0.2, 18.7±0.2, and 20.9±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 18.7±0.2, 20.9±0.2, and 21.2±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 16.4±0.2, 18.7±0.2, 20.9±0.2, and 21.2±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form E is characterized by an XRPD pattern having peaks at 10.6±0.2, 16.4±0.2, 18.7±0.2, 20.9±0.2, 21.2±0.2, and 23.9±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form E is characterized by an XRPD pattern substantially as shown in
FIG. 5 . - In some embodiments, crystalline Form E is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 4 below.
-
TABLE 4 XRPD Peaks for Crystalline Form E Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 5.33 16.58 20.28 9.42 9.39 15.99 10.60 8.34 64.75 12.49 7.09 26.42 13.49 6.57 35.86 13.93 6.36 30.40 14.34 6.18 47.06 15.42 5.75 9.76 16.38 5.41 47.43 18.75 4.73 50.46 19.48 4.56 16.14 20.68 4.30 44.67 20.92 4.25 65.86 21.22 4.19 100.00 22.05 4.03 10.01 22.80 3.90 12.60 23.48 3.79 27.14 23.88 3.73 40.90 24.50 3.63 23.90 25.19 3.53 21.50 26.66 3.34 30.19 27.12 3.29 15.91 28.42 3.14 13.00 32.28 2.77 4.56 - In some embodiments, crystalline Form E is characterized by an endothermic peak at from about 102° C. to about 112° C., or from about 104° C. to about 110° C., or from about 106° C. to about 108° C., as determined by DSC. In some embodiments, crystalline Form E is characterized by an endothermic peak at about 107° C., as determined by DSC.
- In some embodiments, crystalline Form E is characterized by a DSC profile substantially as shown in
FIG. 6 . - In some embodiments, crystalline Form E is characterized by from an about 13.0 wt % to an about 14.0 wt % loss between room temperature and about 200° C. In some embodiments, crystalline Form E is characterized by from an about 13.2 wt % to an about 13.8 wt % loss between room temperature and about 200° C. In some embodiments, crystalline Form E is characterized by from an about 13.5 wt % loss between room temperature and about 200° C.
- In some embodiments, crystalline Form E is characterized by a TGA profile substantially as shown in
FIG. 6 . - In some embodiments, crystalline Form E is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 5 ; b) a DSC profile as shown inFIG. 6 ; or c) a TGA profile as shown inFIG. 6 . - In some embodiments, crystalline Form E is substantially free of other polymorphic forms. In some embodiments, crystalline Form E has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form E and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form F, or
crystalline Form 1, orcrystalline Form 2, orcrystalline Form 8, orcrystalline Form 9. In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, orcrystalline Form 1, orcrystalline Form 2. - In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form E as compared to other solid state forms of a compound of Formula (II).
- In one aspect, the present disclosure relates to crystalline Form F of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments, crystalline Form F is an anhydrate.
- In some embodiments, crystalline Form F is characterized by an XRPD pattern having peaks at 10.7±0.2, 14.3±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form F is characterized by an XRPD pattern having peaks at 10.7±0.2, 14.3±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form F is characterized by an XRPD pattern having peaks at 10.7±0.2, 14.3±0.2, 15.8±0.2, 21.5±0.2, and 21.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form F is characterized by an XRPD pattern having peaks at 10.7±0.2, 14.3 0.2, 15.8 0.2, 21.5±0.2, 21.8±0.2, and 25.0±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form F is characterized by an XRPD pattern substantially as shown in
FIG. 25 . - In some embodiments, crystalline Form F is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 5 below.
-
TABLE 5a Select XRPD Peaks for Crystalline Form F Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 10.72 8.23 100.00 12.47 7.10 19.81 13.22 6.70 20.56 13.90 6.37 35.64 14.33 6.18 72.57 14.74 6.01 31.61 15.24 5.81 16.43 15.44 5.74 6.98 15.84 5.59 56.79 17.11 5.18 43.13 17.78 4.99 20.95 18.27 4.85 7.95 19.17 4.63 37.89 19.88 4.47 48.12 20.50 4.33 28.91 21.07 4.22 10.77 21.46 4.14 72.65 21.79 4.08 74.85 22.37 3.98 13.10 22.90 3.88 14.49 23.81 3.74 10.69 24.49 3.64 20.15 25.01 3.56 64.70 25.36 3.51 9.84 26.10 3.41 7.06 26.51 3.36 33.37 27.62 3.23 4.35 28.84 3.10 4.06 29.39 3.04 4.26 29.88 2.99 6.83 30.66 2.92 21.82 32.35 2.77 9.88 33.94 2.64 7.09 40.95 2.20 5.21 -
TABLE 5b XRPD Peaks for Crystalline Form F Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 7.19 12.30 2.62 10.72 8.23 100.00 12.47 7.10 19.81 12.71 6.97 3.80 13.22 6.70 20.56 13.90 6.37 35.64 14.33 6.18 72.57 14.74 6.01 31.61 15.24 5.81 16.43 15.44 5.74 6.98 15.84 5.59 56.79 17.11 5.18 43.13 17.78 4.99 20.95 18.27 4.85 7.95 19.17 4.63 37.89 19.88 4.47 48.12 20.50 4.33 28.91 21.07 4.22 10.77 21.46 4.14 72.65 21.79 4.08 74.85 22.37 3.98 13.10 22.90 3.88 14.49 23.81 3.74 10.69 24.49 3.64 20.15 25.01 3.56 64.70 25.36 3.51 9.84 26.10 3.41 7.06 26.51 3.36 33.37 27.62 3.23 4.35 27.89 3.20 3.24 28.84 3.10 4.06 29.39 3.04 4.26 29.88 2.99 6.83 30.66 2.92 21.82 31.42 2.85 3.23 32.35 2.77 9.88 32.90 2.72 2.67 33.94 2.64 7.09 35.53 2.53 2.42 36.64 2.45 1.59 37.63 2.39 1.25 38.57 2.33 1.67 39.11 2.30 1.39 40.95 2.20 5.21 42.17 2.14 1.51 44.00 2.06 2.18 45.61 1.99 1.20 46.75 1.94 1.44 47.64 1.91 0.73 - In some embodiments, crystalline Form F is characterized by an endothermic peak at from about 153° C. to about 160° C., or from about 154° C. to about 159° C., or from about 155° C. to about 158° C., as determined by DSC. In some embodiments, crystalline Form F is characterized by an endothermic peak at about 157° C., as determined by DSC.
- In some embodiments, crystalline Form F is characterized by a DSC profile substantially as shown in
FIG. 26 . - In some embodiments, crystalline Form F is characterized by at least one of the following: a) an XRPD pattern as shown in
FIG. 25 ; or b) a DSC profile as shown inFIG. 26 . - In some embodiments, crystalline Form F is substantially free of other polymorphic forms. In some embodiments, crystalline Form F has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form F and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or
crystalline Form 1, orcrystalline Form 2, orcrystalline Form 8, orcrystalline Form 9. - In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form F as compared to other solid state forms of a compound of Formula (II).
- In one aspect, the present disclosure relates to crystalline Form 1 of a hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 1 is a 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride hydrate. - In some embodiments, the melting point of
crystalline Form 1 is from about 140° C. to about 145° C. In some embodiments, the melting point ofcrystalline Form 1 is from about 140° C. to about 143° C. In some embodiments, the melting point ofcrystalline Form 1 is about 140.8° C. - In some embodiments,
crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5±0.2, 22.4±0.2, and 23.9±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5±0.2, 17.2±0.2, 22.4±0.2, and 23.9±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5±0.2, 17.2±0.2, 19.7±0.2, 22.4±0.2, and 23.9±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 1 is characterized by an XRPD pattern having peaks at 12.5±0.2, 17.2±0.2, 19.7±0.2, 22.4±0.2, 23.1±0.2, and 23.9±0.2 degrees two theta when measured by Cu Kα radiation. - In some embodiments,
crystalline Form 1 is characterized by an XRPD pattern substantially as shown inFIG. 7 . - In some embodiments,
crystalline Form 1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 6 below. -
TABLE 6 XRPD Peaks for Crystalline Form 1Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 7.63 11.58 12.85 10.23 8.65 24.44 12.53 7.07 100.00 13.41 6.60 25.51 13.92 6.36 37.74 15.40 5.75 18.89 16.34 5.43 22.09 17.20 5.16 46.14 17.76 4.99 26.80 18.76 4.73 27.32 19.66 4.52 48.32 22.39 3.97 48.78 23.06 3.86 49.26 23.93 3.72 76.96 26.59 3.35 26.56 - In some embodiments,
crystalline Form 1 is characterized by an endothermic peak at from about 136° C. to about 146° C., or from about 138° C. to about 144° C., or from about 140° C. to about 143° C., as determined by DSC. In some embodiments,crystalline Form 1 is characterized by an endothermic peak at about 142.1° C., as determined by DSC. - In some embodiments,
crystalline Form 1 is characterized by a DSC profile substantially as shown inFIG. 8 . - In some embodiments,
crystalline Form 1 is characterized by from an about 3.0 wt % to an about 5.0 wt % loss between about 30° C. and about 100° C. In some embodiments,crystalline Form 1 is characterized by from an about 3.5 wt % to an about 4.5 wt % loss between about 30° C. and about 100° C. In some embodiments,crystalline Form 1 is characterized by an about 4.04 wt % loss between about 30° C. and about 100° C. - In some embodiments,
crystalline Form 1 is characterized by a TGA profile substantially as shown inFIG. 8 . - In some embodiments,
crystalline Form 1 is characterized by from an about 12.0 wt % to an about 14.0 wt % loss between room temperature and about 180° C. In some embodiments,crystalline Form 1 is characterized by from an about 12.8 wt % to an about 13.4 wt % loss between room temperature and about 180° C. In some embodiments,crystalline Form 1 is characterized by an about 13.13 wt % loss between room temperature and about 180° C. - In some embodiments,
crystalline Form 1 is characterized by at least two of the following: a) an XRPD pattern as shown inFIG. 7 ; b) a DSC profile as shown inFIG. 8 ; or c) a TGA profile as shown inFIG. 8 . - In some embodiments,
crystalline Form 1 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 1 and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, orcrystalline Form 2, orcrystalline Form 8, orcrystalline Form 9. In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, orcrystalline Form 2. - In some embodiments, the present disclosure relates to a mixture comprising a majority of
crystalline Form 1 as compared to other solid state forms of a compound of Formula (II). - In one aspect, the present disclosure relates to crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 2 is an anhydrate. - In some embodiments, the melting point of
crystalline Form 2 is from about 184° C. to about 190° C. In some embodiments, the melting point ofcrystalline Form 2 is from about 186° C. to about 188° C. In some embodiments, the melting point ofcrystalline Form 2 is about 187° C. - In some embodiments,
crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7:0.2, and 22.5±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7±0.2, 22.3±0.2, and 22.5±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7±0.2, 22.3±0.2, 22.5±0.2, and 26.0±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 2 is characterized by an XRPD pattern having peaks at 16.6±0.2, 18.7±0.2, 20.8±0.2, 22.3±0.2, 22.5±0.2, and 26.0±0.2 degrees two theta when measured by Cu Kα radiation. - In some embodiments,
crystalline Form 2 is characterized by an XRPD pattern substantially as shown inFIG. 9 . - In some embodiments,
crystalline Form 2 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 7 below. -
TABLE 7a Select XRPD Peaks for Crystalline Form 2Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 8.06 10.97 21.93 12.12 7.30 23.48 13.30 6.66 9.94 14.31 6.19 37.35 14.95 5.93 21.37 15.47 5.73 12.00 16.42 5.40 38.25 16.58 5.35 59.48 17.35 5.11 18.11 18.18 4.88 30.28 18.72 4.74 61.10 19.68 4.51 5.01 20.40 4.35 6.62 20.80 4.27 37.19 22.29 3.99 95.77 22.49 3.95 100.00 23.00 3.87 21.16 23.65 3.76 19.85 25.96 3.43 38.67 26.40 3.38 7.96 26.88 3.32 8.15 28.95 3.08 8.97 30.06 2.97 6.51 -
TABLE 7b XRPD Peaks for Crystalline Form 2Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 8.06 10.97 21.93 12.12 7.30 23.48 13.30 6.66 9.94 14.31 6.19 37.35 14.95 5.93 21.37 15.47 5.73 12.00 16.42 5.40 38.25 16.58 5.35 59.48 17.35 5.11 18.11 18.18 4.88 30.28 18.72 4.74 61.10 19.68 4.51 5.01 20.40 4.35 6.62 20.80 4.27 37.19 22.29 3.99 95.77 22.49 3.95 100.00 23.00 3.87 21.16 23.65 3.76 19.85 25.96 3.43 38.67 26.40 3.38 7.96 26.88 3.32 8.15 28.95 3.08 8.97 30.06 2.97 6.51 31.12 2.87 2.70 34.18 2.62 1.65 - In some embodiments,
crystalline Form 2 is characterized by an endothermic peak at from about 181° C. to about 191° C., or from about 183° C. to about 189° C., or from about 185° C. to about 187° C., as determined by DSC. In some embodiments,crystalline Form 2 is characterized by an endothermic peak at about 186.0° C., as determined by DSC. - In some embodiments,
crystalline Form 2 is characterized by a DSC profile substantially as shown inFIG. 10 . - In some embodiments,
crystalline Form 2 is characterized by from an about 2.5 wt % to an about 3.5 wt % loss between room temperature and about 170° C. In some embodiments,crystalline Form 2 is characterized by from an about 3.0 wt % to an about 3.4 wt % loss between room temperature and about 170° C. In some embodiments,crystalline Form 2 is characterized by an about 3.17 wt % loss between room temperature and about 170° C. - In some embodiments,
crystalline Form 2 is characterized by a TGA profile substantially as shown inFIG. 10 . - In some embodiments,
crystalline Form 2 is characterized by at least two of the following: a) an XRPD pattern as shown inFIG. 9 ; b) a DSC profile as shown inFIG. 10 ; or c) a TGA profile as shown inFIG. 10 . - In some embodiments,
crystalline Form 2 has a unit cell that indexes as monoclinic. - In some embodiments,
crystalline Form 2 has a unit cell with an a value of about 11.113 Å, a b value of about 12.356 Å, and a c value of about 24.048 Å. In other embodiments,Form 2 has a unit cell with a volume of about 3223.93 Å3. - The unit cell parameters for
crystalline Form 2 are as follows: -
Crystal System Monoclinic a [Å] 11.113 b [Å] 12.356 c [Å] 24.048 α [deg] 90 β [deg] 102.48 γ [deg] 90 Volume [Å3] 3223.93 Z CalMolated density 4, 1.419 [g/cm3] Crystal Size [mm3] 0.31 × 0.15 × 0.11 Space Group(s) P21/c - In some embodiments,
crystalline Form 2 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 2 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89° %, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 2 and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, orcrystalline Form 1, orcrystalline Form 8, orcrystalline Form 9. In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, orcrystalline Form 1. - In some embodiments, the present disclosure relates to a mixture comprising a majority of
crystalline Form 2 as compared to other solid state forms of a compound of Formula (II). -
Crystalline Form 2 exhibits chemical and physical properties that are unexpected and bioavailablity properties that are advantageous compared to the free base forms. In particular, as shown inFIG. 21 , 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and gentisic acid exhibit significant hydrogen bonding interactions despite being an interaction between a weak base and a weak acid, respectively. - Additionally, as shown in Example 14,
crystalline Form 2 surprisingly exhibits increased mouse oral exposure levels as compared to other solid state forms of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II). For example, as shown in Example 14, in some embodiments, crystalline Form 2 (gentisic acid co-crystal) exhibits higher exposure levels at about 300 mg/kg than crystalline Form A (freebase). - In another aspect, the present disclosure relates to crystalline Form 3 of a hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula
- In some embodiments, crystalline Form 3 is characterized by an XRPD pattern substantially as shown in
FIG. 15 . - In another aspect, the present disclosure relates to crystalline Form 4 of a hydrobromic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 4 is characterized by an XRPD pattern substantially as shown inFIG. 16 . - In another aspect, the present disclosure relates to crystalline Form 5 of a hydrobromic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 5 is characterized by an XRPD pattern substantially as shown inFIG. 17 . - In another aspect, the present disclosure relates to crystalline Form 6 of an ethanedisulfonic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 6 is characterized by an XRPD pattern substantially as shown inFIG. 18 . - In another aspect, the present disclosure relates to crystalline Form 7 of a methanesulfonic acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 7 is characterized by an XRPD pattern substantially as shown inFIG. 19 . - In one aspect, the present disclosure relates to crystalline Form 8 of a benzoic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):
- In some embodiments,
crystalline Form 8 is an anhydrate. - In some embodiments, the melting point of
crystalline Form 8 is from about 100° C. to about 110° C. In some embodiments, the melting point ofcrystalline Form 8 is from about 102° C. to about 108° C. In some embodiments, the melting point ofcrystalline Form 8 is about 105° C. - In some embodiments,
crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1±0.2, 14.2±0.2, and 16.5±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1±0.2, 16.5±0.2, 19.0±0.2, and 21.0±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1±0.2, 14.2±0.2, 16.5±0.2, and 21.0±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 8 is characterized by an XRPD pattern having peaks at 12.1±0.2, 16.5±0.2, 21.0±0.2, 23.0±0.2, and 25.7±0.2 degrees two theta when measured by Cu Kα radiation. - In some embodiments,
crystalline Form 8 is characterized by an XRPD pattern substantially as shown inFIG. 29 . - In some embodiments,
crystalline Form 8 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 8 below. -
TABLE 8 XRPD Peaks for Crystalline Form 8Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 7.39 11.95 25.5 7.98 11.08 39.2 8.44 10.47 24.9 10.24 8.63 29.7 11.02 8.02 26.5 12.13 7.29 84.4 12.48 7.09 46.2 14.19 6.24 68.4 14.66 6.04 29.9 15.25 5.80 20.7 16.00 5.53 17.3 16.52 5.36 100 16.83 5.26 29.3 17.28 5.13 29.8 18.02 4.92 50.4 18.38 4.82 25.3 18.96 4.68 90.6 19.54 4.54 35.9 21.04 4.22 69.8 21.31 4.17 35.5 21.95 4.05 39.6 22.36 3.97 60.1 22.63 3.93 39.4 22.98 3.87 74.3 23.18 3.83 39.9 23.43 3.79 33.3 24.13 3.69 13.5 24.70 3.60 19.2 25.74 3.46 78.1 26.52 3.36 27.1 26.78 3.33 14.9 27.32 3.26 11.2 28.59 3.12 31.2 28.84 3.09 38.9 29.28 3.05 15.2 29.54 3.02 13.9 29.92 2.98 12.3 30.31 2.95 16.8 30.77 2.90 20.3 31.03 2.88 13.8 31.31 2.85 13.9 31.64 2.83 9.3 32.91 2.72 9.5 33.16 2.70 13.4 33.49 2.67 10.6 33.99 2.64 8.8 34.88 2.57 9 35.81 2.51 7.7 36.40 2.47 9.4 36.64 2.45 8.4 37.04 2.42 8.3 37.40 2.40 13.6 37.66 2.39 8.3 38.19 2.35 12.7 39.39 2.29 8 39.95 2.25 7.2 40.82 2.21 7.4 41.74 2.16 7.2 - In some embodiments,
crystalline Form 8 is characterized by an endothermic peak at from about 100° C. to about 110° C., or from about 102° C. to about 108° C., or from about 104° C. to about 106° C., as determined by DSC. In some embodiments,crystalline Form 8 is characterized by an endothermic peak at about 105.3° C., as determined by DSC. - In some embodiments,
crystalline Form 8 is characterized by a DSC profile substantially as shown inFIG. 30 . - In some embodiments,
crystalline Form 8 is characterized by from an about 14 wt % to an about 24 wt % loss between about 120° C. and about 300° C. In some embodiments,crystalline Form 8 is characterized by from an about 16 wt % to an about 20 wt % loss between about 120° C. and about 300° C. In some embodiments,crystalline Form 8 is characterized by from an about 18 wt % to an about 19 wt % loss between about 120° C. and about 300° C. In some embodiments,crystalline Form 8 is characterized by an about 18.8 wt % loss between about 120° C. and about 300° C. - In some embodiments,
crystalline Form 8 is characterized by a TG-FTIR profile substantially as shown inFIG. 31 . - In some embodiments,
crystalline Form 8 is characterized by at least two of the following: a) an XRPD pattern as shown inFIG. 29 ; b) a DSC profile as shown inFIG. 30 ; or c) a TG-FTIR profile as shown inFIG. 31 . - In some embodiments,
crystalline Form 8 has a unit cell that indexes as monoclinic. - In some embodiments,
crystalline Form 8 has a unit cell with an a value of about 10.61070(10) Å, a b value of about 12.39940(10) Å, and a c value of about 24.15170(10) A. In other embodiments,Form 8 has a unit cell with a volume of about 3114.74(4) Å3. - The unit cell parameters for
crystalline Form 8 are as follows: -
Crystal System Monoclinic a [Å] 10.61070(10) b [Å] 12.39940(10) c [Å] 24.15170(10) α [deg] 90 β [deg] 101.4110(10) γ [deg] 90 Volume [Å3] 3114.74(4) Z, CalMolated density 4, 1.400 [g/cm3] Crystal Size [mm3] 0.047 × 0.043 × 0.033 Space Group(s) P21/n - In some embodiments,
crystalline Form 8 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 8 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 8 and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, orcrystalline Form 1, orcrystalline Form 2, orcrystalline Form 9. - In some embodiments, the present disclosure relates to a mixture comprising a majority of
crystalline Form 8 as compared to other solid state forms of a compound of Formula (II). - In one aspect, the present disclosure relates to
crystalline Form 9 of a salicylic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II). - In some embodiments,
crystalline Form 9 is an anhydrate. - In some embodiments,
crystalline Form 9 is characterized by an XRPD pattern having peaks at 11.0±0.2, 16.5±0.2, and 25.3±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment,crystalline Form 9 is characterized by an XRPD pattern having peaks at 11.0±0.2, 16.5±0.2, 17.3±0.2, and 25.3±0.2 degrees two theta when measured by Cu Kα radiation. - In some embodiments,
crystalline Form 9 is characterized by an XRPD pattern substantially as shown inFIG. 33 . - In some embodiments,
crystalline Form 9 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 9 below. -
TABLE 9 XRPD Peaks for Crystalline Form 9Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 8.00 11.04 22.7 9.84 8.98 12.6 10.25 8.62 13.4 10.97 8.06 72.1 12.16 7.27 44.6 13.21 6.70 11.4 14.30 6.19 28.3 14.71 6.02 17.6 15.34 5.77 14.7 15.76 5.62 14 16.08 5.51 11.2 16.47 5.38 70.7 17.25 5.14 60.9 17.67 5.02 27.2 18.06 4.91 26.8 18.78 4.72 37.9 19.07 4.65 21.2 19.68 4.51 20.8 20.86 4.26 37.1 21.08 4.21 18.9 21.61 4.11 14.2 21.87 4.06 11.9 22.14 4.01 23.9 22.36 3.97 33.6 22.70 3.91 18.9 23.01 3.86 36.7 23.31 3.81 19 23.56 3.77 22 23.87 3.72 8.9 24.22 3.67 12.8 24.49 3.63 7.7 24.89 3.58 11.5 25.31 3.52 100 25.96 3.43 34.7 26.40 3.37 9.8 26.61 3.35 8.9 27.13 3.28 6.1 28.07 3.18 12.1 28.42 3.14 11.8 28.74 3.10 41.6 28.94 3.08 24.2 29.30 3.05 7.6 29.50 3.03 6.6 29.96 2.98 11.4 30.40 2.94 9 30.67 2.91 22.9 30.88 2.89 13.9 31.27 2.86 8.1 31.92 2.80 6.1 32.78 2.73 6 33.12 2.70 7.7 33.37 2.68 6.2 33.70 2.66 10.4 34.02 2.63 4.3 34.91 2.57 4.8 35.23 2.55 5 35.54 2.52 5.9 35.81 2.51 5.5 36.33 2.47 5.4 36.72 2.45 6.7 37.10 2.42 5.9 37.47 2.40 7.3 38.06 2.36 10.1 38.60 2.33 4.6 39.33 2.29 5 39.69 2.27 5.3 40.01 2.25 13 40.65 2.22 5 40.90 2.20 4.2 41.35 2.18 4.2 - In some embodiments,
crystalline Form 9 is characterized by a 1H NMR profile substantially as shown inFIG. 34 . - In some embodiments,
crystalline Form 9 is characterized by at least one of the following: a) an XRPD pattern as shown inFIG. 33 ; or b)FH NMR profile as shown inFIG. 34 . - In some embodiments,
crystalline Form 9 has a unit cell that indexes as monoclinic. - In some embodiments,
crystalline Form 9 has a unit cell with an a value of about 10.8387(11) Å, a b value of about 12.3761(12) Å, and a c value of about 24.242(2) Å. In other embodiments,Form 9 has a unit cell with a volume of about 3173.1(5) Å3. - The unit cell parameters for
crystalline Form 9 are as follows: -
Crystal System Monoclinic a [Å] 10.8387(11) b [Å] 12.3761(12) c [Å] 24.242(2) α [deg] 90 β [deg] 102.631(5) γ [deg] 90 Volume [Å3] 3173.1(5) Z, CalMolated density 4, 1.408 [g/cm3] Crystal Size [mm3] 0.08 × 0.06 × 0.05 Space Group(s) P21/c - In some embodiments,
crystalline Form 9 is substantially free of other polymorphic forms. In some embodiments,crystalline Form 9 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. - In another aspect, the present disclosure relates to a mixture comprising
crystalline Form 9 and a second solid state form of a compound of Formula (II). In some embodiments, the second solid state form of a compound of Formula (II) is crystalline Form A, or crystalline Form C, or crystalline Form D, or crystalline Form E, or crystalline Form F, orcrystalline Form 1, orcrystalline Form 2, orcrystalline Form 8. - In some embodiments, the present disclosure relates to a mixture comprising a majority of
crystalline Form 9 as compared to other solid state forms of a compound of Formula (II). - In one aspect, the present disclosure relates to a solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-11H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the solid state form is an amorphous form of a compound of Formula (III). In some embodiments, the amorphous form is a hydrate, anhydrate, or solvate thereof. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In some embodiments, the present disclosure relates to a mixture comprising a majority of the amorphous form as compared to other solid state forms of a compound of Formula (III).
- In some embodiments, the solid state form is a crystalline form of a compound of Formula (III). In some embodiments, the crystalline form is a hydrate, anhydrate, or solvate thereof.
- In some embodiments, the solid state form of a compound of Formula (III) is selected from the group consisting of:
-
- a) crystalline Form A1, wherein Form A1 is characterized by an XRPD pattern having peaks at 16.1±0.2, 16.7±0.2, and 24.8±0.2 degrees two theta; and
- b) crystalline Form B1, wherein Form B1 is characterized by an XRPD pattern having peaks at 12.9±0.2, 14.5±0.2, and 22.6±0.2 degrees two theta.
- In some embodiments, the solid state form is a pharmaceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III). In some embodiments, the pharmaceutically acceptable salt or co-crystal is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) and a pharmaceutically acceptable acid.
- In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzene sulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, mucic acid, naphthalene sulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluene sulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, gallic acid ethyl ester, 4-hydroxybenzoic acid, 4-hydroxybenzoic acid methyl ester, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxy groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxy group. In some embodiments, the benzoic acid derivative substituted with one hydroxy group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxy groups. In some embodiments, the benzoic acid derivative substituted with two hydroxy groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxy groups. In some embodiments, the benzoic acid derivative substituted with three hydroxy groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments the, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments the pharmaceutically acceptable acid is gallic acid.
- In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) is an amorphous form. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In some embodiments, the pharmaceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) is a crystalline form.
- In some embodiments, the pharmaceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) is a hydrate, anhydrate, or solvate thereof.
- The sections below discuss solid state forms of a compound of Formula (III) that have been identified and selected properties of those solid state forms.
- In one aspect, the present disclosure relates to crystalline Form A1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- In some embodiments, crystalline Form A1 is an anhydrate.
- In some embodiments, the melting point of crystalline Form A1 is from about 148° C. to about 152° C. In some embodiments, the melting point of crystalline Form A1 is from about 150° C. to about 152° C. In some embodiments, the melting point of crystalline Form A1 is about 150.5° C.
- In some embodiments, crystalline Form A1 is characterized by an XRPD pattern having peaks at 16.1±0.2, 16.7±0.2, and 24.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form A1 is characterized by an XRPD pattern having peaks at 16.1±0.2, 16.7±0.2, 22.2±0.2, and 24.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form A1 is characterized by an XRPD pattern having peaks at 16.1±0.2, 16.7±0.2, 20.6+0.2, 22.2±0.2, and 24.8±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form A1 is characterized by an XRPD pattern having peaks at 8.1±0.2, 16.1±0.2, 16.7±0.2, 20.6±0.2, 22.2±0.2, and 24.8±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form A1 is characterized by an XRPD pattern substantially as shown in
FIG. 11 . - In some embodiments, crystalline Form A1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 10 below.
-
TABLE 10a XRPD Peaks for Crystalline Form A1 Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 8.09 10.93 22.58 12.30 7.20 4.82 12.96 6.83 6.73 13.97 6.34 8.89 16.15 5.49 100.00 16.66 5.32 55.77 17.11 5.18 34.30 18.08 4.91 19.54 18.95 4.68 7.76 19.90 4.46 10.05 20.59 4.31 36.39 22.18 4.01 37.56 24.30 3.66 23.74 24.81 3.59 43.37 25.64 3.47 10.28 27.61 3.23 4.36 28.15 3.17 6.48 32.72 2.74 2.99 - In some embodiments, crystalline Form A1 is characterized by an endothermic peak at from about 146° C. to about 154° C., or from about 148° C. to about 152° C., or from about 150° C. to about 152° C., as determined by DSC. In some embodiments, crystalline Form A1 is characterized by an endothermic peak at about 150.5° C., as determined by DSC.
- In some embodiments, crystalline Form A1 is characterized by a DSC profile substantially as shown in
FIG. 12 . - In some embodiments, crystalline Form A1 is characterized by from an about 0.90 wt % to an about 1.0 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form A1 is characterized by from an about 0.92 wt % to an about 0.98 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form A1 is characterized by from an about 0.95 wt % loss between room temperature and about 120° C.
- In some embodiments, crystalline Form A1 is characterized by a TGA profile substantially as shown in
FIG. 12 . - In some embodiments, crystalline Form A1 is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 11 ; b) a DSC profile as shown inFIG. 12 ; or c) a TGA profile as shown inFIG. 12 . - In some embodiments, crystalline Form A1 has a unit cell that indexes as monoclinic.
- In some embodiments, crystalline Form A1 has a unit cell with an a value of about 12.545 Å, a b value of about 8.640 Å, and a c value of about 21.660 Å. In other embodiments, Form A has a unit cell with a volume of about 2336.13 Å3.
- The unit cell parameters for crystalline Form A1 are as follows:
-
Crystal System Monoclinic a [Å] 12.545 b [Å] 8.640 c [Å] 21.660 α [deg] 90 β [deg] 95.66 γ [deg] 90 Volume [Å3] 2336.13 Z CalMolated 4, 1.440 density [g/cm3] Crystal Size [mm3] 0.11 × 0.04 × 0.03 Space Group(s) P21/c - In some embodiments, crystalline Form A1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form A1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. In some embodiments, crystalline Form A1 has a polymorphic purity of at least 80%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form A1 and a second solid state form of a compound of Formula (III). In some embodiments, the second solid state form of a compound of Formula (III) is crystalline Form B1.
- In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form A1 as compared to other solid state forms of a compound of Formula (III).
- In one aspect, the present disclosure relates to crystalline Form B1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III):
- In some embodiments, crystalline Form B1 is an anhydrate.
- In some embodiments, the melting point of crystalline Form B1 is from about 160° C. to about 164° C. In some embodiments, the melting point of crystalline Form B1 is from about 161° C. to about 163° C. In some embodiments, the melting point of crystalline Form B1 is about 162.1° C.
- In some embodiments, crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9±0.2, 14.5±0.2, and 22.6±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9±0.2, 14.5±0.2, 16.7±0.2, and 22.6±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9±0.2, 14.5±0.2, 16.7±0.2, 22.6±0.2, 24.2±0.2 degrees two theta when measured by Cu Kα radiation. In another embodiment, crystalline Form B1 is characterized by an XRPD pattern having peaks at 12.9±0.2, 14.5±0.2, 16.7±0.2, 20.7±0.2, 22.6±0.2, 24.2±0.2 degrees two theta when measured by Cu Kα radiation.
- In some embodiments, crystalline Form B1 is characterized by an XRPD pattern substantially as shown in
FIG. 13 . - In some embodiments, crystalline Form B1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 11 below.
-
TABLE 11 XRPD Peaks for Crystalline Form B1 Pos. [°2Th.] d-spacing [Å] Rel. Int. [%] 8.01 11.03 11.74 12.90 6.86 12.61 14.48 6.12 11.39 16.05 5.52 100.00 16.66 5.32 30.88 17.10 5.19 41.89 18.04 4.92 25.85 19.93 4.45 18.66 20.67 4.30 33.18 22.12 4.02 26.81 22.57 3.94 26.19 23.25 3.83 8.24 24.17 3.68 37.94 24.74 3.60 56.78 25.74 3.46 10.79 27.38 3.26 5.60 - In some embodiments, crystalline Form B1 is characterized by an endothermic peak at from about 156° C. to about 166° C., or from about 159° C. to about 163° C., or from about 160° C. to about 162° C., as determined by DSC. In some embodiments, crystalline Form B1 is characterized by an endothermic peak at about 161.2° C., as determined by DSC.
- In some embodiments, crystalline Form B1 is characterized by a DSC profile substantially as shown in
FIG. 14 . - In some embodiments, crystalline Form B1 is characterized by from an about 1.0 wt % to an about 2.0 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form B1 is characterized by from an about 1.2 wt % to an about 1.8 wt % loss between room temperature and about 120° C. In some embodiments, crystalline Form B1 is characterized by an about 1.58 wt % loss between room temperature and about 120° C.
- In some embodiments, crystalline Form B1 is characterized by a TGA profile substantially as shown in
FIG. 14 . - In some embodiments, crystalline Form B1 is characterized by at least two of the following: a) an XRPD pattern as shown in
FIG. 13 ; b) a DSC profile as shown inFIG. 14 ; or c) a TGA profile as shown inFIG. 14 . - In some embodiments, crystalline Form B1 is substantially free of other polymorphic forms. In some embodiments, crystalline Form B1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
- In another aspect, the present disclosure relates to a mixture comprising crystalline Form B1 and a second solid state form of a compound of Formula (III). In some embodiments, the second solid state form of a compound of Formula (III) is crystalline Form A1.
- In some embodiments, the present disclosure relates to a mixture comprising a majority of crystalline Form B1 as compared to other solid state forms of a compound of Formula (III).
- Solid state forms of the compound of Formula (I), 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II), and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III), as disclosed herein, and mixtures thereof, can be administered to a mammal in the form of a raw chemical without any other components present, or Compounds of the Disclosure can also be administered to a mammal as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier (see, for example, Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th ed. (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., Pharmaceutical Press (2000)). Such a carrier can be selected from pharmaceutically acceptable excipients and auxiliaries. The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995.
- Solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III), as disclosed herein, and mixtures thereof, may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments, crystalline Form A of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments, crystalline Form C of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments, crystalline Form D of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments, crystalline Form E of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments, crystalline Form F of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments,
crystalline Form 1 of the hydrochloric acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments,
crystalline Form 2 of the gentisic acid co-crystal of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments, crystalline Form 3 of the hydrochloric acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments,
crystalline Form 4 of the hydrobromic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments,
crystalline Form 5 of the hydrobromic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments,
crystalline Form 6 of the ethanedisulfonic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments,
crystalline Form 7 of the methanesulfonic acid salt of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments,
crystalline Form 8 of the benzoic acid cocrystal of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments,
crystalline Form 9 of the salicylic acid cocrystal of the compound of Formula (II) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes. - In some embodiments, crystalline Form A1 of the compound of Formula (III) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In some embodiments, crystalline Form B1 of the compound of Formula (III) may be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
- In another aspect, the present disclosure relates to a solid dosage form comprising one or more of the solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III), as disclosed herein, and one or more pharmaceutically acceptable carriers or diluents. Solid dosage forms can include, but are not limited to, tablets, capsules, pills, granules, powders, sachets, chewables, and films.
- In some embodiments, the present disclosure provides a solid dosage form comprising a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein the solid dosage form is for use in a method for treating cancer.
- In another aspect, the present disclosure relates to a pharmaceutical composition comprising one or more of the solid state forms of the compound of Formula (I), the compound of Formula (II), and the compound of Formula (III), as disclosed herein, and one or more pharmaceutically acceptable carriers or diluents.
- In some embodiments, the pharmaceutical composition comprises crystalline Form A of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form C of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form D of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form E of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form F of the compound of Formula (II).
- In some embodiments, the pharmaceutical composition comprises
crystalline Form 1 of the hydrochloric acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 2 of the gentisic acid co-crystal of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises crystalline Form 3 of the hydrochloric acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 4 of the hydrobromic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 5 of the hydrobromic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 6 of the ethanedisulfonic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 7 of the methanesulfonic acid salt of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 8 of the benzoic acid cocrystal of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprisescrystalline Form 9 of the salicylic acid cocrystal of the compound of Formula (II). In some embodiments, the pharmaceutical composition comprises an amorphous form of the compound of Formula (II). - In some embodiments, the pharmaceutical composition comprises a mixture of two or more solid state forms of the compound of Formula (II).
- In some embodiments, the pharmaceutical composition comprises crystalline Form A1 of the compound of Formula (III). In some embodiments, the pharmaceutical composition comprises crystalline Form B1 of the compound of Formula (III). In some embodiments, the pharmaceutical composition comprises an amorphous form of the compound of Formula (III).
- In some embodiments, the pharmaceutical composition comprises a mixture of two or more solid state forms of the compound of Formula (III).
- In some embodiments, the pharmaceutical composition is an orally acceptable dosage form comprising one or more of crystalline Forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, and 9 and amorphous form of a compound of Formula (II).
- In some embodiments, the pharmaceutical composition is an orally acceptable dosage form comprising one or more of crystalline Forms A1 and B1, and amorphous form of a compound of Formula (III).
- In some embodiments, the orally acceptable dosage form can include, but is not limited to, capsules, tablets, aqueous suspensions, and solutions.
- For oral administration, known carriers can be included in the pharmaceutical composition. For example, microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (preferably corn, potato or tapioca starch), methylcellulose, alginic acid and certain complex silicates, together with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and acacia, can be included in a tablet. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred materials in this connection include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
- In some embodiments, the pharmaceutical composition is a parenteral formulation comprising one or more of crystalline Forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, and 9 and amorphous form of a compound of Formula (II).
- In some embodiments, the pharmaceutical composition is a parenteral formulation comprising one or more of crystalline Forms A1 and B1, and amorphous form of a compound of Formula (III).
- For parenteral administration, solutions containing a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) can be prepared in either sesame or peanut oil, in aqueous propylene glycol, or in sterile water or saline. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
- In some embodiments, the pharmaceutical composition may be prepared as liquid suspension or solution using a liquid, such as an oil, water, an alcohol, and combinations of these.
- In some embodiments, the pharmaceutical composition may be prepared as a sterile injectable, which may be aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art.
- In some embodiments, the pharmaceutical composition may be administered in the form of suppositories for rectal administration.
- In some embodiments, the pharmaceutical composition may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used. For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment, lotion, or cream containing the active component suspended or dissolved in one or more carriers.
- In some embodiments, the pharmaceutical composition may also be administered ophthalmically and formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
- In some embodiments, the pharmaceutical composition may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- In some embodiments, the pharmaceutical compositions to be used for in vivo administration can be sterile. This is readily accomplished by filtration through, e.g., sterile filtration membranes.
- Pharmaceutical compositions within the scope of the present disclosure include all compositions where a solid state form of a compound of Formula (I), a compound of Formula (11), or a compound for Formula (III) is combined with one or more pharmaceutically acceptable carriers or diluents. In one embodiment, a solid state form of the compound of Formula (I), the compound of Formula (II), or the compound for Formula (III) is present in the composition in an amount that is effective to achieve its intended therapeutic purpose.
- Pharmaceutical compositions of the present disclosure can be administered to any patient that may experience the beneficial effects of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III). Foremost among such patients are mammals, e.g., humans and companion animals, although the disclosure is not intended to be so limited. In one embodiment, the patient is a human.
- In another aspect, the present disclosure relates to kits which comprise a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III) packaged in a manner that facilitates their use to practice methods of the present disclosure. In one embodiment, the kit includes a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III) (or a composition thereof) packaged in a container, such as a sealed bottle or vessel, with a label affixed to the container or included in the kit that describes use of the compound or composition to practice the method of the disclosure. In one embodiment, the compound or composition is packaged in a unit dosage form. The kit further can include a device suitable for administering the composition according to the intended route of administration. In some embodiments, the present disclosure provides a kit which comprises a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a patient having cancer.
- In some embodiments, the present disclosure provides a pharmaceutical composition comprising a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or diluent, wherein the pharmaceutical composition is for use in a method for treating cancer.
- Solid state forms of the compound of Formula (I), 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II), and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III), as disclosed herein, and mixtures thereof, may be used to inhibit the activity of a USP1 protein. For example, in some embodiments, a method of inhibiting a USP1 protein comprises contacting the USP1 protein with a solid state form of a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), or combinations thereof. The contacting can occur in vitro or in vivo.
- In some embodiments, a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) can be used to treat a “USP1 protein mediated disorder.” A USP1 protein mediated disorder is any pathological condition in which a USP1 protein is known to play a role. In some embodiments, a USP1 protein mediated disorder is a proliferative disease such as cancer.
- Various methods of treating diseases and disorders with the solid state forms of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) are provided herein. Exemplary diseases and disorders that may be treated with the solid state forms include, but are not limited to, cancer.
- In some embodiments, methods of treating cancer with the solid state forms of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) are provided. Such methods comprise administering to a subject with cancer a therapeutically effective amount of a Compound of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III).
- In some embodiments, the cancer to be treated with a solid state form disclosed herein is selected from a hematological cancer, a lymphatic cancer, and a DNA repair pathway deficient cancer. In some embodiments, the cancer to be treated is a cancer that comprises cancer cells with a mutation in a gene encoding p53. In some embodiments, the cancer to be treated is a cancer that comprises cancer cells with a loss of function mutation in a gene encoding p53.
- In some embodiments, the cancer to be treated with a solid state form disclosed herein is selected from non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer. In some embodiments, the cancer is ovarian cancer or breast cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is a triple negative breast cancer.
- In some embodiments, the cancer to be treated with a solid state form disclosed herein is selected from the group consisting of bone cancer, including osteosarcoma and chondrosarcoma; brain cancer, including glioma, glioblastoma, astrocytoma, medulloblastoma, and meningioma; soft tissue cancer, including rhabdoid and sarcoma; kidney cancer; bladder cancer; skin cancer, including melanoma; and lung cancer, including non-small cell lung cancer.
- In some embodiments, the present disclosure provides a method for treating cancer comprising administering one or more of the solid state forms disclosed herein to a patient in need thereof. In some embodiments, the present disclosure provides a method for treating cancer comprising administering one or more of the pharmaceutical compositions disclosed herein to a patient in need thereof. In some embodiments, the present disclosure provides a method for treating cancer comprising administering one or more of the solid dosage forms disclosed herein to a patient in need thereof.
- In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof a solid state form as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form A. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form F. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereofcrystalline Form 1. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereofcrystalline Form 2. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereofcrystalline Form 8. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereofcrystalline Form 9. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form A1. In some embodiments, the present disclosure provides a method for treating cancer comprising administering to a patient in need thereof crystalline Form B1. - In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof a solid state form as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form A. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form F. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereofcrystalline Form 1. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereofcrystalline Form 2. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereofcrystalline Form 8. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereofcrystalline Form 9. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form A1. In some embodiments, the present disclosure provides a method for treating breast cancer comprising administering to a patient in need thereof crystalline Form B1. - In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof a solid state form as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form A. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form F. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereofcrystalline Form 1. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereofcrystalline Form 2. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereofcrystalline Form 8. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereofcrystalline Form 9. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form A1. In some embodiments, the present disclosure provides a method for treating ovarian cancer comprising administering to a patient in need thereof crystalline Form B1. - Various methods of treating cancer with a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) are provided herein. In some embodiments, a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is administered to a subject with cancer, wherein the cancer comprises cancer cells with elevated levels of RAD18. In some embodiments, the elevated levels of RAD18 are elevated RAD18 protein levels. In some embodiments, the elevated levels of RAD18 are elevated RAD18 mRNA levels. In some embodiments, elevated levels ofRAD18 (e.g., RAD18 protein and/or RAD18 mRNA) have been detected (e.g., in a cancer sample obtained from the subject) prior to the administration. That is, in some embodiments, a subject's cancer has been tested for
RAD 18 protein or mRNA prior to beginning treatment with a USP1 inhibitor. - In some embodiments, such methods for treating cancer comprise (a) identifying a cancer in a subject as a USP1 inhibitor-sensitive cancer and then (b) administering a therapeutically effective amount of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) to the subject.
- In some embodiments, such methods comprise (a) detecting levels ofRAD18 (e.g., RAD18 protein and/or RAD18 mRNA) in cancer cells (e.g., in a cancer sample obtained from the subject) and then (b) administering a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) to a subject having a cancer comprising cells with elevated levels of RAD18.
- In some embodiments, such methods comprise administering to a subject with triple negative breast cancer a therapeutically effective amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III).
- In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a homologous-recombination deficient cancer. In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer comprises cancer cells with a mutation in a gene encoding p53. In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer comprises cancer cells with a loss of function mutation in a gene encoding p53. In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer that does not have a defect in the homologous recombination pathway.
- In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a BRCA1 mutant cancer. In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a BRCA2 mutant cancer. In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a BRCA1 mutant cancer and a BRCA2 mutant cancer. In some embodiments, the cancer is not a BRCA1 mutant cancer or a BRCA2 mutant cancer. In some embodiments, the cancer is a BRCA1 deficient cancer. In some embodiments, the cancer is a BRCA2 deficient cancer. In some embodiments, the cancer is a BRCA1 deficient cancer and a BRCA2 mutant cancer.
- In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a PARP inhibitor resistant cancer. In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used to treat a cancer, wherein the cancer is a PARP inhibitor resistant BRCA1-deficient cancer.
- In some embodiments, the cancer is a BRCA1 and/or BRCA2 mutant cancer, wherein the cancer comprises cells with elevated levels of RAD18, e.g., wherein the elevated levels of RAD18 are at least as high as the RAD18 protein and/or mRNA levels in ES2 cells or wherein the elevated levels ofRAD18 are higher than the RAD18 protein and/or mRNA levels in HEP3B217 cells. In some embodiments, a triple negative breast cancer is a BRCA1 and/or BRCA2 mutant cancer.
- In some instances, the cancer is a solid cancer. In some instances, the cancer is a hematological/lymphatic cancer. In some instances, the cancer is a DNA repair pathway deficient cancer. In some instances, the cancer is a homologous-recombination deficient cancer. In some instances, the cancer comprises cancer cells with a mutation in a gene encoding p53. In some instances, the cancer comprises cancer cells with a loss of function mutation in a gene encoding p53. In some instances, the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer (including triple negative breast cancer). In some instances, the cancer is ovarian cancer or breast cancer (including triple negative breast cancer). In some instances, the cancer is ovarian cancer. In some instances, the cancer is breast cancer (including triple negative breast cancer).
- In some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used in combination with one or more additional therapeutic agents to treat cancer. It has been reported that p53 status determines PARP inhibitor sensitization by ionizing radiation in multiple BRCA1 and HR-proficient tumor types (Sizemore et al., Mol. Cancer Res. 16: 1092-1102 (2018)). As shown below, p53 mutant cancers and BRCA mutant cancers have increased sensitivity to USP1 inhibitors. Accordingly, in some embodiments, a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) is used in combination with a PARP inhibitor to treat cancer.
- In some embodiments, the present disclosure provides a use of one or more of the solid state forms disclosed herein for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of one or more of the pharmaceutical compositions disclosed herein for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of one or more of the solid dosage forms disclosed herein for the manufacture of a medicament for treating cancer.
- In some embodiments, the present disclosure provides a use of one or more solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form A for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form F for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 1 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 2 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 8 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 9 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form A1 for the manufacture of a medicament for treating cancer. In some embodiments, the present disclosure provides a use of crystalline Form B1 for the manufacture of a medicament for treating cancer. - In some embodiments, the present disclosure provides a use of one or more solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form A for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form F for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 1 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 2 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 8 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 9 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form A1 for the manufacture of a medicament for treating breast cancer. In some embodiments, the present disclosure provides a use of crystalline Form B1 for the manufacture of a medicament for treating breast cancer. - In some embodiments, the present disclosure provides a use of one or more solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form A for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form F for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 1 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 2 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 8 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use ofcrystalline Form 9 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form A1 for the manufacture of a medicament for treating ovarian cancer. In some embodiments, the present disclosure provides a use of crystalline Form B1 for the manufacture of a medicament for treating ovarian cancer. - In some embodiments, the present disclosure provides a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound for Formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein the solid state form is for use in a method for treating cancer.
- In some embodiments, the present disclosure provides a solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form A for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form F for use in a method for treating cancer. In some embodiments, the present disclosure providescrystalline Form 1 for use in a method for treating cancer. In some embodiments, the present disclosure providescrystalline Form 2 for use in a method for treating cancer. In some embodiments, the present disclosure providescrystalline Form 8 for use in a method for treating cancer. In some embodiments, the present disclosure providescrystalline Form 9 for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form A1 for use in a method for treating cancer. In some embodiments, the present disclosure provides crystalline Form B1 for use in a method for treating cancer. - In some embodiments, the present disclosure provides a solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9 crystalline Form A1, crystalline Form B1, and mixtures thereof, for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form A for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form F for use in a method for treating breast cancer. In some embodiments, the present disclosure providescrystalline Form 1 for use in a method for treating breast cancer. In some embodiments, the present disclosure providescrystalline Form 2 for use in a method for treating breast cancer. In some embodiments, the present disclosure providescrystalline Form 8 for use in a method for treating breast cancer. In some embodiments, the present disclosure providescrystalline Form 9 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form A1 for use in a method for treating breast cancer. In some embodiments, the present disclosure provides crystalline Form B1 for use in a method for treating breast cancer. - In some embodiments, the present disclosure provides a solid state forms as disclosed herein, or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline Form A, crystalline Form C, crystalline Form D, crystalline Form E, crystalline Form F,
crystalline Form 1,crystalline Form 2, crystalline Form 3,crystalline Form 4,crystalline Form 5,crystalline Form 6,crystalline Form 7,crystalline Form 8,crystalline Form 9, crystalline Form A1, crystalline Form B1, and mixtures thereof, for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form A for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form F for use in a method for treating ovarian cancer. In some embodiments, the present disclosure providescrystalline Form 1 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure providescrystalline Form 2 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure providescrystalline Form 8 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure providescrystalline Form 9 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form A1 for use in a method for treating ovarian cancer. In some embodiments, the present disclosure provides crystalline Form B1 for use in a method for treating ovarian cancer. - In one aspect, the present disclosure relates to methods for preparing a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III).
- In some embodiments, the method comprises:
-
- a) adding a suitable amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) to a suitable amount of a suitable solvent system to obtain a suspension;
- b) stirring the suspension; and
- c) collecting the solid product from step b).
- In some embodiments, a suitable pharmaceutically acceptable acid is added during step a).
- In some embodiments, the suitable solvent system is selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropyl alcohol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyl tetrahydrofuran, n-heptane, n-methyl pyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof. In some embodiments, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
- In some embodiments, the method comprises:
-
- a) dissolving a suitable amount of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III) in a suitable amount of a suitable solvent to make a solution;
- b) adding a suitable amount of a suitable anti-solvent;
- c) adding seed crystals of a solid state form of a compound of Formula (I), a compound of Formula (II), or a compound of Formula (III);
- d) stirring the resulting suspension; and
- e) collecting the solid product produced from step d).
- In some embodiments, the method further comprises adding a suitable pharmaceutically acceptable acid during step a).
- In some embodiments, the method further comprises adding a suitable anti-solvent after step c) and before step d).
- In some embodiments, the suitable solvent and anti-solvent are selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropyl alcohol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyl tetrahydrofuran, n-heptane, n-methyl pyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof. In some embodiments, the suitable solvent and anti-solvent are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof. In some embodiments, the suitable solvent is ethyl acetate. In some embodiments, the suitable anti-solvent is n-heptane.
- In some embodiments, the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is added to the suitable solvent system at a temperature of from about room temperature to about 100° C., or from about room temperature to about 75° C., or from about room temperature to about 50° C., or from about room temperature to about 40° C. In some embodiments, the compound of Formula (I), the compound of Formula (II), or the compound of Formula (III) is added to the suitable solvent system at about room temperature.
- In some embodiments, the present disclosure relates to a method for preparing
crystalline Form 2 of a gentisic acid co-crystal of a compound of Formula (II), the method comprising: -
- a) adding a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid to a suitable amount of a suitable solvent system at room temperature to obtain a suspension;
- b) stirring the suspension from step a); and
- c) collecting the solid product from step b).
- In some embodiments, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
- In some embodiments, the present disclosure relates to a method for preparing
crystalline Form 2 of a gentisic acid co-crystal of a compound of Formula (II), the method comprising: -
- a) dissolving a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid in a suitable amount of a suitable solvent at room temperature to make a solution;
- b) adding a suitable amount of a suitable anti-solvent;
- c) adding seed crystals of
crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II); - d) stirring the resulting suspension; and
- e) collecting the solid product produced from step d).
- In some embodiments, the method further comprises adding a suitable anti-solvent after step c) and before step d).
- In some embodiments, the suitable solvent is ethyl acetate. In some embodiments, the suitable anti-solvent is n-heptane.
- In one aspect, the present disclosure relates to Crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- In another aspect, the present disclosure relates to Crystalline Form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- In another aspect, the present disclosure relates to Crystalline Form D of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- In another aspect, the present disclosure relates to Crystalline Form E of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- In another aspect the present disclosure related to Crystalline Form F of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein.
- In another aspect, the present disclosure relates to
Crystalline Form 1 of a hydrochloric acid salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein. - In another aspect, the present disclosure relates to
Crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein. - In another aspect, the present disclosure relates to
Crystalline Form 8 of a benzoic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein. - In another aspect, the present disclosure relates to
Crystalline Form 9 of a salicylic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) prepared by any of the methods disclosed herein. - In another aspect, the present disclosure relates to Crystalline Form A1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) prepared by any of the methods disclosed herein.
- In another aspect, the present disclosure relates to Crystalline Form B1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) prepared by any of the methods disclosed herein.
-
-
XRPD X-ray Powder Diffraction PLM Polarized Light Microscopy TGA Thermogravimetric Analysis DSC Differential Scanning Calorimetry S/AS Solvent/Anti-solvent RT Room/ambient Temperature RH Relative Humidity ACN Acetonitrile CHCl3 Chloroform DCM Dichloromethane DMAc N,N-dimethylacetamide DMSO Dimethyl sulfoxide EtOAc Ethyl acetate EtOH Ethanol H2O Water IPA Isopropyl alcohol IPAc Isopropyl acetate MeOH Methanol MEK Methyl ethyl ketone MIBK 4-methyl-2-pentanone (methyl-iso-butyl ketone) MTBE Methyl-tert-butyl ether NMP N-methyl-2-pyrrolidone THF Tetrahydrofuran 2-MeTHF 2-Methyltetrahydrofuran Cmax Maximum observed plasma concentration Tmax Time to reach Cmax AUClast Area under plasma concentration-time curve from time zero to time of last measurable concentration T1/2 Half-life NOD/SCID Mice homozygous for the severe combined immune deficiency spontaneous mutation Prkdcscid - X-ray powder diffraction (XRPD) patterns were measured on an X'pert 3 X-ray powder diffractomneter using Cu-kα radiation. Each sample was spread on the middle of a zero-background silicon holder. The tube voltage and amperage were set to 45 kV and 40 mA, respectively. A two-theta (2θ°) continuous scan at 46.7 seconds/step from 3° to 40° 2θ was used. XRPD analysis conditions are shown in the table below.
-
Parameters Reflection Mode Model X′ Pert3 X-Ray wavelength Cu, kα, Kα1 (Å): 1.540598, Kα2 (Å): 1.544426 Kα2/Kα1 intensity ratio: 0.50 X-Ray tube setting 45 kV, 40 mA Divergence slit ⅛° Scan mode Continuous Scan range (°2TH) 3°-40° Scan step time (s) 46.7 Step size (°2TH) 0.0263 Test time 5 min 4 s - For the characterization of crystalline Form F, XRPD patterns were measured on an PANanlytical & Xpert3 X-ray powder diffractometer using Cu-kα radiation. Each sample was spread on the middle of a zero-background silicon holder. The tube voltage and amperage were set to 45 kV and 40 mA, respectively. A two-theta (2θ°) continuous scan at 20.96 seconds/step from 2° to 50θ 2θ was used. XRPD analysis conditions are shown in the table below.
-
Parameters Reflection Mode Model PANalytical X′ Pert3 X-Ray wavelength Cu, kα, Kα1 (Å): 1.54060, Kα2 (Å): 1.54443 Kα2/Kα1 intensity ratio: 0.50 X-Ray tube setting 45 kV, 40 mA Divergence slit 0.2177° Scan mode Continuous Scan range (°2TH) 2°-50° Scan step time (s) 20.9550 Step size (°2TH) 0.0167 - Thermogravimetric analysis (TGA) data was collected using a TA Q5000 and Discovery TGA 5500 TGA from TA Instruments. TGA analysis conditions are shown in the table below.
-
Parameters TGA Method Ramp Sample pan Aluminum, open Temperature RT-350° C. Heating rate 10° C./min Purge gas N2 - Differential scanning calorimetry (DSC) data was collected using a TA Q2000 DSC from TA Instruments. DSC analysis conditions are shown in the table below.
-
Parameters DSC Method Ramp Sample pan Aluminum, crimped Temperature 25° C.-300° C. Heating rate 2, 10, 20° C./min Purge gas N2 - For the characterization of crystalline Form F, DSC data was collected using a
Perkin Elmer DSC 4000. DSC analysis conditions are shown in the table below. -
Parameters DSC Method Ramp Sample pan Aluminum, crimped Temperature 25° C.-350° C. Heating rate 10° C./min Purge gas N2 - Polarized light microscopy (PLM) images were captured with a ZEISS Scope A1 microscope.
- 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine was prepared according to the procedures disclosed in U.S. Provisional Patent Application Nos. 62/783,014; 62/799,423; and 62/868,616.
- To an ice cooled solution of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (1 eq) in dimethylformamide (5 mL) was added sodium hydride (60% dispersion in mineral oil) (1.2 eq) portion wise, and the reaction mixture was stirred at same temperature for 10 min. To the resulting reaction mixture was added a 2-iodopropane (1.20 eq) and stirring was continued at room temperature for 16 hours. Progress of the reaction was monitored by thin layer chromatography (TLC) and liquid chromatography-mass spectrometry (LCMS). After completion, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2×200 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude compounds were purified by preparatory high performance liquid chromatography (HPLC) to afford 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II). The purified compound was then recrystallized in heptane and ethyl acetate using methods known to those skilled in the art.
- 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II), obtained as discussed above, was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above. The resulting XRPD pattern, DSC profile, and TGA profile are shown in
FIGS. 1-2 , respectively, and the XRPD peaks are shown in Table 1, above. - Based on the XRPD pattern shown in
FIG. 1 and the XRPD peaks shown in Table 1, as well as the crystal structure and DSC and TGA profiles, 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II), obtained as discussed above, was determined to be a crystalline hydrate and was named crystalline Form A. - About 2.9 mg of crystalline Form A was added to a 3 mL glass vial with 0.5 mL DCM/n-heptane (1:4, v/v) solvent mixture. The mixture was then shaken by an ultrasonic cleaner to accelerate dissolution. The resulting suspension was filtered and the obtained clear solution was transferred to a clean 4-mL shell vial (44.6 mm×14.65 mm). The shell vial was sealed by a PE-Plug with one pinhole. The shell vial was then placed in a fume hood at room temperature for slow evaporation. After 1 day of slow evaporation, block-like crystals were observed.
- A suitable single crystal with good diffraction quality was selected from the block-like crystal samples and was wrapped with Paratone-N (an oil based cryoprotectant). The crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K. Preliminary examination and data collection were performed on a Rigaku XtaLAB Synergy R (CuKα radiation, λ=1.54184 Å) diffractometer and analyzed with the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software package. Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software using the setting angles of 49260 reflections in the range 3.563°<θ<75.668°. The data were collected to a minimum diffraction angle (θ) of 3.591° and a maximum diffraction angle (θ) of 76.0110 at 120 K. The final point group completeness is 100%. The mean I/σ of the data is 69.7 and the highest resolution is truncated at 0.79 Å.
- Frames were integrated with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 57,364 reflections were collected, of which 5292 were unique. Lorentz and polarization corrections were applied to the data. An empirical absorption correction was performed using CrysAlisPro (V1.171.40.19a, Rigaku, 2018) using spherical harmonicas implemented in SCALE3 ABSPACK. The absorption coefficient μ of this material is 0.883 mm-1 at this wavelength (λ=1.542 Å) and the minimum and maximum transmissions are 0.94414 and 1.0000, respectively. The agreement factor for the averaging was 5.19% based on intensity.
- The structure was solved in the space group P21/c with the ShelXT structure solution program using Intrinsic Phasing and refined with ShelL (Version 2018′3) refinement package using full-matrix least-squares on F2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were calculated geometrically and refined using the riding model.
- A calculated XRPD pattern was generated for copper (“Cu”) radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure. Crystal structure representations were generated by Olex2 and Diamond. The atomic thermal displacement ellipsoids drawing was generated by ORTEP-III.
- A suitable single crystal was separated from the block-like crystals and selected for single-crystal X-ray diffraction data collection. The crystal system of the single crystal was monoclinic and the space group is P21/c. Crystallographic data and the refinement parameters are shown in Table 12.
-
TABLE 12 Crystallographic data of crystalline Form A Empirical formula C27H25F3N8O•0.42(H2O) Formula weight 541.75 Temperature 119.99(10) K Wavelength CuKα (λ = 1.54184 Å) Crystal system, space group Monoclinic, P21/c Unit cell dimensions a = 12.05400(10) Å b = 8.77450(10) Å c = 24.83660(10) Å α = 90° β = 97.6260(10)° γ = 90° Volume 2603.68(4) Å3 Z, CalMolated density 4, 1.382 g/cm3 Absorption coefficient 0.883 mm−1 F(000) 1128.0 Crystal size 0.12 × 0.11 × 0.1 mm 32 Theta range for data 7.182 to 152.022 collection Limiting indices −13 ≤ h ≤ 15 −10 ≤ k ≤ 11 −31 ≤ l ≤ 31 Reflections collected/ 57364/5292 [Rint = 0.0519, Independent reflections Rsigma = 0.0143] Refinement method Full-matrix least-squares on F2 Completeness 100% Data/restraints/parameters 5292/16/408 Goodness-of-fit on F2 1.084 Final R indices [I ≥ 2sigma(I)] R1 = 0.0463, wR2 = 0.1142 Final R indices [all data] R1 = 0.0467, wR2 = 0.1144 Largest diff. peak and hole 0.50/−0.41 e · Å−3 - As shown in
FIG. 20 , the asymmetric unit of the single crystal structure is comprised of one freebase compound of Formula (II) molecule and a non-integer number of water molecules, which suggested that crystalline Form A is hydrate. The number of water molecule in the asymmetric unit was freely refined to be 0.42, according to the thermal parameters. - A suitable amount of crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) was purged with nitrogen gas (N2) for 20 minutes at 30° C. to form a new crystalline form.
- The new crystalline Form was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 3 , and the XRPD peaks are shown in Table 2, above. Based on the XRPD pattern shown inFIG. 3 and the XRPD peaks shown in Table 2, the new crystalline form was determined to be an anhydrate and was named crystalline Form C. - A suitable amount of crystalline Form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) was heated to 150° C. under nitrogen gas to form a new crystalline form.
- The new crystalline Form was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 4 , and the XRPD peaks are shown in Table 3, above. Based on the XRPD pattern shown inFIG. 4 and the XRPD peaks shown in Table 3, the new crystalline form was determined to be an anhydrate and was named crystalline Form D. - Approximately 20 mg of crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) was placed in a 3 mL vial. The 3 mL vial was then placed in a 20 mL vial with approximately 4 mL of DCM. The 20 mL vial was sealed and kept at room temperature for 10 days. After 10 days, the resulting solution was allowed to evaporate at room temperature to obtain solid material.
- The resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above. The resulting XRPD pattern, DSC profile, and TGA profile are shown in
FIGS. 5-6 , respectively, and the XRPD peaks are shown in Table 4, above. - Based on the XRPD pattern shown in
FIG. 5 and the XRPD peaks shown in Table 4, as well as the DSC and TGA profiles, the obtained solid material was determined to be a crystalline DCM solvate and was named crystalline Form E. - Approximately 20 mg of crystalline Form A was mixed in a 1:1 ratio with hydrochloric acid in an HPLC vial. 0.5 mL of EtOAc/n-heptane (1:1, v/v) was then added to form a suspension, which was stirred at about 1000 rpm at room temperature for about 3 days. The resulting solid material was isolated by centrifugation and dried under vacuum at room temperature.
- The resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above. The resulting XRPD pattern, DSC profile, and TGA profile are shown in
FIGS. 7-8 , respectively, and the XRPD peaks are shown in Table 6, above. - Based on the XRPD pattern shown in
FIG. 7 and the XRPD peaks shown in Table 6, as well as the DSC and TGA profiles, the obtained solid material was determined to be a crystalline hydrate of an HCl salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and was namedcrystalline Form 1. - Method A: Approximately 40 mg of crystalline Form A and 11.6 mg of gentisic acid were combined with 0.5 mL EtOAc/n-Heptane to obtain a suspension. The suspension was stirred at room temperature for 2 days, and the solid material was isolated by vacuum filtration and dried under vacuum at room temperature. The resulting solid material can be used as “seeds” to prepare
crystalline Form 1 at larger scales. - Method B: Approximately 500 mg of crystalline Form A and 11.6 mg of gentisic acid were combined with 7 mL EtOAc to obtain a solution. 5.0 mL n-heptane was then added dropwise, along with 10.2 mg of gentisic acid co-crystal “seeds” prepared according to method A, and finally 8.0 mL n-heptane to obtain a suspension. The suspension was stirred at room temperature for two days. The resulting solid material was isolated by vacuum filtration and dried under vacuum at room temperature.
- The resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above. The resulting XRPD pattern, DSC profile, and TGA profile are shown in
FIGS. 9-10 , respectively, and the XRPD peaks are shown in Table 7, above. - Based on the XRPD pattern shown in
FIG. 9 and the XRPD peaks shown in Table 7, as well as the crystal structure and DSC and TGA profiles, the obtained solid material was determined to be a crystalline anhydrate of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II) and was namedcrystalline Form 2. - About 3.0 mg of
crystalline Form 2 was added to a 3 mL glass vial with 0.5 mL TIF/n-heptane (2:5, v/v) solvent mixture. The mixture was then shaken by an ultrasonic cleaner to accelerate dissolution. The resulting suspension was filtered and the obtained clear solution was transferred to a clean 4-mL shell vial (44.6 mm×14.65 mm). The shell vial was sealed by a PE-Plug with one pinhole. The shell vial was then placed in a fume hood at room temperature for slow evaporation. After 6 days of slow evaporation, block-like crystals were observed, - A suitable single crystal with good diffraction quality was selected out from the block-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant). The crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K. Preliminary examination and data collection were performed on a Rigaku XtaLAB Synergy R (CuKα radiation, λ=1.54184 Å) diffractometer and analyzed with the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software package. Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software using the setting angles of 50053 reflections in the range 3.5390<θ<75.936°. The data were collected to a minimum diffraction angle (θ) of 3.765° and a maximum diffraction angle (θ) of 76.018° at 120 K. The final point group completeness is 100%. The mean I/σ of the data is 75.8 and the highest resolution is truncated at 0.79 Å.
- Frames were integrated with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 58850 reflections were collected, of which 6566 were unique. Lorentz and polarization corrections were applied to the data. An empirical absorption correction was performed using CrysAlisPro (V1.171.40.19a, Rigaku, 2018) using spherical harmonicas implemented in SCALE3 ABSPACK. The absorption coefficient μ of this material is 0.927 mm−1 at this wavelength (λ=1.542 Å) and the minimum and maximum transmissions are 0.75213 and 1.0000, respectively. The agreement factor for the averaging was 3.94% based on intensity.
- The structure was solved in the space group P21/c with the ShelXT structure solution program using Intrinsic Phasing and refined with ShelXL (Version 2018.3) refinement package using full-matrix least-squares on F2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms (H2) connected with the oxygen atoms (O2) was determined and refine freely based on the Fourier Map. Other hydrogen atoms were calculated geometrically and refined using the riding model.
- A calculated XRPD pattern was generated for copper (“Cu”) radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure. Crystal structure representations were generated by Olex2 and Diamond. The thermal ellipsoids drawing was generated by ORTEP-III.
- A suitable single crystal was separated and selected out from the block-like crystals and selected for single-crystal x-ray diffraction data collection. The crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P21/c. Crystallographic data and the refinement parameters are listed in Table 13.
-
TABLE 13 Crystallographic data of crystalline Form 2Empirical formula C34H31F3N8O5 Formula weight 688.67 Temperature 120.00(10) K Wavelength CuKα (λ = 1.54184 Å) Crystal system, space group Monoclinic, P21/c Unit cell dimensions a = 11.11290(10) Å b = 12.35560(10) Å c = 24.0484(2) Å α = 90° β = 102.4840(10)° γ = 90° Volume 3223.93(5) Å3 Z, CalMolated density 4, 1.419 g/cm3 Absorption coefficient 0.927 mm−1 F(000) 1432.0 Crystal size 0.31 × 0.15 × 0.11 mm 32 Theta range for data 7.53 to 152.036 collection Limiting indices −13 ≤ h ≤ 13 −15 ≤ k ≤ 14 −30 ≤ l ≤ 29 Reflections collected/ 58850/6566 [Rint = 0.0394, Independent reflections Rsigma = 0.0132] Refinement method Full-matrix least-squares on F2 Completeness 100% Data/restraints/parameters 6566/20/500 Goodness-of-fit on F2 1.160 Final R indices [I ≥ 2sigma(I)] R1 = 0.0426, wR2 = 0.0973 Final R indices [all data] R1 = 0.0427, wR2 = 0.0976 Largest diff. peak and hole 0.27/−0.23 e · Å−3 - As shown in
FIG. 21 , the asymmetric unit of the single crystal structure is comprised of one neutral compound of Formula (II) molecule and one gentisic acid neutral molecule, which indicated thatcrystalline Form 2 was actually a co-crystal of the starting compound with gentisic acid. - Approximately 20 mg of crystalline Form A was mixed with hydrochloric acid in a 1:2 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of MTBE was then added to form a suspension, which was magnetically stirred (˜1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- The resulting solid material was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 15 . The new crystalline form was named crystalline Form 3. - Approximately 20 mg of crystalline Form A was mixed with hydrobromic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of MTBE was then added to form a suspension, which was magnetically stirred (˜1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- The resulting solid material was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 16 . The new crystalline form was namedcrystalline Form 4. - Approximately 20 mg of crystalline Form A was mixed with hydrobromic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of EtOAc/n-Heptane (1:1, v/v) was then added to form a suspension, which was magnetically stirred (˜1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- The resulting solid material was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 17 . The new crystalline form was namedcrystalline Form 5. - Approximately 20 mg of crystalline Form A was mixed with ethanedisulfonic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of Acetone/n-Heptane (1:4, v/v) was then added to form a suspension, which was magnetically stirred (˜1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- The resulting solid material was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 18 . The new crystalline form was namedcrystalline Form 6. - Approximately 20 mg of crystalline Form A was mixed with methanesulfonic acid in a 1:1 molar ratio (Form A/acid) in an HPLC vial. 0.5 mL of Acetone/n-Heptane (1:4, v/v) was then added to form a suspension, which was magnetically stirred (˜1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- The resulting solid material was subjected to XRPD analysis using the conditions discussed above. The resulting XRPD pattern is shown in
FIG. 19 . The new crystalline form was namedcrystalline Form 7. - Purified 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) was prepared according to the procedures disclosed in U.S. Provisional Patent Application Nos. 62/783,014; 62/799,423; and 62/868,616. The purified compound was then recrystallized in hexane and isopropanol using methods known to those skilled in the art.
- 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1H-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III) obtained as discussed above, was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above. The resulting XRPD pattern, DSC profile, and TGA profile are shown in
FIGS. 11-12 , respectively, and the XRPD peaks are shown in Table 10, above. - Based on the XRPD pattern shown in
FIG. 11 and the XRPD peaks shown in Table 7, as well as the crystal structure and DSC and TGA profiles, 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1H-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (III), obtained as discussed above, was determined to be a crystalline anhydrate and was named crystalline Form A1 - Approximately 4.8 mg of crystalline Form A1 was added into a 3 mL glass vial with 0.5 mL EtOH/n-heptane (1:3, v/v) solvent mixture. After being shaken by an ultrasonic cleaner to accelerate dissolution, the suspension was filtered and the obtained clear solution was transferred to a clean 4 mL shell vial (44.6 mm×14.65 mm). The shell vial was sealed by PE-Plug with one pinhole. The shell vial was then placed in a fume hood at room temperature for slow evaporation. After 5 days of slow evaporation, thin rod-like crystals were observed.
- A suitable single crystal with good diffraction quality was selected from the thin rod-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant). The crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K. Preliminary examination and data collection were performed on a Rigaku XtaLAB Synergy R (CuKα radiation, λ=1.54184 Å) diffractometer and analyzed with the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software package. Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software using the setting angles of 24455 reflections in the range 3.516°<θ<75.351°. The data were collected to a minimum diffraction angle (θ) of 3.541° and a maximum diffraction angle (θ) of 75.982° at 120 K. The final point group completeness is 100%. The mean I/σ of the data is 71.4 and the highest resolution is truncated at 0.79 Å.
- Frames were integrated with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 52006 reflections were collected, of which 4790 were unique. Lorentz and polarization corrections were applied to the data. An empirical absorption correction was performed using CrysAlisPro (V1.171.40.19a, Rigaku, 2018) using spherical harmonicsas implemented in SCALE3 ABSPACK. The absorption coefficient μ of this material is 0.932 mm−1 at this wavelength (λ=1.542 Å) and the minimum and maximum transmissions are 0.72018 and 1.0000, respectively. Intensities of equivalent reflections were averaged, the agreement factor for the averaging was 3.24% based on intensity.
- The structure was solved in the space group P21/c with the ShelXT structure solution program using Intrinsic Phasing and refined with ShelXL (Version 2018/3) refinement package using full-matrix least-squares on F2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were calculated geometrically and refined using the riding model.
- The calculated XRPD pattern was generated for Cu radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure. The crystal structure representations were generated by Olex2 and Diamond. The atomic thermal displacement ellipsoids drawing was generated by ORTEP-III.
- A suitable single crystal was separated out from the thin rod-like crystals and selected for single-crystal X-ray diffraction data collection. The crystal system of the single crystal was determined to be monoclinic and the space group was P21/c. Crystallographic data and the refinement parameters are listed in Table 14.
-
TABLE 14 Crystallographic data of crystalline Form A1 Empirical formula C25H21F3N8O Formula weight 506.50 Temperature 120.01(10) K Wavelength CuKα (λ = 1.54184 Å) Crystal system, space group Monoclinic, P21/c Unit cell dimensions a = 12.54460(7) Å b = 8.63964(5) Å c = 21.66044(12) Å α = 90° β = 95.6607(5)° γ = 90° Volume 2336.13(2) Å3 Z, CalMolated density 4, 1.440 g/cm3 Absorption coefficient 0.932 mm−1 F(000) 1048.0 Crystal size 0.11 × 0.04 × 0.03 mm 32 Theta range for data collection 7.082 to 151.964 Limiting indices −11 ≤ h ≤ 15 −10 ≤ k ≤ 10 −27 ≤ l ≤ 27 Reflections collected/ 52006/4790 [Rint = 0.0324, Independent reflections Rsigma = 0.0140] Refinement method Full-matrix least-squares on F2 Completeness 100% Data/restraints/parameters 4790/0/336 Goodness-of-fit on F2 1.054 Final R indices [I ≥ 2sigma(I)] R1 = 0.0434, wR2 = 0.1085 Final R indices fall data] R1 = 0.0460, wR2 = 0.1114 Largest diff. peak and hole 0.35/−0.35 e · Å−3 - As shown in
FIG. 22 , the asymmetric unit of the single crystal structure was comprised of only one compound of Formula (III) molecule, which suggested that crystalline Form A1 is an anhydrate. - Approximately 20 mg of crystalline Form A1 was suspended in 0.5 mL of EtOAc/n-Heptane (1:2, v/v) in an HPLC vial and magnetically stirred (˜1000 rpm) at RT for about 3 days. The resulting solid material was dried at room temperature under vacuum.
- The resulting solid material was subjected to XRPD, TGA, and DSC analysis using the conditions discussed above. The resulting XRPD pattern, DSC profile, and TGA profile are shown in
FIGS. 13-14 , respectively, and the XRPD peaks are shown in Table 11, above. - Based on the XRPD pattern shown in
FIG. 13 and the XRPD peaks shown in Table 8, as well as the DSC and TGA profiles, the obtained solid material was determined to be a crystalline anhydrate and was named crystalline Form B1. - Mouse pharmacokinetic (PK) studies were conducted using Crystalline Form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as disclosed herein,
Crystalline Form 2 of a gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as disclosed herein, andCrystalline Form 8 of a benzoic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as disclosed herein. - The PK studies consisted of single dose oral exposure studies, which were conducted in female NOD/SCID mice (approximately 6 to 8 weeks, and 20-30 g at the time of study) using a compound dose of 300 mg/kg and a dosing volume of 10 mL/kg. The mice were fasted overnight prior to dosing. Animals had free access to food and water post-dosing.
- Blood was sampled serially from the dorsal metatarsal vein at pre-dose, 0.25, 0.5, 1, 2, 4, 8, 24, 48 (
crystalline Form 2 only), and 72 hours (crystalline Form 2 only) post PO dosing. Approximately 0.03 mL blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4° C. to provide plasma. The plasma samples were then stored in a freezer at −75±15° C. prior to LC-MS/MS analysis. - Concentrations of each compound in the plasma samples were then analyzed using an LC-MS/MS method. WinNonlin (Phoenix™, version 6.1) or other similar software was used for PK calculations. The following PK parameters were calculated, whenever possible from the plasma concentration versus time data: Cmax, Tmax, T1/2, AUCinf, and AUClast. The PK data were described using descriptive statistics such as mean with standard deviation.
- The results for crystalline form A are shown in Table 15 below and in
FIG. 23 . -
TABLE 15 Summary of Crystalline Form A PK Parameters PK Parameters Unit Mouse 7 Mouse 8Mouse 9Mean SD CV(%) T1/2 h NA 6.79 18.6 12.7 NA NA Tmax h 8.00 4.00 4.00 5.33 2.31 43.3 Cmax ng/mL 4450 2890 3750 3697 781 21.1 AUClast h*ng/mL 72653 40678 68658 60663 17422 28.7 - The results for
crystalline Form 2 are shown in Table 16 below and inFIG. 24 . -
TABLE 16 Summary of Crystalline Form 2 PK ParametersPK Parameters Unit Mouse 7 Mouse 8Mouse 9Mean SD CV(%) T1/2 h 4.03 4.22 4.27 4.17 0.13 3.12 Tmax h 8.00 12.0 12.0 10.7 2.3 21.7 Cmax ng/mL 28800 28900 29000 28900 100 0.346 AUClast h*ng/mL 827348 835713 594288 752450 137036 18.2 - A mixture of Formula II (1 g) in 50% acetone/water (10 vol) was heated to reflux and held at that temperature for at least 30 minutes. The resulting clear solution was then cooled to room temperature and stirred overnight. The resulting slurry was filtered and dried to provide Form F (800 mg) as a white solid.
- The resulting white solid material was subjected to XRPD and DSC analysis using the conditions discussed above. The resulting XRPD pattern and DSC profile are shown in
FIGS. 25 and 26 , respectively, and the XRPD peaks are shown in Table 5. - Based on the XRPD pattern shown in
FIG. 25 and the XRPD peaks shown in Table 5, as well as the DSC profile shown inFIG. 26 , the obtained solid material was determined to be a crystalline anhydrate and was named crystalline Form F. - Additional co-crystal screens were carried out to identify further solid state forms of Formula (II).
- Differential scanning calorimetry (DSC) was carried out with a TA Instruments Q2000 instrument (closed aluminum sample pan aluminum sample pan with a pinhole in the lid, heating rate 20 K/min). The melting point is understood as the peak maximum.
- Light microscopy was performed on a Leitz Orthoplan polarized microscope part #130880, generally a 10×10 magnification was applied.
- X-ray powder diffraction (XRPD) was carried out with a Stoe Stadi P diffractometer equipped with a Mythen1K detector operating with Cu-Kcal radiation. The measurements with this instrument were performed in transmission at a tube voltage of 40 kV and 40 mA tube power. A curved Ge monochromator allows testing with Cu-Kα1 radiation. The following parameters were set: 0.020 2θ step size, 12 s step time, 1.5-50.5° 2θ scanning range, and 1° 2θ detector step (detector mode in step scan). For a typical sample preparation about 10 mg of sample was placed between two acetate foils and mounted into a Stoe transmission sample holder. The sample was rotated during the measurement. All sample preparation and measurement was done in an ambient air atmosphere.
- TG-FTIR measurements were carried out with a Netzsch Thermo-Microblanace TG209 coupled to a Bruker FTIR Spectrometer Vector 22 (sample pans with a pinhole, N2 atmosphere,
heating rate 10° C./min to 300 or 350° C.). - The starting material was a freebase form of Formula (II).
- Cocrystal screening experiments with Formula II were carried out with adipic acid, benzoic acid, ethyl maltol, gallic acid (3,4,5-trihydroxybenzoic acid), gallic acid ethyl ester, 4-hydroxy benzoic acid, 4-hydroxy benzoic acid methyl ester, nicotinic acid, nicotinamide, L-proline, saccharin, salicylic acid, D-sorbitol, and succinic acid. The experimental parameters and results for the cocrystal screening experiments are listed in Table 17.
-
TABLE 17 Summary of co-crystal screening experiments and results Experiment Description Characterization Result 1 Material as received: Formula (II). XRPD Free base 2 1.0 ml acetic acid added to 80 mg of Formula (II). Visual inspection Glassy Clear solution obtained, then let solvent evaporate residue, slowly in air at r.t. amorphous. 3 100 mg of Formula (II) and 120 mg of adipic acid XRPD Free base + (1:4 eq) were dissolved together in THF (8 mL), free adipic then 6 mL of heptane were added. A light turbidity acid formed, and the suspension was agitated for 3 days. The mixture was sonicated for two minutes and filtered. The resulting white solid was submitted to XRPD. 4 80 mg of Formula (II) and 20 mg of benzoic acid XRPD Free base + (1:1.1 eq) were ground together in a ball mill for 10 free benzoic min with 50 μL of ethyl acetate as solvent. The acid resulting white solid was submitted to XRPD. 5 80 mg of Formula (II) and 80 mg of benzoic acid XRPD Crystalline, (1:4.4 eq) were dissolved together in EtOAc (1 mL), benzoic acid then 4 mL of heptane were added. A light turbidity cocrystal. formed, and the suspension was agitated for 3 days. 1:1 API:BNZ The mixture was sonicated for two minutes and according to filtered. The resulting white solid was submitted to NMR XRPD. 6 80 mg of Formula (II) and 20 mg of benzoic acid XRPD Free base (1:1.1 eq) were dissolved together in EtOAc (0.5 mL), then 3 mL of heptane were added. A light turbidity formed, and the suspension was agitated for 1 day. The mixture was filtered. The resulting white solid was submitted to XRPD. 7 540 mg of Formula (II) dissolved in 10 ml XRPD Mixture of isopropanol. Produced a stock solution of benzoic free base acid in isopropanol (1.8890 g in 14 ml~1M). Then and benzoic 4.0 ml of the benzoic acid stock solution was added acid to the solution with the API and some isopropanol cocrystal. was slowly evaporated using a slight nitrogen purge. After two days a thick suspension was obtained which was diluted with 2 ml heptane and 2 ml isopropanol. The solid was then separated by filtration and submitted for XRPD. 8 600 mg of Formula (II) and 600 mg of benzoic acid XRPD Benzoic acid (1:4.4 eq) were dissolved together in EtOAc (5 mL), cocrystal. 19 mL of heptane were added slowly (over 2-3 1:1 minutes). A light turbidity formed, and the suspension was agitated for 1 day. The day after white solid was present on the walls, the mixture was sonicated for 1-2 minutes and filtered. The resulting white solid was submitted to XRPD. Ca. 700 mg of white product was recovered. 9 700 mg of Formula (II) and 700 mg of benzoic acid XRPD Benzoic acid (1:4.4 eq) were dissolved together in EtOAc (5 mL), cocrystal. 20 mL of heptane were added slowly (over 2-3 1:1 minutes). A light turbidity formed, and the Purity = suspension was stirred overnight at room 99.78% temperature. After overnight stirring the suspension was filtered and the resulting white solid was submitted for XRPD and further characterizations after drying at r.t. for about 30 minutes. Ca. 700 mg of white product was recovered. 10 Prepared a stock solution with 4-hydroxbenzoic Visual inspection No crystalline acid (4HB) in acetone (268 mg in 2.0 ml product acetone~1.0M) obtained. 11 The remaining amount of the 4HB stock solution Visual inspection No crystalline (~1.78 ml) was diluted with 3.0 ml heptane. This product led to a precipitate that was dissolved by adding 1.0 obtained. ml of acetone; thus a nearly saturated solution was obtained which was added to about 100 mg of Formula (II). 12 To 60 mg of Formula (II) was added 120 mg of D- Visual inspection No crystalline panthenol and one ml acetone. A clear solution was product obtained to which 4 ml heptane was added; obtained. however, this led to a sticky mass/emulsion that did not crystallize. 13 80 mg of Formula (II) and 26 mg of ethyl maltol XRPD Free base + (1:1.1 eq) were ground in a ball mill for 10 min with Ethyl maltol 50 μL of ethyl acetate as solvent and solid product was submitted for XRPD. 15 1.0 ml of a stock solution of gallic acid in acetone Visual inspection No crystalline (0.23M) mixed with a stock solution of Formula product (II) in acetone (0.1M) the allow the solvent to obtained. evaporate in air at r.t. Since just a glassy residue was obtained, the residue was again dissolved in 5.0 ml acetone and 5.0 ml heptane was added. No precipitate was observed; thus the solvents were allowed to evaporate again from an open vial; however, no crystalline product was obtained. 16 278 mg of Formula (II) (0.5 mmol) dissolved in 5.0 XRPD Free base acetone, and 330 mg of gallic acid (2.0 mmol) dissolved in 5.0 ml acetone. Then added 1.5 m of the gallic acid solution to the free drug substance solution and let solvent evaporate slowly from open vial at r.t. However, a glassy residue was obtained. To the glassy residue was added 1 ml water and 1 ml isopropanol. A suspension with crystalline material was obtained which was filtered and the solid product submitted for XRPD. 17 300 mg of Formula (II) (0.5 mmol) and 430 mg of XRPD Gallic acid gallic acid (2.0 mmol) were dissolved together in 5.0 of EtOH. A thick suspension was obtained at the beginning, but heating gently (ca. 50° C.), all dissolved. The solution was let evaporate for three days, a suspension with crystalline material was obtained which was filtered and the solid product submitted for XRPD. 18 80 mg of Formula (II) and 20 mg of glutaric acid XRPD Free base + (1:1.1 eq) were ground together in a ball mill for 10 free glutaric min with 50 μL of acetone as solvent. The resulting acid white solid was submitted to XRPD. 19 100 mg D,L-mandelic acid was added to 50 mg of Visual inspection No crystalline Formula (II) and 1.0 ml acetone was added. A clear product solution was obtained to which 4 ml heptane was obtained. added. After stirring for four days most of the solid material stuck to the glass wall. Therefore all was dissolved by adding 10 TBME and the solvents were allowed to evaporate under nitrogen. 20 80 mg of Formula (II) and 80 mg of 4- XRPD: XRPD hydroxybenzoic acid methyl ester (1:3:5 eq) were shows a dissolved in 4.0 ml acetone. Then 6 ml heptane was mixture of added but no precipitate was observed. After MHB and addition of 22 ml heptane, in total, a suspension was free base. obtained from which the solid product was separated by filtration and submitted to XRPD. 21 80 mg of Formula (II) and 20 mg of nicotinic acid XRPD Possible (1:1.2 eq) were ground in a ball mill for 10 min with MeOH 60 μL of MeOH as the solvent. The resulting white solvate + solid was submitted to XRPD. free nicotinic acid 22 80 mg of Formula (II) and 20 mg of nicotinamide XRPD Possible (1:1.2 eq) were ground in a ball mill for 10 min with MeOH 60 μL of MeOH as the solvent. The resulting white solvate + solid was submitted to XRPD. free nicotinamide 23 50 mg of Formula (II) were dissolved in 1 mL of a XRPD Free base + saturated solution of nicotinamide (ca. 0.25M) in free acetone, the mixture was transparent. The solution nicotinamide was concentrated overnight until dryness. The resulting white solid was submitted to XRPD. 24 80 mg of Formula (II) and 20 mg of nicotinamide XRPD Free base + (1:1.1 eq) were dissolved together in EtOAc free (0.5 mL), then 3 mL of heptane were added. A nicotinamide precipitate appeared. The mixture was filtered. The resulting white solid was submitted to XRPD. 25 80 mg of Formula (II) and 20 mg of proline (1:1.1 XRPD Possible eq) were ground in a ball mill for 10 min with 60 MeOH μL of MeOH as the solvent. The resulting white solvate + solid was submitted to XRPD. free proline 26 100 mg of Formula (II) and 160 mg of saccharine XRPD Free base + (1:4 eq) were dissolved together in Acetone (4 mL), free then 4 mL of heptane were added and the solution saccharine became cloudy. The mixture was stirred for 3 days at r.t. Filtered and submitted to XRPD. 27 50 mg of Formula (II) and 100 mg of salicylic acid XRPD Crystalline, (1:4.4 eq) were dissolved in EtOAc (2 mL), and possible then 16 mL of heptane was added. A light turbidity salicylic acid formed, and the suspension was agitated for 3 days. co-crystal The mixture was sonicated for two minutes and with some filtered. The resulting white solid was submitted to excess of XRPD. salicylic acid. 28 The XRPD pattern showed that an excess of XRPD Salicylic salicylic was present, thus the solid product was acid co-crystal washed with i-PrOH (3 mL), filtered again and still with some submitted to XRPD and NMR. excess of salicylic acid. TG-FTIR suggests solvent free form. 29 157 mg of Formula (II) dissolved in 3.0 ml XRPD Salicylic acid isopropanol (heated to dissolve). Produced a stock cocrystal. 1:1 solution of salicylic acid in isopropanol (~1.1M) and added 1.0 ml of this solution to the drug substance solution. Seeded with SP273-SAL-P1-w and stirred at r.t. Let slowly evaporate part of the solvent (about one ml was evaporated after three days) then filtered and submitted solid for XRPD. 30 80 mg of Formula (II) and 30 mg of sorbitol (1:1.2 XRPD Possible eq) were ground in a ball mill for 10 min with 60 MeOH μL of MeOH as solvent. The resulting white solid solvate + was submitted to XRPD. free sorbitol 31 40 mg of Formula (II) were dissolved in 1 mL of a XRPD Free base + saturated solution of sorbitol (ca. 0.05M) in EtOH at free sorbitol 75° C., the mixture was transparent. The solution was concentrated overnight, few crystals appeared at the walls (very little substance), concentrated another 24 h, the solution evaporated completely leaving a white solid. The resulting white solid was submitted to XRPD. 32 50 mg of Formula (II) and 100 mg of succinic acid XRPD Succinic (1:5 eq) were dissolved together in acetone (4 mL) acid, no heating at 35° C. All dissolved. The clear solution cocrystal was stirred for 1 day. The day after a suspension formation. appeared. Filtered and submitted to XRPD. - The benzoic acid cocrystal from
experiment 5 in Table 17 was analyzed via XRPD. DSC, and TG-FTIR analysis using the aforementioned conditions. The resulting XRPD pattern, DSC profile, and TG-FTIR profile are shown inFIGS. 29-31 , respectively, and the XRPD peaks are shown in Table 8. - Based on the XRPD pattern shown in
FIG. 29 as well as the DSC and TGA profiles, the obtained solid material was determined to be a benzoic acid cocrystal and was namedcrystalline Form 8. - About 82.4 mg of Formula (II) benzoic acid co-crystal starting material was added into a 3-mL glass vial with the addition of 2.0 mL EtOAc/n-hexane (1:6, v/v) solvent mixture. The suspension was magnetically stirred (1000 rpm) at RT for 5 days and filtered by 0.45 m PTFE membrane. Then 0.5 mL of the clear filtrate was transferred to a clean 4-mL shell vial (44.6 mm×14.65 mm). The shell vial was sealed by PE-Plug with one pinhole and placed in a fume hood at room temperature for slow evaporation. After 14 days' slow evaporation, block-like crystals were obtained.
- A suitable single crystal with good diffraction quality was selected out from the block-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant). The crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 120 K. Preliminary examination and data collection were performed on a Rigaku XtaLAB Synergy R (Cu/Kα X-ray radiation, λ=1.54184 Å) diffractometer and analyzed with the CrysAlisPro (V1.171.40.67a, Rigaku, 2019) software package.
- Cell parameters and an orientation matrix for data collection were retrieved and refined (T-vector Dirax algorithm) by CrysAlisPro (V1.171.40.67a, Rigaku, 2019) software using the setting angles of 37110 reflections in the range 3.716°<θ<75.227°. The data were collected to a minimum diffraction angle (θ) of 3.734° and a maximum diffraction angle (θ) of 76.055° at 120 K. The completeness is 100%. The mean 1/σ of the data is 64.1 and the highest resolution is truncated at 0.79 Å.
- Frames were integrated with CrysAlisPro (V1.171.40.67a, Rigaku, 2019). A total of 66366 reflections were collected, of which 6371 were unique. Lorentz and polarization corrections were applied to the data. An empirical absorption correction was performed using CrysAlisPro (V1.171.40.67a, Rigaku, 2019) using spherical harmonicas implemented in SCALE3 ABSPACK. The absorption coefficient μ of this material is 0.882 mm−1 at this wavelength (λ=1.542 Å) and the minimum and maximum transmissions are 0.7464 and 1.0000, respectively. Intensities of equivalent reflections were averaged. The agreement factor for the averaging was 3.65% based on intensity.
- The structure was solved in the space group P21/n with the ShelXT(Sheldrick, G. M. Acta Cryst. 2015, A71, 3-8) structure solution program using Intrinsic Phasing and refined with ShelXL (Version 2018:3) refinement package (Sheldrick, G. M. Acta Cryst. 2015, C71, 3-8) using full-matrix least-squares on F2 contained in OLEX2 (Dolomanov, O. V., Bourhis, L. J., Gildea, R. J, Howard, J. A. K. & Puschmann, H. J. Appl. Cryst. 2009, 42, 339-341). All non-hydrogen atoms were refined anisotropically. The hydrogen atoms (H2) connected with the oxygen atoms (O2) was determined and refined freely based on the Fourier Map. Other hydrogen atoms were calculated geometrically and refined using the riding model.
- The calculated XRPD pattern was generated for Cu radiation using Mercwy program (Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., Taylor, R., Towler, M. & van de Streek, J. J. Appl. Cryst. 2006, 39, 453-457) and the atomic coordinates, space group, and unit cell parameters from the single crystal structure.
- The crystal structure representations were generated by Olex2 and Diamond (Brandenburg, K. DIAMOND, 1999, Crystal Impact GbR, Bonn, Germany). The thermal ellipsoids drawing was generated by ORTEP-III (L. J. Farrugia. J. Appl. Cryst. 2012, 45, 849-854).
- A suitable single crystal was separated and selected out from the block-like crystals and selected for single-crystal x-ray diffraction data collection. The crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P21/n. Crystallographic data and refinement parameters are shown in Table 18.
-
TABLE 18 Crystallographic data of crystalline Form 8Empirical formula C34H31F3N8O3 Formula weight 656.67 Temperature 120.00(10) K Wavelength CuKα (λ = 1.54184 Å) Crystal system, space group Monoclinic, P21/n Unit cell dimensions a = 10.61070(10) Å b = 12.39940(10) Å c = 24.15170(10) Å α = 90° β = 101.4110(10)° γ = 90° Volume 3114.74(4) Å3 Z, CalMolated density 4, 1.440 g/cm3 Absorption coefficient 0.882 mm−1 F(000) 1368.0 Crystal size 0.047 × 0.043 × 0.033 mm 32 Theta range for data 7.012 to 110.646 collection Limiting indices −12 ≤ h ≤ 13 −15 ≤ k ≤ 15 −29 ≤ 1 ≤ 30 Reflections 66366/6371 [Rint = 0.0365, collected/Independent Rsigma = 0.0156] reflections Refinement method Full-matrix least-squares on F2 Completeness 100% Data/restraints/parameters 6371/0/440 Goodness-of-fit on F2 1.046 Final R indices [I ≥ 2sigma(I)] R1 = 0.0417, wR2 = 0.1067 Final R indices [all data] R1 = 0.0446, wR2 = 0.1088 Largest diff. peak and hole 0.64/−0.25 e · Å−3 - As shown in
FIG. 32 , the asymmetric unit of the single crystal structure was comprised of one neutral Formula (II) molecule and one neutral benzoic acid molecule, which indicated that the crystal is a benzoic acid cocrystal of Formula (II). - The salicylic acid cocrystal from experiment 29 in Table 17 was analyzed via XRPD and 1H NMR analysis using the aforementioned conditions. The resulting XRPD and 1H NMR patterns are shown in
FIGS. 33-34 , respectively. - Based on the XRPD pattern shown in
FIG. 33 as well as the 3H NMR profile (FIG. 34 ), the obtained solid material was determined to be a salicylic acid cocrystal and was namedcrystalline Form 9. - About 3.2 mg of Formula (II) salicylic acid cocrystal was added into a 3-mL glass vial with the additional of 0.5 mL acetone/n-heptane (1:8, v/v) solvent mixture. Ultrasonication was applied to accelerate dissolution of solid sample, after which the suspension was filtered by a filter (0.45 μm PTFR membrane). Then the clear filtrate was transferred to a clean 4-mL shell vial (44.6 mm×14.65 mm). The shell vial was sealed by PE-Plug with one pinhole. The shell vial was placed in a fume hood at room temperature for slow evaporation. After 2 days' slow evaporation, rod-like crystals were observed.
- A suitable single crystal with good diffraction quality was selected out from the rod-like crystal sample and was wrapped with Paratone-N (an oil based cryoprotectant). The crystal was mounted on a mylar loop in a random orientation and immersed in a stream of nitrogen at 184 K. Preliminary examination and data collection were performed on a Bruker D8 Venture (METALJET Ga X-ray source, PHOTON II) diffractometer and analyzed with the APEX3 software package.
- Cell parameters and an orientation matrix for data collection were retrieved and refined by SAINT (Version: 8.37A) software using the setting angles of 9918 reflections in the range 3.2520<θ<54.786°. The data were collected to a minimum diffraction angle (θ) of 3.506° and a maximum diffraction angle (θ) of 55.323° at 184 K. The completeness is 99.84%. The mean 1/σ of the data is 13.0 and the highest resolution is truncated at 0.82 Å.
- Frames were integrated with SAINT (Version: 8.37A). A total of 38333 reflections were collected, of which 6058 were unique. Lorentz and polarization corrections were applied to the data. An absorption correction was performed using SADABS (Version: 2016/2) with multi-scan method. The absorption coefficient μ of this material is 0.579 mm-1 at this wavelength (=1.34139 Å) and the minimum and maximum transmissions are 0.5107 and 0.7508, respectively. The agreement factor for the averaging was 12.23% based on intensity.
- The structure was solved in the space group P21/c with the ShelXT1 structure solution program using Intrinsic Phasing and refined with ShelXL2 (Version 2018/3) refinement package using full-matrix least-squares on F2 contained in OLEX2. All non-hydrogen atoms were refined anisotropically. The hydrogen atoms (H2) connected with the oxygen atoms (O2) was determined and refined freely based on the Fourier Map. Other hydrogen atoms were calculated geometrically and refined using the riding model.
- The calculated XRPD pattern was generated for Cu radiation using Mercury program and the atomic coordinates, space group, and unit cell parameters from the single crystal structure. The crystal structure representations were generated by Olex2 and Diamond.
- A suitable single crystal was separated and selected out from the block-like crystals and selected for single-crystal x-ray diffraction data collection. The crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P21/c. Crystallographic data and the refinement parameters are listed in Table 19.
-
TABLE 19 Crystallographic data of crystalline Form 9Empirical formula C34H31F3N8O4 Formula weight 672.67 Temperature 184.08 K Wavelength CuKα (λ = 1.34139 Å) Crystal system, space group Monoclinic, P21/c Unit cell dimensions a = 10.8387(11) Å b = 12.3761(12) Å c = 24.242(2) Å α = 90° β = 102.631(5)° γ = 90° Volume 3173.1(5) Å3 Z, CalMolated density 4, 1.408 g/cm3 Absorption coefficient 0.579 mm−1 F(000) 1400.0 Crystal size 0.08 × 0.06 × 0.05 mm 32 Theta range for data 7.012 to 110.646 collection Limiting indices −12 ≤ h ≤ 13 −15 ≤ k ≤ 14 −29 ≤ 1 ≤ 29 Reflections 38333/6058 [Rint = 0.1223, collected/Independent Rsigma = 0.0767] reflections Refinement method Full-matrix least-squares on F2 Completeness 100% Data/restraint/parameters 6058/0/454 Goodness-of-fit on F2 1.048 Final R indices [I ≥ 2sigma(I)] R1 = 0.0644, wR2 = 0.1585 Final R indices [all data] R1 = 0.1065, wR2 = 0.1867 Largest diff. peak and hole 0.44/−0.35 e · Å−3 - As shown in
FIG. 35 , the asymmetric unit of the single crystal structure was comprised of one neutral Formula (II) molecule and a neutral salicylic acid molecule, which indicated that the crystal is a salicylic acid cocrystal of Formula (II). - Mouse pharmacokinetic (PK) studies were conducted using
Crystalline Form 8 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as disclosed herein. - The PK studies consisted of single dose oral exposure studies, which were conducted in female NOD/SCID mice (approximately 6 to 8 weeks, and 20-30 g at the time of study) using a compound dose of 300 mg/kg and a dosing volume of 10 mL/kg. The mice were fasted overnight prior to dosing. Animals had free access to food and water post-dosing.
- Blood was sampled serially from the dorsal metatarsal vein at pre-dose, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post PO dosing. Approximately 0.03 mL blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4° C. to provide plasma. The plasma samples were then stored in a freezer at −75±15° C. prior to LC-MS/MS analysis.
- Concentrations of compound in the plasma samples were then analyzed using an LC-MS/MS method. WinNonlin (Phoenix™, version 6.1) or other similar software was used for PK calculations. The following PK parameters were calculated, whenever possible from the plasma concentration versus time data: Cmax, Tmax, T1/2, AUCinf, and AUClast. The PK data were described using descriptive statistics such as mean with standard deviation.
- The results for
crystalline Form 8 are shown in Table 20 below and inFIG. 36 . -
TABLE 20 Summary of Crystalline Form 8 PK ParametersPK Parameters Unit Mouse 10 Mouse 11Mouse 12Mean SD CV(%) T1/2 h NA 11.4 2.08 6.8 NA NA Tmax h 8.00 0.500 2.00 3.50 3.97 113 Cmax ng/mL 8810 18200 17300 14770 5181 35.1 AUClast h*ng/mL 144793 167910 233433 182045 45980 25.3 - Female NOD SCID mice of an age between 6-8 weeks and a body weight range of 18-22 g were purchased from Beijing Anikeeper Biotech Co, Ltd. Animals were habituated to the environment for at least 7 days prior to study initiation. Mice were dosed with
Crystalline Form 2 at either 100 mg/kg or 300 mg/kg dose levels via oral gavage for 28 days. After 24 hours following 27 doses of compound, three mice were euthanized via CO2. After four hours following 28 doses of compound, three mice were euthanized via CO2. At each time point the whole brain was collected. In addition, approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000G for 5 minutes at 4° C. to provide plasma. Samples were then stored in a freezer at −75±15° C. prior to LC-MS/MS analysis. Concentrations of compound in brain homogenates (ng/g) and plasma (ng/ml) were then analyzed using an LC-MS/MS method. The PK data were described using descriptive statistics such as mean with standard deviation. - As shown in Table 20 and
FIG. 37 , measurable drug level was observed in the brain tissue. There was no apparent accumulation of the drug in the brain after repeated dosing. -
TABLE 20 Summary of brain penetration of crystalline Form 2 in NOD SCID miceCrystalline Form 2Parameters 4 h (Day 28) 24 h (Day 28) 100 mg/kg Brain Conc. (ng/g) 1525 ± 559 19.5 Plasma Conc. (ng/mL) 5040 ± 694 178 ± 165 B/P Ratio 0.306 ± 00.125 0.091 ± 0.014 300 mg/kg Brain Conc. (ng/g) 6500 ± 1050 66.1 ± 81.7 Plasma Conc. (ng/mL) 15333 ± 2318 667 ± 852 B/P Ratio 0.424 ± 0.018 0.102 ± 0.007 - Male and female Sprague Dawley rats were purchased from Beijing Anikeeper Biotech Co, Ltd. Animals were habituated to the environment prior to study initiation. Rats were dosed with single dose of 100 mg/kg
crystalline Form 2 via oral gavage. The rats were fasted overnight prior to dosing. Animals had access to food from 2 hours post dose and free access to water throughout the study. Approximately 0.2 mL of blood was sampled via jugular vein at each time point and centrifuged at 4000G for 5 minutes at 4° C. to provide plasma. Samples were then stored in a freezer at −75±15° C. prior to LC-MS/MS analysis. Whole brain was collected after hemoperfusion and snap frozen on dry ice prior to storage at −75±15° C. Prior to LC-MS/MS analysis whole brains were weighed and homogenized with water by tissue weight (g) to water volume (ml) ratio 1:3 before analysis. Actual concentration is the measured value multiplied by the dilution factor. The PK data were described using descriptive statistics such as mean with standard deviation. - As shown in Table 21 and
FIG. 38 , measurable drug level was observed in the brain tissue. A similar elimination profile was also observed between plasma and brain tissue, suggesting a rapid equilibrium between systemic circulation and brain tissue. -
TABLE 21 Summary of brain penetration of crystalline Form 2 in SD male and female ratsCrystalline Form 2Parameters Plasma Brain Male Cmax (ng/mL or ng/g) 5297 3903 tmax (h) 8.00 8.00 t1/2 (h) 9.13 7.43 AUC0-∞ (ng · h/mL or ng · h/g) 101618 60596 B/P Conc. Ratio at tmax 0.731 Female Cmax (ng/mL or ng/g) 9760 5613 tmax (h) 8.00 8.00 t1/2 (h) 16.9 12.8 AUC0-∞ (ng · h/mL or ng · h/g) 266414 120933 B/P Conc. Ratio at tmax 0.580 - Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof.
- Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
- All patents and publications cited herein are fully incorporated by reference herein in their entirety.
Claims (48)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/334,976 US20240034738A1 (en) | 2020-10-30 | 2023-06-14 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063107765P | 2020-10-30 | 2020-10-30 | |
US17/512,802 US11718624B2 (en) | 2020-10-30 | 2021-10-28 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
US18/334,976 US20240034738A1 (en) | 2020-10-30 | 2023-06-14 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/512,802 Division US11718624B2 (en) | 2020-10-30 | 2021-10-28 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240034738A1 true US20240034738A1 (en) | 2024-02-01 |
Family
ID=81384285
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/512,802 Active US11718624B2 (en) | 2020-10-30 | 2021-10-28 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
US18/334,976 Pending US20240034738A1 (en) | 2020-10-30 | 2023-06-14 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/512,802 Active US11718624B2 (en) | 2020-10-30 | 2021-10-28 | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (2) | US11718624B2 (en) |
EP (1) | EP4236958A1 (en) |
JP (1) | JP2023548148A (en) |
KR (1) | KR20230098186A (en) |
CN (1) | CN116615424A (en) |
AU (1) | AU2021371305A1 (en) |
CA (1) | CA3196564A1 (en) |
IL (1) | IL302352A (en) |
MX (1) | MX2023004937A (en) |
TW (1) | TW202233621A (en) |
WO (1) | WO2022094096A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021218805A1 (en) * | 2020-02-14 | 2022-09-01 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (USP1) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors |
WO2023083285A1 (en) * | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
TW202334142A (en) | 2021-11-12 | 2023-09-01 | 香港商英矽智能科技知識產權有限公司 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
WO2023208130A1 (en) * | 2022-04-29 | 2023-11-02 | 江苏亚虹医药科技股份有限公司 | Pyrimidine compound, method for preparing same, and pharmaceutical use thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
DE69128350T2 (en) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | NUCLEIC ACID LIGANDS |
AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
WO1996023899A1 (en) | 1995-02-01 | 1996-08-08 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
ATE230850T1 (en) | 1996-10-08 | 2003-01-15 | Bisys B V U | METHOD AND MEANS FOR SELECTING PEPTIDES AND PROTEINS WITH SPECIFIC AFFINITY FOR A TARGET MOLECULE |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
WO2007149484A2 (en) | 2006-06-20 | 2007-12-27 | Dana-Farber Cancer Institute | Inhibitors of usp1 deubiquitinating enzyme complex |
WO2008066624A2 (en) | 2006-10-20 | 2008-06-05 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
EP2108019A2 (en) * | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases |
MY150993A (en) | 2007-10-05 | 2014-03-31 | Verastem Inc | Pyrimidine substituted purine derivatives |
WO2009111354A2 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
GB0917934D0 (en) | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
CN102666545B (en) * | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor |
WO2011137320A2 (en) * | 2010-04-30 | 2011-11-03 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
US20160298096A1 (en) | 2013-11-18 | 2016-10-13 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
US9725425B1 (en) * | 2014-02-25 | 2017-08-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
KR101766194B1 (en) | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | Novel 3-(isoxazol-3-yl)-pyrazolo[3,4-d]pyrimidin-4-amine compounds as RET kinase inhibitor |
WO2017087837A1 (en) | 2015-11-20 | 2017-05-26 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
KR20210105887A (en) * | 2018-12-20 | 2021-08-27 | 케이에스큐 세러퓨틱스 인코포레이티드 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
EP4090332A4 (en) | 2020-01-15 | 2024-02-14 | Ksq Therapeutics Inc | Compositions of substituted pyrazolopyrimidines and uses thereof |
AU2021218805A1 (en) | 2020-02-14 | 2022-09-01 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (USP1) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors |
WO2022174184A1 (en) | 2021-02-15 | 2022-08-18 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
-
2021
- 2021-10-28 CN CN202180074194.8A patent/CN116615424A/en active Pending
- 2021-10-28 KR KR1020237014960A patent/KR20230098186A/en unknown
- 2021-10-28 JP JP2023526247A patent/JP2023548148A/en active Pending
- 2021-10-28 EP EP21887528.4A patent/EP4236958A1/en active Pending
- 2021-10-28 US US17/512,802 patent/US11718624B2/en active Active
- 2021-10-28 IL IL302352A patent/IL302352A/en unknown
- 2021-10-28 WO PCT/US2021/057072 patent/WO2022094096A1/en active Application Filing
- 2021-10-28 CA CA3196564A patent/CA3196564A1/en active Pending
- 2021-10-28 AU AU2021371305A patent/AU2021371305A1/en active Pending
- 2021-10-28 TW TW110140063A patent/TW202233621A/en unknown
- 2021-10-28 MX MX2023004937A patent/MX2023004937A/en unknown
-
2023
- 2023-06-14 US US18/334,976 patent/US20240034738A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11718624B2 (en) | 2023-08-08 |
KR20230098186A (en) | 2023-07-03 |
IL302352A (en) | 2023-06-01 |
EP4236958A1 (en) | 2023-09-06 |
WO2022094096A1 (en) | 2022-05-05 |
US20220162213A1 (en) | 2022-05-26 |
AU2021371305A1 (en) | 2023-06-15 |
TW202233621A (en) | 2022-09-01 |
MX2023004937A (en) | 2023-05-17 |
CA3196564A1 (en) | 2022-05-05 |
CN116615424A (en) | 2023-08-18 |
JP2023548148A (en) | 2023-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11718624B2 (en) | Solid state forms of substituted pyrazolopyrimidines and uses thereof | |
CN109311832B (en) | Pamoic acid salt of vortioxetine and crystal forms thereof | |
PT1924585E (en) | Novel crystalline form of a pyridazino [4 , 5-b] indole derivative | |
US9902698B2 (en) | 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
US20240059662A1 (en) | Solid forms of a compound | |
US11230559B2 (en) | Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate | |
TWI462915B (en) | Novel fumarate salts of a histamine h3 receptor antagonist | |
US20120283274A1 (en) | Crystalline forms of substituted pyrazolopyrimidines | |
TW201512201A (en) | Polymorphs and salts of a compound | |
US20140128444A1 (en) | Novel crystalline salts of asenapine with organic di-acids and tri-acids | |
US20210094961A1 (en) | Form of ponatinib | |
US20190263760A1 (en) | Crystalline Forms of Lesinurad | |
WO2019042443A1 (en) | Compound having tyrosine protein kinase jak3-degradation activity | |
US11066401B2 (en) | Pyrimidine compound, chloride salt thereof, and manufacturing and application of same | |
KR20150072454A (en) | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | |
KR20130033242A (en) | Clopidogrel co-crysral | |
US20220119414A1 (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
US20220119415A1 (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
US11440908B2 (en) | Crystalline forms of dasatinib | |
JP7194828B2 (en) | crystalline salt of corridarmin | |
WO2023147311A1 (en) | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors | |
CN116847840A (en) | Polymorphs of crystalline forms of 3, 10-dimethoxy-5, 8,13 a-tetrahydro-6H-isoquinolino [3,2-a ] isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof | |
WO2021208850A1 (en) | Nitroimidazole derivative, preparation method therefor and use thereof | |
TW202404604A (en) | New solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KSQ THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLVIAS AG;REEL/FRAME:064580/0834 Effective date: 20221116 Owner name: SOLVIAS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLATTER, FRIEDRICH;LAPADULA, GIUSEPPE;REEL/FRAME:064580/0821 Effective date: 20221018 Owner name: KSQ THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, HANLAN;WILT, JEREMY CLINTON;SIGNING DATES FROM 20220315 TO 20220407;REEL/FRAME:064580/0795 Owner name: KSQ THERAPEUTICS, INC., MASSACHUSETTS Free format text: CHANGE OF ADDRESS;ASSIGNOR:KSQ THERAPEUTICS, INC.;REEL/FRAME:064585/0753 Effective date: 20220920 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |